#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Effects of delaying binge drinking on adolescent brain development: a longitudinal neuroimaging study
#Text=Background
#Text=Onset of alcohol use by 14 relative to 21 years of age strongly predicts elevated risk for severe alcohol use problems, with 27% versus 4% of individuals exhibiting alcohol dependence within 10 years of onset.
1-1	0-7	Effects	_	
1-2	8-10	of	_	
1-3	11-19	delaying	_	
1-4	20-25	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[1]	
1-5	26-34	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[1]	
1-6	35-37	on	_	
1-7	38-48	adolescent	_	
1-8	49-54	brain	_	
1-9	55-66	development	_	
1-10	66-67	:	_	
1-11	68-69	a	_	
1-12	70-82	longitudinal	_	
1-13	83-95	neuroimaging	_	
1-14	96-101	study	_	
1-15	102-112	Background	_	
1-16	113-118	Onset	_	
1-17	119-121	of	_	
1-18	122-129	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-19	130-133	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-20	134-136	by	_	
1-21	137-139	14	_	
1-22	140-148	relative	_	
1-23	149-151	to	_	
1-24	152-154	21	_	
1-25	154-155	 	_	
1-26	155-160	years	_	
1-27	161-163	of	_	
1-28	164-167	age	_	
1-29	168-176	strongly	_	
1-30	177-185	predicts	_	
1-31	186-194	elevated	_	
1-32	195-199	risk	_	
1-33	200-203	for	_	
1-34	204-210	severe	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-35	211-218	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-36	219-222	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-37	223-231	problems	_	
1-38	231-232	,	_	
1-39	233-237	with	_	
1-40	238-241	27%	_	
1-41	242-248	versus	_	
1-42	249-251	4%	_	
1-43	252-254	of	_	
1-44	255-266	individuals	_	
1-45	266-267	 	_	
1-46	267-277	exhibiting	_	
1-47	278-285	alcohol	_	
1-48	286-296	dependence	_	
1-49	297-303	within	_	
1-50	304-306	10	_	
1-51	306-307	 	_	
1-52	307-312	years	_	
1-53	313-315	of	_	
1-54	316-321	onset	_	
1-55	321-322	.	_	

#Text=What remains unclear is whether this early alcohol use (i) is a marker for later problems, reflected as a pre-existing developmental predisposition, (ii) causes global neural atrophy or (iii) specifically disturbs neuro-maturational processes implicated in addiction, such as executive functions or reward processing.
2-1	323-327	What	_	
2-2	328-335	remains	_	
2-3	336-343	unclear	_	
2-4	344-346	is	_	
2-5	347-354	whether	_	
2-6	355-359	this	_	
2-7	360-365	early	_	
2-8	366-373	alcohol	_	
2-9	374-377	use	_	
2-10	378-379	(	_	
2-11	379-380	i	_	
2-12	380-381	)	_	
2-13	382-384	is	_	
2-14	385-386	a	_	
2-15	387-393	marker	_	
2-16	394-397	for	_	
2-17	398-403	later	_	
2-18	404-412	problems	_	
2-19	412-413	,	_	
2-20	414-423	reflected	_	
2-21	424-426	as	_	
2-22	427-428	a	_	
2-23	429-441	pre-existing	_	
2-24	442-455	developmental	_	
2-25	456-470	predisposition	_	
2-26	470-471	,	_	
2-27	472-473	(	_	
2-28	473-475	ii	_	
2-29	475-476	)	_	
2-30	477-483	causes	_	
2-31	484-490	global	_	
2-32	491-497	neural	_	
2-33	498-505	atrophy	_	
2-34	506-508	or	_	
2-35	509-510	(	_	
2-36	510-513	iii	_	
2-37	513-514	)	_	
2-38	515-527	specifically	_	
2-39	528-536	disturbs	_	
2-40	537-555	neuro-maturational	_	
2-41	556-565	processes	_	
2-42	566-576	implicated	_	
2-43	577-579	in	_	
2-44	580-589	addiction	_	
2-45	589-590	,	_	
2-46	591-595	such	_	
2-47	596-598	as	_	
2-48	599-608	executive	_	
2-49	609-618	functions	_	
2-50	619-621	or	_	
2-51	622-628	reward	_	
2-52	629-639	processing	_	
2-53	639-640	.	_	

#Text=Since our group has demonstrated that a novel intervention program targeting personality traits associated with adolescent alcohol use can prevent the uptake of drinking and binge drinking by 40 to 60%, a crucial question is whether prevention of early onset alcohol misuse will protect adolescent neurodevelopment and which domains of neurodevelopment can be protected.
3-1	641-646	Since	_	
3-2	647-650	our	_	
3-3	651-656	group	_	
3-4	657-660	has	_	
3-5	661-673	demonstrated	_	
3-6	674-678	that	_	
3-7	679-680	a	_	
3-8	681-686	novel	_	
3-9	687-699	intervention	_	
3-10	700-707	program	_	
3-11	708-717	targeting	_	
3-12	718-729	personality	_	
3-13	730-736	traits	_	
3-14	737-747	associated	_	
3-15	748-752	with	_	
3-16	753-763	adolescent	_	
3-17	764-771	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]	
3-18	772-775	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]	
3-19	776-779	can	_	
3-20	780-787	prevent	_	
3-21	788-791	the	_	
3-22	792-798	uptake	_	
3-23	799-801	of	_	
3-24	802-810	drinking	_	
3-25	811-814	and	_	
3-26	815-820	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[5]	
3-27	821-829	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[5]	
3-28	830-832	by	_	
3-29	833-835	40	_	
3-30	836-838	to	_	
3-31	839-842	60%	_	
3-32	842-843	,	_	
3-33	844-845	a	_	
3-34	846-853	crucial	_	
3-35	854-862	question	_	
3-36	863-865	is	_	
3-37	866-873	whether	_	
3-38	874-884	prevention	_	
3-39	885-887	of	_	
3-40	888-893	early	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
3-41	894-899	onset	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
3-42	900-907	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
3-43	908-914	misuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
3-44	915-919	will	_	
3-45	920-927	protect	_	
3-46	928-938	adolescent	_	
3-47	939-955	neurodevelopment	_	
3-48	956-959	and	_	
3-49	960-965	which	_	
3-50	966-973	domains	_	
3-51	974-976	of	_	
3-52	977-993	neurodevelopment	_	
3-53	994-997	can	_	
3-54	998-1000	be	_	
3-55	1001-1010	protected	_	
3-56	1010-1011	.	_	

#Text=Methods
#Text=A subsample of 120 youth at high risk for substance misuse and 30 low-risk youth will be recruited from the Co-Venture trial (Montreal, Canada) to take part in this 5-year follow-up neuroimaging study.
4-1	1012-1019	Methods	_	
4-2	1020-1021	A	_	
4-3	1022-1031	subsample	_	
4-4	1032-1034	of	_	
4-5	1035-1038	120	_	
4-6	1039-1044	youth	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
4-7	1045-1047	at	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
4-8	1048-1052	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
4-9	1053-1057	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
4-10	1058-1061	for	_	
4-11	1062-1071	substance	_	
4-12	1072-1078	misuse	_	
4-13	1079-1082	and	_	
4-14	1083-1085	30	_	
4-15	1086-1094	low-risk	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]|http://maven.renci.org/NeuroBridge/neurobridge#LowRisk[10]	
4-16	1095-1100	youth	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
4-17	1101-1105	will	_	
4-18	1106-1108	be	_	
4-19	1109-1118	recruited	_	
4-20	1119-1123	from	_	
4-21	1124-1127	the	_	
4-22	1128-1138	Co-Venture	_	
4-23	1139-1144	trial	_	
4-24	1145-1146	(	_	
4-25	1146-1154	Montreal	_	
4-26	1154-1155	,	_	
4-27	1156-1162	Canada	_	
4-28	1162-1163	)	_	
4-29	1164-1166	to	_	
4-30	1167-1171	take	_	
4-31	1172-1176	part	_	
4-32	1177-1179	in	_	
4-33	1180-1184	this	_	
4-34	1185-1186	5	_	
4-35	1186-1187	-	_	
4-36	1187-1191	year	_	
4-37	1192-1201	follow-up	_	
4-38	1202-1214	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[11]	
4-39	1215-1220	study	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[11]	
4-40	1220-1221	.	_	

#Text=The Co-Venture trial is a community-based cluster-randomised trial evaluating the effectiveness of school-based personality-targeted interventions on substance use and cognitive outcomes involving approximately 3800 Grade 7 youths.
5-1	1222-1225	The	_	
5-2	1226-1236	Co-Venture	_	
5-3	1237-1242	trial	_	
5-4	1243-1245	is	_	
5-5	1246-1247	a	_	
5-6	1248-1263	community-based	_	
5-7	1264-1282	cluster-randomised	_	
5-8	1283-1288	trial	_	
5-9	1289-1299	evaluating	_	
5-10	1300-1303	the	_	
5-11	1304-1317	effectiveness	_	
5-12	1318-1320	of	_	
5-13	1321-1333	school-based	_	
5-14	1334-1354	personality-targeted	_	
5-15	1355-1368	interventions	_	
5-16	1369-1371	on	_	
5-17	1372-1381	substance	_	
5-18	1382-1385	use	_	
5-19	1386-1389	and	_	
5-20	1390-1399	cognitive	_	
5-21	1400-1408	outcomes	_	
5-22	1409-1418	involving	_	
5-23	1419-1432	approximately	_	
5-24	1433-1437	3800	_	
5-25	1438-1443	Grade	_	
5-26	1444-1445	7	_	
5-27	1446-1452	youths	_	
5-28	1452-1453	.	_	

#Text=Half of the 120 high-risk participants will have received the preventative intervention program.
6-1	1454-1458	Half	_	
6-2	1459-1461	of	_	
6-3	1462-1465	the	_	
6-4	1466-1469	120	_	
6-5	1470-1479	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[12]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
6-6	1480-1492	participants	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[12]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
6-7	1493-1497	will	_	
6-8	1498-1502	have	_	
6-9	1503-1511	received	_	
6-10	1512-1515	the	_	
6-11	1516-1528	preventative	_	
6-12	1529-1541	intervention	_	
6-13	1542-1549	program	_	
6-14	1549-1550	.	_	

#Text=Cognitive tasks and structural and functional neuroimaging scans will be conducted at baseline, and at 24- and 48-month follow-up.
7-1	1551-1560	Cognitive	_	
7-2	1561-1566	tasks	_	
7-3	1567-1570	and	_	
7-4	1571-1581	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	
7-5	1582-1585	and	_	
7-6	1586-1596	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]	
7-7	1597-1609	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]	
7-8	1610-1615	scans	_	
7-9	1616-1620	will	_	
7-10	1621-1623	be	_	
7-11	1624-1633	conducted	_	
7-12	1634-1636	at	_	
7-13	1637-1645	baseline	_	
7-14	1645-1646	,	_	
7-15	1647-1650	and	_	
7-16	1651-1653	at	_	
7-17	1654-1656	24	_	
7-18	1656-1657	-	_	
7-19	1658-1661	and	_	
7-20	1662-1664	48	_	
7-21	1664-1665	-	_	
7-22	1665-1670	month	_	
7-23	1671-1680	follow-up	_	
7-24	1680-1681	.	_	

#Text=Two functional paradigms will be used: the Stop-Signal Task to measure motor inhibitory control and a modified version of the Monetary Incentive Delay Task to evaluate reward processing.
8-1	1682-1685	Two	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-2	1686-1696	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[16]	
8-3	1697-1706	paradigms	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[16]	
8-4	1707-1711	will	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-5	1712-1714	be	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-6	1715-1719	used	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-7	1719-1720	:	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-8	1721-1724	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-9	1725-1736	Stop-Signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-10	1737-1741	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-11	1742-1744	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-12	1745-1752	measure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-13	1753-1758	motor	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-14	1759-1769	inhibitory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-15	1770-1777	control	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-16	1778-1781	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-17	1782-1783	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-18	1784-1792	modified	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-19	1793-1800	version	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-20	1801-1803	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-21	1804-1807	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-22	1808-1816	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-23	1817-1826	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-24	1827-1832	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-25	1833-1837	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-26	1838-1840	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-27	1841-1849	evaluate	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-28	1850-1856	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-29	1857-1867	processing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
8-30	1867-1868	.	_	

#Text=Discussion
#Text=The expected results should help identify biological vulnerability factors, and quantify the consequences of early alcohol abuse as well as the benefits of early intervention using brain metrics.
9-1	1869-1879	Discussion	_	
9-2	1880-1883	The	_	
9-3	1884-1892	expected	_	
9-4	1893-1900	results	_	
9-5	1901-1907	should	_	
9-6	1908-1912	help	_	
9-7	1913-1921	identify	_	
9-8	1922-1932	biological	_	
9-9	1933-1946	vulnerability	_	
9-10	1947-1954	factors	_	
9-11	1954-1955	,	_	
9-12	1956-1959	and	_	
9-13	1960-1968	quantify	_	
9-14	1969-1972	the	_	
9-15	1973-1985	consequences	_	
9-16	1986-1988	of	_	
9-17	1989-1994	early	_	
9-18	1995-2002	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]	
9-19	2003-2008	abuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]	
9-20	2009-2011	as	_	
9-21	2012-2016	well	_	
9-22	2017-2019	as	_	
9-23	2020-2023	the	_	
9-24	2024-2032	benefits	_	
9-25	2033-2035	of	_	
9-26	2036-2041	early	_	
9-27	2042-2054	intervention	_	
9-28	2055-2060	using	_	
9-29	2061-2066	brain	_	
9-30	2067-2074	metrics	_	
9-31	2074-2075	.	_	

#Text=Background
#Text=Harmful alcohol use begins in adolescence, a period characterized by developments in cognition, behavior and brain maturation.
10-1	2076-2086	Background	_	
10-2	2087-2094	Harmful	_	
10-3	2095-2102	alcohol	_	
10-4	2103-2106	use	_	
10-5	2107-2113	begins	_	
10-6	2114-2116	in	_	
10-7	2117-2128	adolescence	_	
10-8	2128-2129	,	_	
10-9	2130-2131	a	_	
10-10	2132-2138	period	_	
10-11	2139-2152	characterized	_	
10-12	2153-2155	by	_	
10-13	2156-2168	developments	_	
10-14	2169-2171	in	_	
10-15	2172-2181	cognition	_	
10-16	2181-2182	,	_	
10-17	2183-2191	behavior	_	
10-18	2192-2195	and	_	
10-19	2196-2201	brain	_	
10-20	2202-2212	maturation	_	
10-21	2212-2213	.	_	

#Text=Onset of alcohol use by 14 relative to 21 years of age strongly predicts elevated risk for severe alcohol use problems, with 27% versus 4% of individuals exhibiting alcohol dependence within 10 years of onset.
11-1	2214-2219	Onset	_	
11-2	2220-2222	of	_	
11-3	2223-2230	alcohol	_	
11-4	2231-2234	use	_	
11-5	2235-2237	by	_	
11-6	2238-2240	14	_	
11-7	2241-2249	relative	_	
11-8	2250-2252	to	_	
11-9	2253-2255	21	_	
11-10	2255-2256	 	_	
11-11	2256-2261	years	_	
11-12	2262-2264	of	_	
11-13	2265-2268	age	_	
11-14	2269-2277	strongly	_	
11-15	2278-2286	predicts	_	
11-16	2287-2295	elevated	_	
11-17	2296-2300	risk	_	
11-18	2301-2304	for	_	
11-19	2305-2311	severe	_	
11-20	2312-2319	alcohol	_	
11-21	2320-2323	use	_	
11-22	2324-2332	problems	_	
11-23	2332-2333	,	_	
11-24	2334-2338	with	_	
11-25	2339-2342	27%	_	
11-26	2343-2349	versus	_	
11-27	2350-2352	4%	_	
11-28	2352-2353	 	_	
11-29	2353-2355	of	_	
11-30	2356-2367	individuals	_	
11-31	2368-2378	exhibiting	_	
11-32	2379-2386	alcohol	_	
11-33	2387-2397	dependence	_	
11-34	2398-2404	within	_	
11-35	2405-2407	10	_	
11-36	2407-2408	 	_	
11-37	2408-2413	years	_	
11-38	2414-2416	of	_	
11-39	2417-2422	onset	_	
11-40	2422-2423	.	_	

#Text=The reasons for this increased vulnerability to alcohol effects in youth need to be clarified.
12-1	2424-2427	The	_	
12-2	2428-2435	reasons	_	
12-3	2436-2439	for	_	
12-4	2440-2444	this	_	
12-5	2445-2454	increased	_	
12-6	2455-2468	vulnerability	_	
12-7	2469-2471	to	_	
12-8	2472-2479	alcohol	_	
12-9	2480-2487	effects	_	
12-10	2488-2490	in	_	
12-11	2491-2496	youth	_	
12-12	2497-2501	need	_	
12-13	2502-2504	to	_	
12-14	2505-2507	be	_	
12-15	2508-2517	clarified	_	
12-16	2517-2518	.	_	

#Text=Important maturational changes in brain anatomy, connectivity, and function continue well into late adolescence.
13-1	2519-2528	Important	_	
13-2	2529-2541	maturational	_	
13-3	2542-2549	changes	_	
13-4	2550-2552	in	_	
13-5	2553-2558	brain	_	
13-6	2559-2566	anatomy	_	
13-7	2566-2567	,	_	
13-8	2568-2580	connectivity	_	
13-9	2580-2581	,	_	
13-10	2582-2585	and	_	
13-11	2586-2594	function	_	
13-12	2595-2603	continue	_	
13-13	2604-2608	well	_	
13-14	2609-2613	into	_	
13-15	2614-2618	late	_	
13-16	2619-2630	adolescence	_	
13-17	2630-2631	.	_	

#Text=Longitudinal empirical evidence suggests that brain maturation in both grey and white matter follows a postero-anterior trajectory across the cortex, where frontal areas, and white matter tracts that originate there, mature in parallel with higher order executive functional changes in later adolescence (e.g., inhibitory performance or working memory), relative to other, more basic cognitive functions (e.g., attention).
14-1	2632-2644	Longitudinal	_	
14-2	2645-2654	empirical	_	
14-3	2655-2663	evidence	_	
14-4	2664-2672	suggests	_	
14-5	2673-2677	that	_	
14-6	2678-2683	brain	_	
14-7	2684-2694	maturation	_	
14-8	2695-2697	in	_	
14-9	2698-2702	both	_	
14-10	2703-2707	grey	_	
14-11	2708-2711	and	_	
14-12	2712-2717	white	_	
14-13	2718-2724	matter	_	
14-14	2725-2732	follows	_	
14-15	2733-2734	a	_	
14-16	2735-2751	postero-anterior	_	
14-17	2752-2762	trajectory	_	
14-18	2763-2769	across	_	
14-19	2770-2773	the	_	
14-20	2774-2780	cortex	_	
14-21	2780-2781	,	_	
14-22	2782-2787	where	_	
14-23	2788-2795	frontal	_	
14-24	2796-2801	areas	_	
14-25	2801-2802	,	_	
14-26	2803-2806	and	_	
14-27	2807-2812	white	_	
14-28	2813-2819	matter	_	
14-29	2820-2826	tracts	_	
14-30	2827-2831	that	_	
14-31	2832-2841	originate	_	
14-32	2842-2847	there	_	
14-33	2847-2848	,	_	
14-34	2849-2855	mature	_	
14-35	2856-2858	in	_	
14-36	2859-2867	parallel	_	
14-37	2868-2872	with	_	
14-38	2873-2879	higher	_	
14-39	2880-2885	order	_	
14-40	2886-2895	executive	_	
14-41	2896-2906	functional	_	
14-42	2907-2914	changes	_	
14-43	2915-2917	in	_	
14-44	2918-2923	later	_	
14-45	2924-2935	adolescence	_	
14-46	2936-2937	(	_	
14-47	2937-2940	e.g	_	
14-48	2940-2941	.	_	
14-49	2941-2942	,	_	
14-50	2943-2953	inhibitory	_	
14-51	2954-2965	performance	_	
14-52	2966-2968	or	_	
14-53	2969-2976	working	_	
14-54	2977-2983	memory	_	
14-55	2983-2984	)	_	
14-56	2984-2985	,	_	
14-57	2986-2994	relative	_	
14-58	2995-2997	to	_	
14-59	2998-3003	other	_	
14-60	3003-3004	,	_	
14-61	3005-3009	more	_	
14-62	3010-3015	basic	_	
14-63	3016-3025	cognitive	_	
14-64	3026-3035	functions	_	
14-65	3036-3037	(	_	
14-66	3037-3040	e.g	_	
14-67	3040-3041	.	_	
14-68	3041-3042	,	_	
14-69	3043-3052	attention	_	
14-70	3052-3053	)	_	
14-71	3053-3054	.	_	

#Text=On a functional basis, there is preliminary evidence for the dual system model, in which top-down cognitive control networks develop linearly with age between childhood and adulthood, while the reward sensitivity system (striatum, medial and orbital prefrontal cortices) follows a non-linear maturation that eventually caps by mid-adolescence.
15-1	3055-3057	On	_	
15-2	3058-3059	a	_	
15-3	3060-3070	functional	_	
15-4	3071-3076	basis	_	
15-5	3076-3077	,	_	
15-6	3078-3083	there	_	
15-7	3084-3086	is	_	
15-8	3087-3098	preliminary	_	
15-9	3099-3107	evidence	_	
15-10	3108-3111	for	_	
15-11	3112-3115	the	_	
15-12	3116-3120	dual	_	
15-13	3121-3127	system	_	
15-14	3128-3133	model	_	
15-15	3133-3134	,	_	
15-16	3135-3137	in	_	
15-17	3138-3143	which	_	
15-18	3144-3152	top-down	_	
15-19	3153-3162	cognitive	_	
15-20	3163-3170	control	_	
15-21	3171-3179	networks	_	
15-22	3180-3187	develop	_	
15-23	3188-3196	linearly	_	
15-24	3197-3201	with	_	
15-25	3202-3205	age	_	
15-26	3206-3213	between	_	
15-27	3214-3223	childhood	_	
15-28	3224-3227	and	_	
15-29	3228-3237	adulthood	_	
15-30	3237-3238	,	_	
15-31	3239-3244	while	_	
15-32	3245-3248	the	_	
15-33	3249-3255	reward	_	
15-34	3256-3267	sensitivity	_	
15-35	3268-3274	system	_	
15-36	3275-3276	(	_	
15-37	3276-3284	striatum	_	
15-38	3284-3285	,	_	
15-39	3286-3292	medial	_	
15-40	3293-3296	and	_	
15-41	3297-3304	orbital	_	
15-42	3305-3315	prefrontal	_	
15-43	3316-3324	cortices	_	
15-44	3324-3325	)	_	
15-45	3326-3333	follows	_	
15-46	3334-3335	a	_	
15-47	3336-3346	non-linear	_	
15-48	3347-3357	maturation	_	
15-49	3358-3362	that	_	
15-50	3363-3373	eventually	_	
15-51	3374-3378	caps	_	
15-52	3379-3381	by	_	
15-53	3382-3397	mid-adolescence	_	
15-54	3397-3398	.	_	

#Text=When looking at the effects of alcohol misuse on brain maturation, neuropsychological studies in youth suggest that early alcohol abuse correlates with cognitive impairments in verbal, non-verbal and spatial working memory tasks, as well as attention and executive functions.
16-1	3399-3403	When	_	
16-2	3404-3411	looking	_	
16-3	3412-3414	at	_	
16-4	3415-3418	the	_	
16-5	3419-3426	effects	_	
16-6	3427-3429	of	_	
16-7	3430-3437	alcohol	_	
16-8	3438-3444	misuse	_	
16-9	3445-3447	on	_	
16-10	3448-3453	brain	_	
16-11	3454-3464	maturation	_	
16-12	3464-3465	,	_	
16-13	3466-3484	neuropsychological	_	
16-14	3485-3492	studies	_	
16-15	3493-3495	in	_	
16-16	3496-3501	youth	_	
16-17	3502-3509	suggest	_	
16-18	3510-3514	that	_	
16-19	3515-3520	early	_	
16-20	3521-3528	alcohol	_	
16-21	3529-3534	abuse	_	
16-22	3535-3545	correlates	_	
16-23	3546-3550	with	_	
16-24	3551-3560	cognitive	_	
16-25	3561-3572	impairments	_	
16-26	3573-3575	in	_	
16-27	3576-3582	verbal	_	
16-28	3582-3583	,	_	
16-29	3584-3594	non-verbal	_	
16-30	3595-3598	and	_	
16-31	3599-3606	spatial	_	
16-32	3607-3614	working	_	
16-33	3615-3621	memory	_	
16-34	3622-3627	tasks	_	
16-35	3627-3628	,	_	
16-36	3629-3631	as	_	
16-37	3632-3636	well	_	
16-38	3637-3639	as	_	
16-39	3640-3649	attention	_	
16-40	3650-3653	and	_	
16-41	3654-3663	executive	_	
16-42	3664-3673	functions	_	
16-43	3673-3674	.	_	

#Text=At the brain level, an association was found between smaller hippocampal volumes and early onset of alcohol dependence in adolescence, possibly accounting for the memory deficits noted above.
17-1	3675-3677	At	_	
17-2	3678-3681	the	_	
17-3	3682-3687	brain	_	
17-4	3688-3693	level	_	
17-5	3693-3694	,	_	
17-6	3695-3697	an	_	
17-7	3698-3709	association	_	
17-8	3710-3713	was	_	
17-9	3714-3719	found	_	
17-10	3720-3727	between	_	
17-11	3728-3735	smaller	_	
17-12	3736-3747	hippocampal	_	
17-13	3748-3755	volumes	_	
17-14	3756-3759	and	_	
17-15	3760-3765	early	_	
17-16	3766-3771	onset	_	
17-17	3772-3774	of	_	
17-18	3775-3782	alcohol	_	
17-19	3783-3793	dependence	_	
17-20	3794-3796	in	_	
17-21	3797-3808	adolescence	_	
17-22	3808-3809	,	_	
17-23	3810-3818	possibly	_	
17-24	3819-3829	accounting	_	
17-25	3830-3833	for	_	
17-26	3834-3837	the	_	
17-27	3838-3844	memory	_	
17-28	3845-3853	deficits	_	
17-29	3854-3859	noted	_	
17-30	3860-3865	above	_	
17-31	3865-3866	.	_	

#Text=Moreover, functional neuroimaging studies have detected abnormal brain activations in adolescents with an alcohol use disorder, relative to healthy volunteers, when they were tested during spatial working memory tasks even though task performance did not differ.
18-1	3867-3875	Moreover	_	
18-2	3875-3876	,	_	
18-3	3877-3887	functional	_	
18-4	3888-3900	neuroimaging	_	
18-5	3901-3908	studies	_	
18-6	3909-3913	have	_	
18-7	3914-3922	detected	_	
18-8	3923-3931	abnormal	_	
18-9	3932-3937	brain	_	
18-10	3938-3949	activations	_	
18-11	3950-3952	in	_	
18-12	3953-3964	adolescents	_	
18-13	3965-3969	with	_	
18-14	3970-3972	an	_	
18-15	3973-3980	alcohol	_	
18-16	3981-3984	use	_	
18-17	3985-3993	disorder	_	
18-18	3993-3994	,	_	
18-19	3995-4003	relative	_	
18-20	4004-4006	to	_	
18-21	4007-4014	healthy	_	
18-22	4015-4025	volunteers	_	
18-23	4025-4026	,	_	
18-24	4027-4031	when	_	
18-25	4032-4036	they	_	
18-26	4037-4041	were	_	
18-27	4042-4048	tested	_	
18-28	4049-4055	during	_	
18-29	4056-4063	spatial	_	
18-30	4064-4071	working	_	
18-31	4072-4078	memory	_	
18-32	4079-4084	tasks	_	
18-33	4085-4089	even	_	
18-34	4090-4096	though	_	
18-35	4097-4101	task	_	
18-36	4102-4113	performance	_	
18-37	4114-4117	did	_	
18-38	4118-4121	not	_	
18-39	4122-4128	differ	_	
18-40	4128-4129	.	_	

#Text=These findings suggest that the combination of neuroimaging with cognitive measures might be needed to capture the subtle developmental effects of adolescent onset alcohol misuse, which might translate to future addiction.
19-1	4130-4135	These	_	
19-2	4136-4144	findings	_	
19-3	4145-4152	suggest	_	
19-4	4153-4157	that	_	
19-5	4158-4161	the	_	
19-6	4162-4173	combination	_	
19-7	4174-4176	of	_	
19-8	4177-4189	neuroimaging	_	
19-9	4190-4194	with	_	
19-10	4195-4204	cognitive	_	
19-11	4205-4213	measures	_	
19-12	4214-4219	might	_	
19-13	4220-4222	be	_	
19-14	4223-4229	needed	_	
19-15	4230-4232	to	_	
19-16	4233-4240	capture	_	
19-17	4241-4244	the	_	
19-18	4245-4251	subtle	_	
19-19	4252-4265	developmental	_	
19-20	4266-4273	effects	_	
19-21	4274-4276	of	_	
19-22	4277-4287	adolescent	_	
19-23	4288-4293	onset	_	
19-24	4294-4301	alcohol	_	
19-25	4302-4308	misuse	_	
19-26	4308-4309	,	_	
19-27	4310-4315	which	_	
19-28	4316-4321	might	_	
19-29	4322-4331	translate	_	
19-30	4332-4334	to	_	
19-31	4335-4341	future	_	
19-32	4342-4351	addiction	_	
19-33	4351-4352	.	_	

#Text=Neurodevelopmental profiles of at-risk youth for alcoholism
#Text=Impulsivity (IMP)
#Text=Two major risk factors for adolescent onset of alcohol misuse are a family history of alcoholism and disinhibited psychopathology, both of which are characterized by a failure of self-control.
20-1	4353-4371	Neurodevelopmental	_	
20-2	4372-4380	profiles	_	
20-3	4381-4383	of	_	
20-4	4384-4391	at-risk	_	
20-5	4392-4397	youth	_	
20-6	4398-4401	for	_	
20-7	4402-4412	alcoholism	_	
20-8	4413-4424	Impulsivity	_	
20-9	4425-4426	(	_	
20-10	4426-4429	IMP	_	
20-11	4429-4430	)	_	
20-12	4431-4434	Two	_	
20-13	4435-4440	major	_	
20-14	4441-4445	risk	_	
20-15	4446-4453	factors	_	
20-16	4454-4457	for	_	
20-17	4458-4468	adolescent	_	
20-18	4469-4474	onset	_	
20-19	4475-4477	of	_	
20-20	4478-4485	alcohol	_	
20-21	4486-4492	misuse	_	
20-22	4493-4496	are	_	
20-23	4497-4498	a	_	
20-24	4499-4505	family	_	
20-25	4506-4513	history	_	
20-26	4514-4516	of	_	
20-27	4517-4527	alcoholism	_	
20-28	4528-4531	and	_	
20-29	4532-4544	disinhibited	_	
20-30	4545-4560	psychopathology	_	
20-31	4560-4561	,	_	
20-32	4562-4566	both	_	
20-33	4567-4569	of	_	
20-34	4570-4575	which	_	
20-35	4576-4579	are	_	
20-36	4580-4593	characterized	_	
20-37	4594-4596	by	_	
20-38	4597-4598	a	_	
20-39	4599-4606	failure	_	
20-40	4607-4609	of	_	
20-41	4610-4622	self-control	_	
20-42	4622-4623	.	_	

#Text=Various higher order cognitive functions that also involve inhibitory control, such as working memory and delay discounting, as well as their mediating fronto-striatal (inhibition), fronto-parietal (working memory) and striato-limbic (reward sensitivity) neural networks, are abnormal in children with disinhibited personalities and childhood disorders of impulsiveness.
21-1	4624-4631	Various	_	
21-2	4632-4638	higher	_	
21-3	4639-4644	order	_	
21-4	4645-4654	cognitive	_	
21-5	4655-4664	functions	_	
21-6	4665-4669	that	_	
21-7	4670-4674	also	_	
21-8	4675-4682	involve	_	
21-9	4683-4693	inhibitory	_	
21-10	4694-4701	control	_	
21-11	4701-4702	,	_	
21-12	4703-4707	such	_	
21-13	4708-4710	as	_	
21-14	4711-4718	working	_	
21-15	4719-4725	memory	_	
21-16	4726-4729	and	_	
21-17	4730-4735	delay	_	
21-18	4736-4747	discounting	_	
21-19	4747-4748	,	_	
21-20	4749-4751	as	_	
21-21	4752-4756	well	_	
21-22	4757-4759	as	_	
21-23	4760-4765	their	_	
21-24	4766-4775	mediating	_	
21-25	4776-4791	fronto-striatal	_	
21-26	4792-4793	(	_	
21-27	4793-4803	inhibition	_	
21-28	4803-4804	)	_	
21-29	4804-4805	,	_	
21-30	4806-4821	fronto-parietal	_	
21-31	4822-4823	(	_	
21-32	4823-4830	working	_	
21-33	4831-4837	memory	_	
21-34	4837-4838	)	_	
21-35	4839-4842	and	_	
21-36	4843-4857	striato-limbic	_	
21-37	4858-4859	(	_	
21-38	4859-4865	reward	_	
21-39	4866-4877	sensitivity	_	
21-40	4877-4878	)	_	
21-41	4879-4885	neural	_	
21-42	4886-4894	networks	_	
21-43	4894-4895	,	_	
21-44	4896-4899	are	_	
21-45	4900-4908	abnormal	_	
21-46	4909-4911	in	_	
21-47	4912-4920	children	_	
21-48	4921-4925	with	_	
21-49	4926-4938	disinhibited	_	
21-50	4939-4952	personalities	_	
21-51	4953-4956	and	_	
21-52	4957-4966	childhood	_	
21-53	4967-4976	disorders	_	
21-54	4977-4979	of	_	
21-55	4980-4993	impulsiveness	_	
21-56	4993-4994	.	_	

#Text=Our team recently reported that IMP in 14-year olds is inversely associated with grey matter volume in the orbitofrontal cortex and reduced activity within bilateral frontal brain regions during failed inhibition.
22-1	4995-4998	Our	_	
22-2	4999-5003	team	_	
22-3	5004-5012	recently	_	
22-4	5013-5021	reported	_	
22-5	5022-5026	that	_	
22-6	5027-5030	IMP	_	
22-7	5031-5033	in	_	
22-8	5034-5036	14	_	
22-9	5036-5037	-	_	
22-10	5037-5041	year	_	
22-11	5042-5046	olds	_	
22-12	5047-5049	is	_	
22-13	5050-5059	inversely	_	
22-14	5060-5070	associated	_	
22-15	5071-5075	with	_	
22-16	5076-5080	grey	_	
22-17	5081-5087	matter	_	
22-18	5088-5094	volume	_	
22-19	5095-5097	in	_	
22-20	5098-5101	the	_	
22-21	5102-5115	orbitofrontal	_	
22-22	5116-5122	cortex	_	
22-23	5123-5126	and	_	
22-24	5127-5134	reduced	_	
22-25	5135-5143	activity	_	
22-26	5144-5150	within	_	
22-27	5151-5160	bilateral	_	
22-28	5161-5168	frontal	_	
22-29	5169-5174	brain	_	
22-30	5175-5182	regions	_	
22-31	5183-5189	during	_	
22-32	5190-5196	failed	_	
22-33	5197-5207	inhibition	_	
22-34	5207-5208	.	_	

#Text=Furthermore, IMP and brain-related measures during failures of inhibition were prospectively predictive of substance misuse and disinhibited psychopathology over a two-year period in adolescence.
23-1	5209-5220	Furthermore	_	
23-2	5220-5221	,	_	
23-3	5222-5225	IMP	_	
23-4	5226-5229	and	_	
23-5	5230-5243	brain-related	_	
23-6	5244-5252	measures	_	
23-7	5253-5259	during	_	
23-8	5260-5268	failures	_	
23-9	5269-5271	of	_	
23-10	5272-5282	inhibition	_	
23-11	5283-5287	were	_	
23-12	5288-5301	prospectively	_	
23-13	5302-5312	predictive	_	
23-14	5313-5315	of	_	
23-15	5316-5325	substance	_	
23-16	5326-5332	misuse	_	
23-17	5333-5336	and	_	
23-18	5337-5349	disinhibited	_	
23-19	5350-5365	psychopathology	_	
23-20	5366-5370	over	_	
23-21	5371-5372	a	_	
23-22	5373-5381	two-year	_	
23-23	5382-5388	period	_	
23-24	5389-5391	in	_	
23-25	5392-5403	adolescence	_	
23-26	5403-5404	.	_	

#Text=Finally, there is some preliminary evidence for an interaction effect, suggesting that individuals prone to alcohol dependence, due to family history of alcoholism, are particularly susceptible to the effects of alcohol on global cognitive function.
24-1	5405-5412	Finally	_	
24-2	5412-5413	,	_	
24-3	5414-5419	there	_	
24-4	5420-5422	is	_	
24-5	5423-5427	some	_	
24-6	5428-5439	preliminary	_	
24-7	5440-5448	evidence	_	
24-8	5449-5452	for	_	
24-9	5453-5455	an	_	
24-10	5456-5467	interaction	_	
24-11	5468-5474	effect	_	
24-12	5474-5475	,	_	
24-13	5476-5486	suggesting	_	
24-14	5487-5491	that	_	
24-15	5492-5503	individuals	_	
24-16	5504-5509	prone	_	
24-17	5510-5512	to	_	
24-18	5513-5520	alcohol	_	
24-19	5521-5531	dependence	_	
24-20	5531-5532	,	_	
24-21	5533-5536	due	_	
24-22	5537-5539	to	_	
24-23	5540-5546	family	_	
24-24	5547-5554	history	_	
24-25	5555-5557	of	_	
24-26	5558-5568	alcoholism	_	
24-27	5568-5569	,	_	
24-28	5570-5573	are	_	
24-29	5574-5586	particularly	_	
24-30	5587-5598	susceptible	_	
24-31	5599-5601	to	_	
24-32	5602-5605	the	_	
24-33	5606-5613	effects	_	
24-34	5614-5616	of	_	
24-35	5617-5624	alcohol	_	
24-36	5625-5627	on	_	
24-37	5628-5634	global	_	
24-38	5635-5644	cognitive	_	
24-39	5645-5653	function	_	
24-40	5653-5654	.	_	

#Text=Sensation seeking (SS)
#Text=The desire for intense and novel experiences, or SS, is associated with risk-taking and reckless behavior among youth, with heavier drinking and with risk for adverse drinking consequences.
25-1	5655-5664	Sensation	_	
25-2	5665-5672	seeking	_	
25-3	5673-5674	(	_	
25-4	5674-5676	SS	_	
25-5	5676-5677	)	_	
25-6	5678-5681	The	_	
25-7	5682-5688	desire	_	
25-8	5689-5692	for	_	
25-9	5693-5700	intense	_	
25-10	5701-5704	and	_	
25-11	5705-5710	novel	_	
25-12	5711-5722	experiences	_	
25-13	5722-5723	,	_	
25-14	5724-5726	or	_	
25-15	5727-5729	SS	_	
25-16	5729-5730	,	_	
25-17	5731-5733	is	_	
25-18	5734-5744	associated	_	
25-19	5745-5749	with	_	
25-20	5750-5761	risk-taking	_	
25-21	5762-5765	and	_	
25-22	5766-5774	reckless	_	
25-23	5775-5783	behavior	_	
25-24	5784-5789	among	_	
25-25	5790-5795	youth	_	
25-26	5795-5796	,	_	
25-27	5797-5801	with	_	
25-28	5802-5809	heavier	_	
25-29	5810-5818	drinking	_	
25-30	5819-5822	and	_	
25-31	5823-5827	with	_	
25-32	5828-5832	risk	_	
25-33	5833-5836	for	_	
25-34	5837-5844	adverse	_	
25-35	5845-5853	drinking	_	
25-36	5854-5866	consequences	_	
25-37	5866-5867	.	_	

#Text=We recently reported that SS is associated with a pattern of responding to cognitive/motivational tasks that involves a sensitivity to reward that is predictive of binge drinking over and above the contribution of co-occurring conduct problems.
26-1	5868-5870	We	_	
26-2	5871-5879	recently	_	
26-3	5880-5888	reported	_	
26-4	5889-5893	that	_	
26-5	5894-5896	SS	_	
26-6	5897-5899	is	_	
26-7	5900-5910	associated	_	
26-8	5911-5915	with	_	
26-9	5916-5917	a	_	
26-10	5918-5925	pattern	_	
26-11	5926-5928	of	_	
26-12	5929-5939	responding	_	
26-13	5940-5942	to	_	
26-14	5943-5952	cognitive	_	
26-15	5952-5953	/	_	
26-16	5953-5965	motivational	_	
26-17	5966-5971	tasks	_	
26-18	5972-5976	that	_	
26-19	5977-5985	involves	_	
26-20	5986-5987	a	_	
26-21	5988-5999	sensitivity	_	
26-22	6000-6002	to	_	
26-23	6003-6009	reward	_	
26-24	6010-6014	that	_	
26-25	6015-6017	is	_	
26-26	6018-6028	predictive	_	
26-27	6029-6031	of	_	
26-28	6032-6037	binge	_	
26-29	6038-6046	drinking	_	
26-30	6047-6051	over	_	
26-31	6052-6055	and	_	
26-32	6056-6061	above	_	
26-33	6062-6065	the	_	
26-34	6066-6078	contribution	_	
26-35	6079-6081	of	_	
26-36	6082-6094	co-occurring	_	
26-37	6095-6102	conduct	_	
26-38	6103-6111	problems	_	
26-39	6111-6112	.	_	

#Text=SS and IMP appear to differentiate adolescent substance use behavior: SS is associated with early onset use, binge drinking and drug experimentation, but IMP is associated with higher quantity of use after substance use onset.
27-1	6113-6115	SS	_	
27-2	6116-6119	and	_	
27-3	6120-6123	IMP	_	
27-4	6124-6130	appear	_	
27-5	6131-6133	to	_	
27-6	6134-6147	differentiate	_	
27-7	6148-6158	adolescent	_	
27-8	6159-6168	substance	_	
27-9	6169-6172	use	_	
27-10	6173-6181	behavior	_	
27-11	6181-6182	:	_	
27-12	6183-6185	SS	_	
27-13	6186-6188	is	_	
27-14	6189-6199	associated	_	
27-15	6200-6204	with	_	
27-16	6205-6210	early	_	
27-17	6211-6216	onset	_	
27-18	6217-6220	use	_	
27-19	6220-6221	,	_	
27-20	6222-6227	binge	_	
27-21	6228-6236	drinking	_	
27-22	6237-6240	and	_	
27-23	6241-6245	drug	_	
27-24	6246-6261	experimentation	_	
27-25	6261-6262	,	_	
27-26	6263-6266	but	_	
27-27	6267-6270	IMP	_	
27-28	6271-6273	is	_	
27-29	6274-6284	associated	_	
27-30	6285-6289	with	_	
27-31	6290-6296	higher	_	
27-32	6297-6305	quantity	_	
27-33	6306-6308	of	_	
27-34	6309-6312	use	_	
27-35	6313-6318	after	_	
27-36	6319-6328	substance	_	
27-37	6329-6332	use	_	
27-38	6333-6338	onset	_	
27-39	6338-6339	.	_	

#Text=At the neurobiological level, we also showed that these clinical profiles could be dissociated using brain activation patterns during failed response inhibition (IMP) vs. response to reward anticipation (SS).
28-1	6340-6342	At	_	
28-2	6343-6346	the	_	
28-3	6347-6362	neurobiological	_	
28-4	6363-6368	level	_	
28-5	6368-6369	,	_	
28-6	6370-6372	we	_	
28-7	6373-6377	also	_	
28-8	6378-6384	showed	_	
28-9	6385-6389	that	_	
28-10	6390-6395	these	_	
28-11	6396-6404	clinical	_	
28-12	6405-6413	profiles	_	
28-13	6414-6419	could	_	
28-14	6420-6422	be	_	
28-15	6423-6434	dissociated	_	
28-16	6435-6440	using	_	
28-17	6441-6446	brain	_	
28-18	6447-6457	activation	_	
28-19	6458-6466	patterns	_	
28-20	6467-6473	during	_	
28-21	6474-6480	failed	_	
28-22	6481-6489	response	_	
28-23	6490-6500	inhibition	_	
28-24	6501-6502	(	_	
28-25	6502-6505	IMP	_	
28-26	6505-6506	)	_	
28-27	6507-6509	vs	_	
28-28	6509-6510	.	_	
28-29	6511-6519	response	_	
28-30	6520-6522	to	_	
28-31	6523-6529	reward	_	
28-32	6530-6542	anticipation	_	
28-33	6543-6544	(	_	
28-34	6544-6546	SS	_	
28-35	6546-6547	)	_	
28-36	6547-6548	.	_	

#Text=Existing neuroimaging studies with high-risk adolescents are, for the most part, cross-sectional, so it remains unclear whether the structural and functional deficits attributed to the effects of alcohol misuse exist in individuals at risk for alcoholism prior to the onset of alcohol misuse or if early onset use causes the development of new deficits over and above existing neurocognitive abnormalities, or in interaction with such abnormalities.
29-1	6549-6557	Existing	_	
29-2	6558-6570	neuroimaging	_	
29-3	6571-6578	studies	_	
29-4	6579-6583	with	_	
29-5	6584-6593	high-risk	_	
29-6	6594-6605	adolescents	_	
29-7	6606-6609	are	_	
29-8	6609-6610	,	_	
29-9	6611-6614	for	_	
29-10	6615-6618	the	_	
29-11	6619-6623	most	_	
29-12	6624-6628	part	_	
29-13	6628-6629	,	_	
29-14	6630-6645	cross-sectional	_	
29-15	6645-6646	,	_	
29-16	6647-6649	so	_	
29-17	6650-6652	it	_	
29-18	6653-6660	remains	_	
29-19	6661-6668	unclear	_	
29-20	6669-6676	whether	_	
29-21	6677-6680	the	_	
29-22	6681-6691	structural	_	
29-23	6692-6695	and	_	
29-24	6696-6706	functional	_	
29-25	6707-6715	deficits	_	
29-26	6716-6726	attributed	_	
29-27	6727-6729	to	_	
29-28	6730-6733	the	_	
29-29	6734-6741	effects	_	
29-30	6742-6744	of	_	
29-31	6745-6752	alcohol	_	
29-32	6753-6759	misuse	_	
29-33	6760-6765	exist	_	
29-34	6766-6768	in	_	
29-35	6769-6780	individuals	_	
29-36	6781-6783	at	_	
29-37	6784-6788	risk	_	
29-38	6789-6792	for	_	
29-39	6793-6803	alcoholism	_	
29-40	6804-6809	prior	_	
29-41	6810-6812	to	_	
29-42	6813-6816	the	_	
29-43	6817-6822	onset	_	
29-44	6823-6825	of	_	
29-45	6826-6833	alcohol	_	
29-46	6834-6840	misuse	_	
29-47	6841-6843	or	_	
29-48	6844-6846	if	_	
29-49	6847-6852	early	_	
29-50	6853-6858	onset	_	
29-51	6859-6862	use	_	
29-52	6863-6869	causes	_	
29-53	6870-6873	the	_	
29-54	6874-6885	development	_	
29-55	6886-6888	of	_	
29-56	6889-6892	new	_	
29-57	6893-6901	deficits	_	
29-58	6902-6906	over	_	
29-59	6907-6910	and	_	
29-60	6911-6916	above	_	
29-61	6917-6925	existing	_	
29-62	6926-6940	neurocognitive	_	
29-63	6941-6954	abnormalities	_	
29-64	6954-6955	,	_	
29-65	6956-6958	or	_	
29-66	6959-6961	in	_	
29-67	6962-6973	interaction	_	
29-68	6974-6978	with	_	
29-69	6979-6983	such	_	
29-70	6984-6997	abnormalities	_	
29-71	6997-6998	.	_	

#Text=The Preventure Programme
#Text=The Preventure Programme is a school-based alcohol prevention programme targeting four specific personality risk factors for adolescent alcohol misuse: impulsivity, sensation seeking, hopelessness and anxiety sensitivity.
30-1	6999-7002	The	_	
30-2	7003-7013	Preventure	_	
30-3	7014-7023	Programme	_	
30-4	7024-7027	The	_	
30-5	7028-7038	Preventure	_	
30-6	7039-7048	Programme	_	
30-7	7049-7051	is	_	
30-8	7052-7053	a	_	
30-9	7054-7066	school-based	_	
30-10	7067-7074	alcohol	_	
30-11	7075-7085	prevention	_	
30-12	7086-7095	programme	_	
30-13	7096-7105	targeting	_	
30-14	7106-7110	four	_	
30-15	7111-7119	specific	_	
30-16	7120-7131	personality	_	
30-17	7132-7136	risk	_	
30-18	7137-7144	factors	_	
30-19	7145-7148	for	_	
30-20	7149-7159	adolescent	_	
30-21	7160-7167	alcohol	_	
30-22	7168-7174	misuse	_	
30-23	7174-7175	:	_	
30-24	7176-7187	impulsivity	_	
30-25	7187-7188	,	_	
30-26	7189-7198	sensation	_	
30-27	7199-7206	seeking	_	
30-28	7206-7207	,	_	
30-29	7208-7220	hopelessness	_	
30-30	7221-7224	and	_	
30-31	7225-7232	anxiety	_	
30-32	7233-7244	sensitivity	_	
30-33	7244-7245	.	_	

#Text=The Substance Use Risk Profile Scale (SURPS) has been developed by our team to enable us to identify high-risk youth based on these personality risk dimensions.
31-1	7246-7249	The	_	
31-2	7250-7259	Substance	_	
31-3	7260-7263	Use	_	
31-4	7264-7268	Risk	_	
31-5	7269-7276	Profile	_	
31-6	7277-7282	Scale	_	
31-7	7283-7284	(	_	
31-8	7284-7289	SURPS	_	
31-9	7289-7290	)	_	
31-10	7291-7294	has	_	
31-11	7295-7299	been	_	
31-12	7300-7309	developed	_	
31-13	7310-7312	by	_	
31-14	7313-7316	our	_	
31-15	7317-7321	team	_	
31-16	7322-7324	to	_	
31-17	7325-7331	enable	_	
31-18	7332-7334	us	_	
31-19	7335-7337	to	_	
31-20	7338-7346	identify	_	
31-21	7347-7356	high-risk	_	
31-22	7357-7362	youth	_	
31-23	7363-7368	based	_	
31-24	7369-7371	on	_	
31-25	7372-7377	these	_	
31-26	7378-7389	personality	_	
31-27	7390-7394	risk	_	
31-28	7395-7405	dimensions	_	
31-29	7405-7406	.	_	

#Text=The intervention programme, based on a cognitive-behavioral model, involves delivering two 90-min group sessions to adolescents who screen positive on one of these four personality traits in school screening.
32-1	7407-7410	The	_	
32-2	7411-7423	intervention	_	
32-3	7424-7433	programme	_	
32-4	7433-7434	,	_	
32-5	7435-7440	based	_	
32-6	7441-7443	on	_	
32-7	7444-7445	a	_	
32-8	7446-7466	cognitive-behavioral	_	
32-9	7467-7472	model	_	
32-10	7472-7473	,	_	
32-11	7474-7482	involves	_	
32-12	7483-7493	delivering	_	
32-13	7494-7497	two	_	
32-14	7498-7500	90	_	
32-15	7500-7501	-	_	
32-16	7501-7504	min	_	
32-17	7505-7510	group	_	
32-18	7511-7519	sessions	_	
32-19	7520-7522	to	_	
32-20	7523-7534	adolescents	_	
32-21	7535-7538	who	_	
32-22	7539-7545	screen	_	
32-23	7546-7554	positive	_	
32-24	7555-7557	on	_	
32-25	7558-7561	one	_	
32-26	7562-7564	of	_	
32-27	7565-7570	these	_	
32-28	7571-7575	four	_	
32-29	7576-7587	personality	_	
32-30	7588-7594	traits	_	
32-31	7595-7597	in	_	
32-32	7598-7604	school	_	
32-33	7605-7614	screening	_	
32-34	7614-7615	.	_	

#Text=Five randomized controlled trials with high school students revealed that personality-targeted interventions reduce rates of drinking and binge drinking by up to 50%, and these effects have been shown to last up to 3 years.
33-1	7616-7620	Five	_	
33-2	7621-7631	randomized	_	
33-3	7632-7642	controlled	_	
33-4	7643-7649	trials	_	
33-5	7650-7654	with	_	
33-6	7655-7659	high	_	
33-7	7660-7666	school	_	
33-8	7667-7675	students	_	
33-9	7676-7684	revealed	_	
33-10	7685-7689	that	_	
33-11	7690-7710	personality-targeted	_	
33-12	7711-7724	interventions	_	
33-13	7725-7731	reduce	_	
33-14	7732-7737	rates	_	
33-15	7738-7740	of	_	
33-16	7741-7749	drinking	_	
33-17	7750-7753	and	_	
33-18	7754-7759	binge	_	
33-19	7760-7768	drinking	_	
33-20	7769-7771	by	_	
33-21	7772-7774	up	_	
33-22	7775-7777	to	_	
33-23	7778-7781	50%	_	
33-24	7781-7782	,	_	
33-25	7783-7786	and	_	
33-26	7787-7792	these	_	
33-27	7793-7800	effects	_	
33-28	7801-7805	have	_	
33-29	7806-7810	been	_	
33-30	7811-7816	shown	_	
33-31	7817-7819	to	_	
33-32	7820-7824	last	_	
33-33	7825-7827	up	_	
33-34	7828-7830	to	_	
33-35	7831-7832	3	_	
33-36	7832-7833	 	_	
33-37	7833-7838	years	_	
33-38	7838-7839	.	_	

#Text=Despite these very promising findings, these outcomes may underestimate the true benefits of early intervention as our previous evaluations did not assess brain function and maturation.
34-1	7840-7847	Despite	_	
34-2	7848-7853	these	_	
34-3	7854-7858	very	_	
34-4	7859-7868	promising	_	
34-5	7869-7877	findings	_	
34-6	7877-7878	,	_	
34-7	7879-7884	these	_	
34-8	7885-7893	outcomes	_	
34-9	7894-7897	may	_	
34-10	7898-7911	underestimate	_	
34-11	7912-7915	the	_	
34-12	7916-7920	true	_	
34-13	7921-7929	benefits	_	
34-14	7930-7932	of	_	
34-15	7933-7938	early	_	
34-16	7939-7951	intervention	_	
34-17	7952-7954	as	_	
34-18	7955-7958	our	_	
34-19	7959-7967	previous	_	
34-20	7968-7979	evaluations	_	
34-21	7980-7983	did	_	
34-22	7984-7987	not	_	
34-23	7988-7994	assess	_	
34-24	7995-8000	brain	_	
34-25	8001-8009	function	_	
34-26	8010-8013	and	_	
34-27	8014-8024	maturation	_	
34-28	8024-8025	.	_	

#Text=Methods
#Text=Objectives and hypotheses
#Text=Compare high-risk (IMP and SS) and low-risk youth on measures of brain structure and function to quantify neurocognitive endophenotypes of these two risk profiles prior to exposure to alcohol in adolescence.
35-1	8026-8033	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[18]|http://www.case.edu/ProvCaRe/provcare#StudyMethod[19]	
35-2	8034-8044	Objectives	http://www.case.edu/ProvCaRe/provcare#StudyMethod[18]	
35-3	8045-8048	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[18]	
35-4	8049-8059	hypotheses	http://www.case.edu/ProvCaRe/provcare#StudyMethod[18]	
35-5	8060-8067	Compare	_	
35-6	8068-8077	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[21]	
35-7	8078-8079	(	_	
35-8	8079-8082	IMP	_	
35-9	8083-8086	and	_	
35-10	8087-8089	SS	_	
35-11	8089-8090	)	_	
35-12	8091-8094	and	_	
35-13	8095-8103	low-risk	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]|http://maven.renci.org/NeuroBridge/neurobridge#LowRisk[23]	
35-14	8104-8109	youth	_	
35-15	8110-8112	on	_	
35-16	8113-8121	measures	_	
35-17	8122-8124	of	_	
35-18	8125-8130	brain	_	
35-19	8131-8140	structure	_	
35-20	8141-8144	and	_	
35-21	8145-8153	function	_	
35-22	8154-8156	to	_	
35-23	8157-8165	quantify	_	
35-24	8166-8180	neurocognitive	_	
35-25	8181-8195	endophenotypes	_	
35-26	8196-8198	of	_	
35-27	8199-8204	these	_	
35-28	8205-8208	two	_	
35-29	8209-8213	risk	_	
35-30	8214-8222	profiles	_	
35-31	8223-8228	prior	_	
35-32	8229-8231	to	_	
35-33	8232-8240	exposure	_	
35-34	8241-8243	to	_	
35-35	8244-8251	alcohol	_	
35-36	8252-8254	in	_	
35-37	8255-8266	adolescence	_	
35-38	8266-8267	.	_	

#Text=We expect to observe impaired fronto-striatal connectivity and function during response inhibition in IMP as well as altered function of frontal and sub-cortical regions (i.e., basal ganglia and ventral striatum) during reward anticipation in SS.
36-1	8268-8270	We	_	
36-2	8271-8277	expect	_	
36-3	8278-8280	to	_	
36-4	8281-8288	observe	_	
36-5	8289-8297	impaired	_	
36-6	8298-8313	fronto-striatal	_	
36-7	8314-8326	connectivity	_	
36-8	8327-8330	and	_	
36-9	8331-8339	function	_	
36-10	8340-8346	during	_	
36-11	8347-8355	response	_	
36-12	8356-8366	inhibition	_	
36-13	8367-8369	in	_	
36-14	8370-8373	IMP	_	
36-15	8374-8376	as	_	
36-16	8377-8381	well	_	
36-17	8382-8384	as	_	
36-18	8385-8392	altered	_	
36-19	8393-8401	function	_	
36-20	8402-8404	of	_	
36-21	8405-8412	frontal	_	
36-22	8413-8416	and	_	
36-23	8417-8429	sub-cortical	_	
36-24	8430-8437	regions	_	
36-25	8438-8439	(	_	
36-26	8439-8442	i.e	_	
36-27	8442-8443	.	_	
36-28	8443-8444	,	_	
36-29	8445-8450	basal	_	
36-30	8451-8458	ganglia	_	
36-31	8459-8462	and	_	
36-32	8463-8470	ventral	_	
36-33	8471-8479	striatum	_	
36-34	8479-8480	)	_	
36-35	8481-8487	during	_	
36-36	8488-8494	reward	_	
36-37	8495-8507	anticipation	_	
36-38	8508-8510	in	_	
36-39	8511-8513	SS	_	
36-40	8513-8514	.	_	

#Text=Measure the correlates of adolescent drinking and binge drinking on the development of brain structure and function in adolescence, controlling for baseline differences in personality, cognitive profiles, and neural measures that are implicated in the predisposition to early onset alcohol misuse.
37-1	8515-8522	Measure	_	
37-2	8523-8526	the	_	
37-3	8527-8537	correlates	_	
37-4	8538-8540	of	_	
37-5	8541-8551	adolescent	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[24]	
37-6	8552-8560	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[24]	
37-7	8561-8564	and	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[24]	
37-8	8565-8570	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[24]	
37-9	8571-8579	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[24]	
37-10	8580-8582	on	_	
37-11	8583-8586	the	_	
37-12	8587-8598	development	_	
37-13	8599-8601	of	_	
37-14	8602-8607	brain	_	
37-15	8608-8617	structure	_	
37-16	8618-8621	and	_	
37-17	8622-8630	function	_	
37-18	8631-8633	in	_	
37-19	8634-8645	adolescence	_	
37-20	8645-8646	,	_	
37-21	8647-8658	controlling	_	
37-22	8659-8662	for	_	
37-23	8663-8671	baseline	_	
37-24	8672-8683	differences	_	
37-25	8684-8686	in	_	
37-26	8687-8698	personality	_	
37-27	8698-8699	,	_	
37-28	8700-8709	cognitive	_	
37-29	8710-8718	profiles	_	
37-30	8718-8719	,	_	
37-31	8720-8723	and	_	
37-32	8724-8730	neural	_	
37-33	8731-8739	measures	_	
37-34	8740-8744	that	_	
37-35	8745-8748	are	_	
37-36	8749-8759	implicated	_	
37-37	8760-8762	in	_	
37-38	8763-8766	the	_	
37-39	8767-8781	predisposition	_	
37-40	8782-8784	to	_	
37-41	8785-8790	early	_	
37-42	8791-8796	onset	_	
37-43	8797-8804	alcohol	_	
37-44	8805-8811	misuse	_	
37-45	8811-8812	.	_	

#Text=By comparing youth who take up drinking to those who do not (regardless of intervention status), we will test the extent to which binge drinking trajectories are associated with delayed or altered development of fronto-striatal and fronto-limbic networks that mediate response inhibition and anticipation of reward/punishment.
38-1	8813-8815	By	_	
38-2	8816-8825	comparing	_	
38-3	8826-8831	youth	_	
38-4	8832-8835	who	_	
38-5	8836-8840	take	_	
38-6	8841-8843	up	_	
38-7	8844-8852	drinking	_	
38-8	8853-8855	to	_	
38-9	8856-8861	those	_	
38-10	8862-8865	who	_	
38-11	8866-8868	do	_	
38-12	8869-8872	not	_	
38-13	8873-8874	(	_	
38-14	8874-8884	regardless	_	
38-15	8885-8887	of	_	
38-16	8888-8900	intervention	_	
38-17	8901-8907	status	_	
38-18	8907-8908	)	_	
38-19	8908-8909	,	_	
38-20	8910-8912	we	_	
38-21	8913-8917	will	_	
38-22	8918-8922	test	_	
38-23	8923-8926	the	_	
38-24	8927-8933	extent	_	
38-25	8934-8936	to	_	
38-26	8937-8942	which	_	
38-27	8943-8948	binge	_	
38-28	8949-8957	drinking	_	
38-29	8958-8970	trajectories	_	
38-30	8971-8974	are	_	
38-31	8975-8985	associated	_	
38-32	8986-8990	with	_	
38-33	8991-8998	delayed	_	
38-34	8999-9001	or	_	
38-35	9002-9009	altered	_	
38-36	9010-9021	development	_	
38-37	9022-9024	of	_	
38-38	9025-9040	fronto-striatal	_	
38-39	9041-9044	and	_	
38-40	9045-9058	fronto-limbic	_	
38-41	9059-9067	networks	_	
38-42	9068-9072	that	_	
38-43	9073-9080	mediate	_	
38-44	9081-9089	response	_	
38-45	9090-9100	inhibition	_	
38-46	9101-9104	and	_	
38-47	9105-9117	anticipation	_	
38-48	9118-9120	of	_	
38-49	9121-9127	reward	_	
38-50	9127-9128	/	_	
38-51	9128-9138	punishment	_	
38-52	9138-9139	.	_	

#Text=Three hypotheses will be examined. i) Global effects: abnormalities will be observed systematically across all measures of brain function and structure, ii) Developmental specificity: alcohol-induced abnormalities will be specific to regions and cognitive processes that are maturing in adolescence, and iii) Interaction effect: alcohol will exacerbate the abnormalities shown to characterize each high-risk group at baseline.
39-1	9140-9145	Three	_	
39-2	9146-9156	hypotheses	_	
39-3	9157-9161	will	_	
39-4	9162-9164	be	_	
39-5	9165-9173	examined	_	
39-6	9173-9174	.	_	
39-7	9175-9176	i	_	
39-8	9176-9177	)	_	
39-9	9178-9184	Global	_	
39-10	9185-9192	effects	_	
39-11	9192-9193	:	_	
39-12	9194-9207	abnormalities	_	
39-13	9208-9212	will	_	
39-14	9213-9215	be	_	
39-15	9216-9224	observed	_	
39-16	9225-9239	systematically	_	
39-17	9240-9246	across	_	
39-18	9247-9250	all	_	
39-19	9251-9259	measures	_	
39-20	9260-9262	of	_	
39-21	9263-9268	brain	_	
39-22	9269-9277	function	_	
39-23	9278-9281	and	_	
39-24	9282-9291	structure	_	
39-25	9291-9292	,	_	
39-26	9293-9295	ii	_	
39-27	9295-9296	)	_	
39-28	9297-9310	Developmental	_	
39-29	9311-9322	specificity	_	
39-30	9322-9323	:	_	
39-31	9324-9339	alcohol-induced	_	
39-32	9340-9353	abnormalities	_	
39-33	9354-9358	will	_	
39-34	9359-9361	be	_	
39-35	9362-9370	specific	_	
39-36	9371-9373	to	_	
39-37	9374-9381	regions	_	
39-38	9382-9385	and	_	
39-39	9386-9395	cognitive	_	
39-40	9396-9405	processes	_	
39-41	9406-9410	that	_	
39-42	9411-9414	are	_	
39-43	9415-9423	maturing	_	
39-44	9424-9426	in	_	
39-45	9427-9438	adolescence	_	
39-46	9438-9439	,	_	
39-47	9440-9443	and	_	
39-48	9444-9447	iii	_	
39-49	9447-9448	)	_	
39-50	9449-9460	Interaction	_	
39-51	9461-9467	effect	_	
39-52	9467-9468	:	_	
39-53	9469-9476	alcohol	_	
39-54	9477-9481	will	_	
39-55	9482-9492	exacerbate	_	
39-56	9493-9496	the	_	
39-57	9497-9510	abnormalities	_	
39-58	9511-9516	shown	_	
39-59	9517-9519	to	_	
39-60	9520-9532	characterize	_	
39-61	9533-9537	each	_	
39-62	9538-9547	high-risk	_	
39-63	9548-9553	group	_	
39-64	9554-9556	at	_	
39-65	9557-9565	baseline	_	
39-66	9565-9566	.	_	

#Text=Test causal hypotheses by testing whether delaying drinking (through the Preventure Programme) can produce observable protective effects on structural and functional brain development.
40-1	9567-9571	Test	_	
40-2	9572-9578	causal	_	
40-3	9579-9589	hypotheses	_	
40-4	9590-9592	by	_	
40-5	9593-9600	testing	_	
40-6	9601-9608	whether	_	
40-7	9609-9617	delaying	_	
40-8	9618-9626	drinking	_	
40-9	9627-9628	(	_	
40-10	9628-9635	through	_	
40-11	9636-9639	the	_	
40-12	9640-9650	Preventure	_	
40-13	9651-9660	Programme	_	
40-14	9660-9661	)	_	
40-15	9662-9665	can	_	
40-16	9666-9673	produce	_	
40-17	9674-9684	observable	_	
40-18	9685-9695	protective	_	
40-19	9696-9703	effects	_	
40-20	9704-9706	on	_	
40-21	9707-9717	structural	_	
40-22	9718-9721	and	_	
40-23	9722-9732	functional	_	
40-24	9733-9738	brain	_	
40-25	9739-9750	development	_	
40-26	9750-9751	.	_	

#Text=By comparing high-risk youth who received intervention to those who did not, we will estimate an intervention effect on structural and functional brain outcomes, which again might be expressed globally across the brain, or more specifically in those areas developing during adolescence or most abnormal in high-risk groups (as revealed in objective 1).
41-1	9752-9754	By	_	
41-2	9755-9764	comparing	_	
41-3	9765-9774	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
41-4	9775-9780	youth	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
41-5	9781-9784	who	_	
41-6	9785-9793	received	_	
41-7	9794-9806	intervention	_	
41-8	9807-9809	to	_	
41-9	9810-9815	those	_	
41-10	9816-9819	who	_	
41-11	9820-9823	did	_	
41-12	9824-9827	not	_	
41-13	9827-9828	,	_	
41-14	9829-9831	we	_	
41-15	9832-9836	will	_	
41-16	9837-9845	estimate	_	
41-17	9846-9848	an	_	
41-18	9849-9861	intervention	_	
41-19	9862-9868	effect	_	
41-20	9869-9871	on	_	
41-21	9872-9882	structural	_	
41-22	9883-9886	and	_	
41-23	9887-9897	functional	_	
41-24	9898-9903	brain	_	
41-25	9904-9912	outcomes	_	
41-26	9912-9913	,	_	
41-27	9914-9919	which	_	
41-28	9920-9925	again	_	
41-29	9926-9931	might	_	
41-30	9932-9934	be	_	
41-31	9935-9944	expressed	_	
41-32	9945-9953	globally	_	
41-33	9954-9960	across	_	
41-34	9961-9964	the	_	
41-35	9965-9970	brain	_	
41-36	9970-9971	,	_	
41-37	9972-9974	or	_	
41-38	9975-9979	more	_	
41-39	9980-9992	specifically	_	
41-40	9993-9995	in	_	
41-41	9996-10001	those	_	
41-42	10002-10007	areas	_	
41-43	10008-10018	developing	_	
41-44	10019-10025	during	_	
41-45	10026-10037	adolescence	_	
41-46	10038-10040	or	_	
41-47	10041-10045	most	_	
41-48	10046-10054	abnormal	_	
41-49	10055-10057	in	_	
41-50	10058-10067	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[28]	
41-51	10068-10074	groups	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[28]	
41-52	10075-10076	(	_	
41-53	10076-10078	as	_	
41-54	10079-10087	revealed	_	
41-55	10088-10090	in	_	
41-56	10091-10100	objective	_	
41-57	10101-10102	1	_	
41-58	10102-10103	)	_	
41-59	10103-10104	.	_	

#Text=In 2011, the Co-Venture Trial was funded by the Canadian Institutes of Health Research (CIHR) to test the 4-year impact of the Preventure programme on delaying early onset drinking and binge drinking in students as well as long-term addiction outcomes.
42-1	10105-10107	In	_	
42-2	10108-10112	2011	_	
42-3	10112-10113	,	_	
42-4	10114-10117	the	_	
42-5	10118-10128	Co-Venture	_	
42-6	10129-10134	Trial	_	
42-7	10135-10138	was	_	
42-8	10139-10145	funded	_	
42-9	10146-10148	by	_	
42-10	10149-10152	the	_	
42-11	10153-10161	Canadian	_	
42-12	10162-10172	Institutes	_	
42-13	10173-10175	of	_	
42-14	10176-10182	Health	_	
42-15	10183-10191	Research	_	
42-16	10192-10193	(	_	
42-17	10193-10197	CIHR	_	
42-18	10197-10198	)	_	
42-19	10199-10201	to	_	
42-20	10202-10206	test	_	
42-21	10207-10210	the	_	
42-22	10211-10212	4	_	
42-23	10212-10213	-	_	
42-24	10213-10217	year	_	
42-25	10218-10224	impact	_	
42-26	10225-10227	of	_	
42-27	10228-10231	the	_	
42-28	10232-10242	Preventure	_	
42-29	10243-10252	programme	_	
42-30	10253-10255	on	_	
42-31	10256-10264	delaying	_	
42-32	10265-10270	early	_	
42-33	10271-10276	onset	_	
42-34	10277-10285	drinking	_	
42-35	10286-10289	and	_	
42-36	10290-10295	binge	_	
42-37	10296-10304	drinking	_	
42-38	10305-10307	in	_	
42-39	10308-10316	students	_	
42-40	10317-10319	as	_	
42-41	10320-10324	well	_	
42-42	10325-10327	as	_	
42-43	10328-10337	long-term	_	
42-44	10338-10347	addiction	_	
42-45	10348-10356	outcomes	_	
42-46	10356-10357	.	_	

#Text=A subsequent CIHR grant was awarded for the Neuroventure study, allowing us to add longitudinal neuroimaging measures to test the following objectives/hypotheses: 
#Text=The Co-Venture Trial (from which the participants are recruited)
#Text=This study uses a cluster-randomized controlled design in which 31 schools (cluster) agreed to conduct annual surveys for 5 years with all consenting adolescents (N = 3826) who were enrolled in Grade 7 in September 2012.
43-1	10358-10359	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-2	10360-10370	subsequent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-3	10371-10375	CIHR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-4	10376-10381	grant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-5	10382-10385	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-6	10386-10393	awarded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-7	10394-10397	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-8	10398-10401	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-9	10402-10414	Neuroventure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-10	10415-10420	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-11	10420-10421	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-12	10422-10430	allowing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-13	10431-10433	us	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-14	10434-10436	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-15	10437-10440	add	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-16	10441-10453	longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-17	10454-10466	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-18	10467-10475	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-19	10476-10478	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-20	10479-10483	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-21	10484-10487	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-22	10488-10497	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-23	10498-10508	objectives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-24	10508-10509	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-25	10509-10519	hypotheses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-26	10519-10520	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-27	10522-10525	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-28	10526-10536	Co-Venture	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-29	10537-10542	Trial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-30	10543-10544	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-31	10544-10548	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-32	10549-10554	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-33	10555-10558	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-34	10559-10571	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-35	10572-10575	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-36	10576-10585	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-37	10585-10586	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-38	10587-10591	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-39	10592-10597	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-40	10598-10602	uses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-41	10603-10604	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-42	10605-10623	cluster-randomized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-43	10624-10634	controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-44	10635-10641	design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-45	10642-10644	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-46	10645-10650	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-47	10651-10653	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-48	10654-10661	schools	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-49	10662-10663	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-50	10663-10670	cluster	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-51	10670-10671	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-52	10672-10678	agreed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-53	10679-10681	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-54	10682-10689	conduct	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-55	10690-10696	annual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-56	10697-10704	surveys	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-57	10705-10708	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-58	10709-10710	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-59	10710-10711	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-60	10711-10716	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-61	10717-10721	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-62	10722-10725	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-63	10726-10736	consenting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-64	10737-10748	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-65	10749-10750	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-66	10750-10751	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-67	10752-10753	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-68	10754-10758	3826	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-69	10758-10759	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-70	10760-10763	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-71	10764-10768	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-72	10769-10777	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-73	10778-10780	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-74	10781-10786	Grade	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-75	10787-10788	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-76	10789-10791	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-77	10792-10801	September	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-78	10802-10806	2012	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-79	10806-10807	.	_	

#Text=Schools were randomly assigned to i) be trained and assisted in the delivery of the Preventure programme to Grade 7 high-risk adolescents or ii) not be exposed to the intervention.
44-1	10808-10815	Schools	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-2	10816-10820	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-3	10821-10829	randomly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-4	10830-10838	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-5	10839-10841	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-6	10842-10843	i	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-7	10843-10844	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-8	10845-10847	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-9	10848-10855	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-10	10856-10859	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-11	10860-10868	assisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-12	10869-10871	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-13	10872-10875	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-14	10876-10884	delivery	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-15	10885-10887	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-16	10888-10891	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-17	10892-10902	Preventure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-18	10903-10912	programme	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-19	10913-10915	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-20	10916-10921	Grade	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-21	10922-10923	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-22	10924-10933	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[31]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[32]	
44-23	10934-10945	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-24	10946-10948	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-25	10949-10951	ii	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-26	10951-10952	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-27	10953-10956	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-28	10957-10959	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-29	10960-10967	exposed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-30	10968-10970	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-31	10971-10974	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-32	10975-10987	intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-33	10987-10988	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=Adolescents were screened using the SURPS during their Grade 7 year and invited to participate in personality-specific Preventure workshops if they scored one standard deviation above the school mean on one of the four SURPS dimensions.
45-1	10989-11000	Adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-2	11001-11005	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-3	11006-11014	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-4	11015-11020	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-5	11021-11024	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-6	11025-11030	SURPS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[34]	
45-7	11031-11037	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-8	11038-11043	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-9	11044-11049	Grade	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-10	11050-11051	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-11	11051-11052	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-12	11052-11056	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-13	11057-11060	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-14	11061-11068	invited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-15	11069-11071	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-16	11072-11083	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-17	11084-11086	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-18	11087-11107	personality-specific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-19	11108-11118	Preventure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-20	11119-11128	workshops	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-21	11129-11131	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-22	11132-11136	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-23	11137-11143	scored	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-24	11144-11147	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-25	11148-11156	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-26	11157-11166	deviation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-27	11167-11172	above	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-28	11173-11176	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-29	11177-11183	school	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-30	11184-11188	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-31	11189-11191	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-32	11192-11195	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-33	11196-11198	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-34	11199-11202	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-35	11203-11207	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-36	11208-11213	SURPS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[35]	
45-37	11214-11224	dimensions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
45-38	11224-11225	.	_	

#Text=The Co-Venture clinical Trial is registered on www.ClinicalTrials.gov, “Co-Venture: a Cluster Randomized Trial Investigating the Effects of Selective Intervention on Adolescent Cognitive Development and Addiction”, study NCT01655615.
46-1	11226-11229	The	_	
46-2	11230-11240	Co-Venture	_	
46-3	11241-11249	clinical	_	
46-4	11250-11255	Trial	_	
46-5	11256-11258	is	_	
46-6	11259-11269	registered	_	
46-7	11270-11272	on	_	
46-8	11273-11295	www.ClinicalTrials.gov	_	
46-9	11295-11296	,	_	
46-10	11297-11298	“	_	
46-11	11298-11308	Co-Venture	_	
46-12	11308-11309	:	_	
46-13	11310-11311	a	_	
46-14	11312-11319	Cluster	_	
46-15	11320-11330	Randomized	_	
46-16	11331-11336	Trial	_	
46-17	11337-11350	Investigating	_	
46-18	11351-11354	the	_	
46-19	11355-11362	Effects	_	
46-20	11363-11365	of	_	
46-21	11366-11375	Selective	_	
46-22	11376-11388	Intervention	_	
46-23	11389-11391	on	_	
46-24	11392-11402	Adolescent	_	
46-25	11403-11412	Cognitive	_	
46-26	11413-11424	Development	_	
46-27	11425-11428	and	_	
46-28	11429-11438	Addiction	_	
46-29	11438-11439	”	_	
46-30	11439-11440	,	_	
46-31	11441-11446	study	_	
46-32	11447-11458	NCT01655615	_	
46-33	11458-11459	.	_	

#Text=Neuroventure: neuroimaging add-on study
#Text=Participants
#Text=Consort diagram for the Neuroventure Study.
47-1	11460-11472	Neuroventure	_	
47-2	11472-11473	:	_	
47-3	11474-11486	neuroimaging	_	
47-4	11487-11493	add-on	_	
47-5	11494-11499	study	_	
47-6	11500-11512	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-7	11513-11520	Consort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-8	11521-11528	diagram	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-9	11529-11532	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-10	11533-11536	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-11	11537-11549	Neuroventure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-12	11550-11555	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
47-13	11555-11556	.	_	

#Text=*For the Neuroventure project, we considered a low-risk personality to have a z-score below 0.5 on both Negative thinking (NT) and Anxiety sensitivity (AS) traits, and a z-score below 0.0 on both SS and IMP traits, to be adequate matches for the SS and IMP groups
#Text=Recruitment data in the still ongoing project.
48-1	11557-11558	*	_	
48-2	11558-11561	For	_	
48-3	11562-11565	the	_	
48-4	11566-11578	Neuroventure	_	
48-5	11579-11586	project	_	
48-6	11586-11587	,	_	
48-7	11588-11590	we	_	
48-8	11591-11601	considered	_	
48-9	11602-11603	a	_	
48-10	11604-11612	low-risk	_	
48-11	11613-11624	personality	_	
48-12	11625-11627	to	_	
48-13	11628-11632	have	_	
48-14	11633-11634	a	_	
48-15	11635-11642	z-score	_	
48-16	11643-11648	below	_	
48-17	11649-11652	0.5	_	
48-18	11653-11655	on	_	
48-19	11656-11660	both	_	
48-20	11661-11669	Negative	_	
48-21	11670-11678	thinking	_	
48-22	11679-11680	(	_	
48-23	11680-11682	NT	_	
48-24	11682-11683	)	_	
48-25	11684-11687	and	_	
48-26	11688-11695	Anxiety	_	
48-27	11696-11707	sensitivity	_	
48-28	11708-11709	(	_	
48-29	11709-11711	AS	_	
48-30	11711-11712	)	_	
48-31	11713-11719	traits	_	
48-32	11719-11720	,	_	
48-33	11721-11724	and	_	
48-34	11725-11726	a	_	
48-35	11727-11734	z-score	_	
48-36	11735-11740	below	_	
48-37	11741-11744	0.0	_	
48-38	11745-11747	on	_	
48-39	11748-11752	both	_	
48-40	11753-11755	SS	_	
48-41	11756-11759	and	_	
48-42	11760-11763	IMP	_	
48-43	11764-11770	traits	_	
48-44	11770-11771	,	_	
48-45	11772-11774	to	_	
48-46	11775-11777	be	_	
48-47	11778-11786	adequate	_	
48-48	11787-11794	matches	_	
48-49	11795-11798	for	_	
48-50	11799-11802	the	_	
48-51	11803-11805	SS	_	
48-52	11806-11809	and	_	
48-53	11810-11813	IMP	_	
48-54	11814-11820	groups	_	
48-55	11821-11832	Recruitment	_	
48-56	11833-11837	data	_	
48-57	11838-11840	in	_	
48-58	11841-11844	the	_	
48-59	11845-11850	still	_	
48-60	11851-11858	ongoing	_	
48-61	11859-11866	project	_	
48-62	11866-11867	.	_	

#Text=*For the Neuroventure project, we considered a low-risk personality to have a z-score below 0.5 on both NT and AS traits, and a z-score below 0.0 on both SS and IMP traits, to be adequate matches for the SS and IMP groups.
49-1	11868-11869	*	_	
49-2	11869-11872	For	_	
49-3	11873-11876	the	_	
49-4	11877-11889	Neuroventure	_	
49-5	11890-11897	project	_	
49-6	11897-11898	,	_	
49-7	11899-11901	we	_	
49-8	11902-11912	considered	_	
49-9	11913-11914	a	_	
49-10	11915-11923	low-risk	_	
49-11	11924-11935	personality	_	
49-12	11936-11938	to	_	
49-13	11939-11943	have	_	
49-14	11944-11945	a	_	
49-15	11946-11953	z-score	_	
49-16	11954-11959	below	_	
49-17	11960-11963	0.5	_	
49-18	11964-11966	on	_	
49-19	11967-11971	both	_	
49-20	11972-11974	NT	_	
49-21	11975-11978	and	_	
49-22	11979-11981	AS	_	
49-23	11982-11988	traits	_	
49-24	11988-11989	,	_	
49-25	11990-11993	and	_	
49-26	11994-11995	a	_	
49-27	11996-12003	z-score	_	
49-28	12004-12009	below	_	
49-29	12010-12013	0.0	_	
49-30	12014-12016	on	_	
49-31	12017-12021	both	_	
49-32	12022-12024	SS	_	
49-33	12025-12028	and	_	
49-34	12029-12032	IMP	_	
49-35	12033-12039	traits	_	
49-36	12039-12040	,	_	
49-37	12041-12043	to	_	
49-38	12044-12046	be	_	
49-39	12047-12055	adequate	_	
49-40	12056-12063	matches	_	
49-41	12064-12067	for	_	
49-42	12068-12071	the	_	
49-43	12072-12074	SS	_	
49-44	12075-12078	and	_	
49-45	12079-12082	IMP	_	
49-46	12083-12089	groups	_	
49-47	12089-12090	.	_	

#Text=**A z-score above 1.0 on the SS personality trait.
50-1	12091-12092	*	_	
50-2	12092-12093	*	_	
50-3	12093-12094	A	_	
50-4	12095-12102	z-score	_	
50-5	12103-12108	above	_	
50-6	12109-12112	1.0	_	
50-7	12113-12115	on	_	
50-8	12116-12119	the	_	
50-9	12120-12122	SS	_	
50-10	12123-12134	personality	_	
50-11	12135-12140	trait	_	
50-12	12140-12141	.	_	

#Text=***A z-score above 1.0 on the IMP personality trait
#Text=Neuroventure will focus on high-risk students with SS and IMP personality profiles as they contribute most to the prediction of early onset substance-related behaviors in adolescence.
51-1	12142-12143	*	_	
51-2	12143-12144	*	_	
51-3	12144-12145	*	_	
51-4	12145-12146	A	_	
51-5	12147-12154	z-score	_	
51-6	12155-12160	above	_	
51-7	12161-12164	1.0	_	
51-8	12165-12167	on	_	
51-9	12168-12171	the	_	
51-10	12172-12175	IMP	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[37]	
51-11	12176-12187	personality	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[37]	
51-12	12188-12193	trait	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[37]	
51-13	12194-12206	Neuroventure	_	
51-14	12207-12211	will	_	
51-15	12212-12217	focus	_	
51-16	12218-12220	on	_	
51-17	12221-12230	high-risk	_	
51-18	12231-12239	students	_	
51-19	12240-12244	with	_	
51-20	12245-12247	SS	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[38]	
51-21	12248-12251	and	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[38]	
51-22	12252-12255	IMP	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[38]	
51-23	12256-12267	personality	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[38]	
51-24	12268-12276	profiles	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[38]	
51-25	12277-12279	as	_	
51-26	12280-12284	they	_	
51-27	12285-12295	contribute	_	
51-28	12296-12300	most	_	
51-29	12301-12303	to	_	
51-30	12304-12307	the	_	
51-31	12308-12318	prediction	_	
51-32	12319-12321	of	_	
51-33	12322-12327	early	_	
51-34	12328-12333	onset	_	
51-35	12334-12351	substance-related	_	
51-36	12352-12361	behaviors	_	
51-37	12362-12364	in	_	
51-38	12365-12376	adolescence	_	
51-39	12376-12377	.	_	

#Text=Thus, a subsample from the Co-Venture Trial of 60 high SS (30 of whom will receive the intervention), 60 high IMP (30 of whom will receive the intervention) and 30 low-risk (low SS and low IMP will not be invited to participate in the interventions) Grade 7 students (50% girls) will be invited to participate in this neuroimaging study (Please refer to Fig. 1 for the consort diagram and to Fig. 2 for the actual recruitment data).
52-1	12378-12382	Thus	_	
52-2	12382-12383	,	_	
52-3	12384-12385	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-4	12386-12395	subsample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-5	12396-12400	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-6	12401-12404	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-7	12405-12415	Co-Venture	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-8	12416-12421	Trial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-9	12422-12424	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-10	12425-12427	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-11	12428-12432	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[40]	
52-12	12433-12435	SS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[40]	
52-13	12436-12437	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-14	12437-12439	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-15	12440-12442	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-16	12443-12447	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-17	12448-12452	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-18	12453-12460	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-19	12461-12464	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-20	12465-12477	intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-21	12477-12478	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-22	12478-12479	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-23	12480-12482	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-24	12483-12487	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
52-25	12488-12491	IMP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
52-26	12492-12493	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-27	12493-12495	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-28	12496-12498	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-29	12499-12503	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-30	12504-12508	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-31	12509-12516	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-32	12517-12520	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-33	12521-12533	intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-34	12533-12534	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-35	12535-12538	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-36	12539-12541	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-37	12542-12550	low-risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-38	12551-12552	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-39	12552-12555	low	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[42]	
52-40	12556-12558	SS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[42]	
52-41	12559-12562	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[42]	
52-42	12563-12566	low	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[42]	
52-43	12567-12570	IMP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[42]	
52-44	12571-12575	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-45	12576-12579	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-46	12580-12582	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-47	12583-12590	invited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-48	12591-12593	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-49	12594-12605	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-50	12606-12608	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-51	12609-12612	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-52	12613-12626	interventions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-53	12626-12627	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
52-54	12628-12633	Grade	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-55	12634-12635	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-56	12636-12644	students	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-57	12645-12646	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-58	12646-12649	50%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-59	12650-12655	girls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-60	12655-12656	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-61	12657-12661	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-62	12662-12664	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-63	12665-12672	invited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-64	12673-12675	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-65	12676-12687	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-66	12688-12690	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-67	12691-12695	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-68	12696-12708	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-69	12709-12714	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
52-70	12715-12716	(	_	
52-71	12716-12722	Please	_	
52-72	12723-12728	refer	_	
52-73	12729-12731	to	_	
52-74	12732-12735	Fig	_	
52-75	12735-12736	.	_	
52-76	12736-12737	 	_	
52-77	12737-12738	1	_	
52-78	12739-12742	for	_	
52-79	12743-12746	the	_	
52-80	12747-12754	consort	_	
52-81	12755-12762	diagram	_	
52-82	12763-12766	and	_	
52-83	12767-12769	to	_	
52-84	12770-12773	Fig	_	
52-85	12773-12774	.	_	
52-86	12774-12775	 	_	
52-87	12775-12776	2	_	
52-88	12777-12780	for	_	
52-89	12781-12784	the	_	
52-90	12785-12791	actual	_	
52-91	12792-12803	recruitment	_	
52-92	12804-12808	data	_	
52-93	12808-12809	)	_	
52-94	12809-12810	.	_	

#Text=An independent informed consent from parents and adolescents will be obtained for the present study.
53-1	12811-12813	An	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-2	12814-12825	independent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-3	12826-12834	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-4	12835-12842	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-5	12843-12847	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-6	12848-12855	parents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-7	12856-12859	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-8	12860-12871	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-9	12872-12876	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-10	12877-12879	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-11	12880-12888	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-12	12889-12892	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-13	12893-12896	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-14	12897-12904	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-15	12905-12910	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
53-16	12910-12911	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	

#Text=Exclusion criteria will include major neuro-developmental disorders (e.g., autism), uncorrectable visual impairment or hearing deficits, severe mental health problems (e.g., schizophrenia, bipolar disorder), uninterruptable central nervous system medication, and any magnetic resonance imaging (MRI) contraindications (e.g., pregnancy, braces, etc.).
54-1	12912-12921	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-2	12922-12930	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-3	12931-12935	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-4	12936-12943	include	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-5	12944-12949	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-6	12950-12969	neuro-developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-7	12970-12979	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-8	12980-12981	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-9	12981-12984	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-10	12984-12985	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-11	12985-12986	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-12	12987-12993	autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-13	12993-12994	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-14	12994-12995	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-15	12996-13009	uncorrectable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-16	13010-13016	visual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-17	13017-13027	impairment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-18	13028-13030	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-19	13031-13038	hearing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-20	13039-13047	deficits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-21	13047-13048	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-22	13049-13055	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-23	13056-13062	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-24	13063-13069	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-25	13070-13078	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-26	13079-13080	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-27	13080-13083	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-28	13083-13084	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-29	13084-13085	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-30	13086-13099	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-31	13099-13100	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-32	13101-13108	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-33	13109-13117	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-34	13117-13118	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-35	13118-13119	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-36	13120-13135	uninterruptable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-37	13136-13143	central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-38	13144-13151	nervous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-39	13152-13158	system	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-40	13159-13169	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-41	13169-13170	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-42	13171-13174	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-43	13175-13178	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-44	13179-13187	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-45	13188-13197	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-46	13198-13205	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-47	13206-13207	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-48	13207-13210	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-49	13210-13211	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-50	13212-13229	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-51	13230-13231	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-52	13231-13234	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-53	13234-13235	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-54	13235-13236	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-55	13237-13246	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-56	13246-13247	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-57	13248-13254	braces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-58	13254-13255	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-59	13256-13259	etc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-60	13259-13260	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-61	13260-13261	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
54-62	13261-13262	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	

#Text=Procedure
#Text=Eligible students will be invited to attend three identical scanning sessions over a 5-year period: the first session during the baseline year of the Co-Venture Trial (for intervention schools, this would refer to the period prior to when intervention sessions are run), and second and third session 24 and 48 months later, respectively (Grade 9 and 11).
55-1	13265-13274	Procedure	_	
55-2	13275-13283	Eligible	_	
55-3	13284-13292	students	_	
55-4	13293-13297	will	_	
55-5	13298-13300	be	_	
55-6	13301-13308	invited	_	
55-7	13309-13311	to	_	
55-8	13312-13318	attend	_	
55-9	13319-13324	three	_	
55-10	13325-13334	identical	_	
55-11	13335-13343	scanning	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[46]	
55-12	13344-13352	sessions	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[46]	
55-13	13353-13357	over	_	
55-14	13358-13359	a	_	
55-15	13360-13361	5	_	
55-16	13361-13362	-	_	
55-17	13362-13366	year	_	
55-18	13367-13373	period	_	
55-19	13373-13374	:	_	
55-20	13375-13378	the	_	
55-21	13379-13384	first	_	
55-22	13385-13392	session	_	
55-23	13393-13399	during	_	
55-24	13400-13403	the	_	
55-25	13404-13412	baseline	_	
55-26	13413-13417	year	_	
55-27	13418-13420	of	_	
55-28	13421-13424	the	_	
55-29	13425-13435	Co-Venture	_	
55-30	13436-13441	Trial	_	
55-31	13442-13443	(	_	
55-32	13443-13446	for	_	
55-33	13447-13459	intervention	_	
55-34	13460-13467	schools	_	
55-35	13467-13468	,	_	
55-36	13469-13473	this	_	
55-37	13474-13479	would	_	
55-38	13480-13485	refer	_	
55-39	13486-13488	to	_	
55-40	13489-13492	the	_	
55-41	13493-13499	period	_	
55-42	13500-13505	prior	_	
55-43	13506-13508	to	_	
55-44	13509-13513	when	_	
55-45	13514-13526	intervention	_	
55-46	13527-13535	sessions	_	
55-47	13536-13539	are	_	
55-48	13540-13543	run	_	
55-49	13543-13544	)	_	
55-50	13544-13545	,	_	
55-51	13546-13549	and	_	
55-52	13550-13556	second	_	
55-53	13557-13560	and	_	
55-54	13561-13566	third	_	
55-55	13567-13574	session	_	
55-56	13575-13577	24	_	
55-57	13578-13581	and	_	
55-58	13582-13584	48	_	
55-59	13584-13585	 	_	
55-60	13585-13591	months	_	
55-61	13592-13597	later	_	
55-62	13597-13598	,	_	
55-63	13599-13611	respectively	_	
55-64	13612-13613	(	_	
55-65	13613-13618	Grade	_	
55-66	13619-13620	9	_	
55-67	13621-13624	and	_	
55-68	13625-13627	11	_	
55-69	13627-13628	)	_	
55-70	13628-13629	.	_	

#Text=Participants will undergo a 65-min structural and functional neuroimaging assessment, and will complete a 2-h battery of neuropsychological tasks post-scan.
56-1	13630-13642	Participants	_	
56-2	13643-13647	will	_	
56-3	13648-13655	undergo	_	
56-4	13656-13657	a	_	
56-5	13658-13660	65	_	
56-6	13660-13661	-	_	
56-7	13661-13664	min	_	
56-8	13665-13675	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	
56-9	13676-13679	and	_	
56-10	13680-13690	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
56-11	13691-13703	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
56-12	13704-13714	assessment	_	
56-13	13714-13715	,	_	
56-14	13716-13719	and	_	
56-15	13720-13724	will	_	
56-16	13725-13733	complete	_	
56-17	13734-13735	a	_	
56-18	13736-13737	2	_	
56-19	13737-13738	-	_	
56-20	13738-13739	h	_	
56-21	13740-13747	battery	_	
56-22	13748-13750	of	_	
56-23	13751-13769	neuropsychological	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[48]	
56-24	13770-13775	tasks	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[48]	
56-25	13776-13785	post-scan	_	
56-26	13785-13786	.	_	

#Text=In addition, participants will be assessed on substance use, global IQ and behavioral measures annually for 4 years post intervention through the Co-Venture Trial.
57-1	13787-13789	In	_	
57-2	13790-13798	addition	_	
57-3	13798-13799	,	_	
57-4	13800-13812	participants	_	
57-5	13813-13817	will	_	
57-6	13818-13820	be	_	
57-7	13821-13829	assessed	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[49]	
57-8	13830-13832	on	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[49]	
57-9	13833-13842	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[49]	
57-10	13843-13846	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[49]	
57-11	13846-13847	,	_	
57-12	13848-13854	global	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[50]	
57-13	13855-13857	IQ	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[50]	
57-14	13858-13861	and	_	
57-15	13862-13872	behavioral	_	
57-16	13873-13881	measures	_	
57-17	13882-13890	annually	_	
57-18	13891-13894	for	_	
57-19	13895-13896	4	_	
57-20	13896-13897	 	_	
57-21	13897-13902	years	_	
57-22	13903-13907	post	_	
57-23	13908-13920	intervention	_	
57-24	13921-13928	through	_	
57-25	13929-13932	the	_	
57-26	13933-13943	Co-Venture	_	
57-27	13944-13949	Trial	_	
57-28	13949-13950	.	_	

#Text=Behavioral assessment
#Text=Adolescents will be administered the Timeline Follow-Back Interview to assess past 6 months alcohol and drug use in a face-to-face interview.
58-1	13951-13961	Behavioral	_	
58-2	13962-13972	assessment	_	
58-3	13973-13984	Adolescents	_	
58-4	13985-13989	will	_	
58-5	13990-13992	be	_	
58-6	13993-14005	administered	_	
58-7	14006-14009	the	_	
58-8	14010-14018	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[51]	
58-9	14019-14030	Follow-Back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[51]	
58-10	14031-14040	Interview	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[51]	
58-11	14041-14043	to	_	
58-12	14044-14050	assess	_	
58-13	14051-14055	past	_	
58-14	14056-14057	6	_	
58-15	14057-14058	 	_	
58-16	14058-14064	months	_	
58-17	14065-14072	alcohol	_	
58-18	14073-14076	and	_	
58-19	14077-14081	drug	_	
58-20	14082-14085	use	_	
58-21	14086-14088	in	_	
58-22	14089-14090	a	_	
58-23	14091-14103	face-to-face	_	
58-24	14104-14113	interview	_	
58-25	14113-14114	.	_	

#Text=To evaluate cognitive functioning, adolescents will complete the STROOP, a measure of response inhibition.
59-1	14115-14117	To	_	
59-2	14118-14126	evaluate	_	
59-3	14127-14136	cognitive	_	
59-4	14137-14148	functioning	_	
59-5	14148-14149	,	_	
59-6	14150-14161	adolescents	_	
59-7	14162-14166	will	_	
59-8	14167-14175	complete	_	
59-9	14176-14179	the	_	
59-10	14180-14186	STROOP	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest	
59-11	14186-14187	,	_	
59-12	14188-14189	a	_	
59-13	14190-14197	measure	_	
59-14	14198-14200	of	_	
59-15	14201-14209	response	_	
59-16	14210-14220	inhibition	_	
59-17	14220-14221	.	_	

#Text=To evaluate non-spatial and spatial working memory, participants will be administered the Self-Ordered Pointing Test (SOPT), and the N-back task (the 2- and 3-Back versions).
60-1	14222-14224	To	_	
60-2	14225-14233	evaluate	_	
60-3	14234-14245	non-spatial	_	
60-4	14246-14249	and	_	
60-5	14250-14257	spatial	_	
60-6	14258-14265	working	_	
60-7	14266-14272	memory	_	
60-8	14272-14273	,	_	
60-9	14274-14286	participants	_	
60-10	14287-14291	will	_	
60-11	14292-14294	be	_	
60-12	14295-14307	administered	_	
60-13	14308-14311	the	_	
60-14	14312-14324	Self-Ordered	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[52]	
60-15	14325-14333	Pointing	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[52]	
60-16	14334-14338	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[52]	
60-17	14339-14340	(	_	
60-18	14340-14344	SOPT	_	
60-19	14344-14345	)	_	
60-20	14345-14346	,	_	
60-21	14347-14350	and	_	
60-22	14351-14354	the	_	
60-23	14355-14361	N-back	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]	
60-24	14362-14366	task	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]	
60-25	14367-14368	(	_	
60-26	14368-14371	the	_	
60-27	14372-14373	2	_	
60-28	14373-14374	-	_	
60-29	14375-14378	and	_	
60-30	14379-14380	3	_	
60-31	14380-14381	-	_	
60-32	14381-14385	Back	_	
60-33	14386-14394	versions	_	
60-34	14394-14395	)	_	
60-35	14395-14396	.	_	

#Text=The Children’s memory scale (CMS)-Dot Location, a sub-test of the CMS, will be used to assess spatial immediate and deferred memory recall.
61-1	14397-14400	The	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[54]	
61-2	14401-14409	Children	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[54]	
61-3	14409-14410	’	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[54]	
61-4	14410-14411	s	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[54]	
61-5	14412-14418	memory	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[54]	
61-6	14419-14424	scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[54]	
61-7	14425-14426	(	_	
61-8	14426-14429	CMS	_	
61-9	14429-14430	)	_	
61-10	14430-14431	-	_	
61-11	14431-14434	Dot	_	
61-12	14435-14443	Location	_	
61-13	14443-14444	,	_	
61-14	14445-14446	a	_	
61-15	14447-14455	sub-test	_	
61-16	14456-14458	of	_	
61-17	14459-14462	the	_	
61-18	14463-14466	CMS	_	
61-19	14466-14467	,	_	
61-20	14468-14472	will	_	
61-21	14473-14475	be	_	
61-22	14476-14480	used	_	
61-23	14481-14483	to	_	
61-24	14484-14490	assess	_	
61-25	14491-14498	spatial	_	
61-26	14499-14508	immediate	_	
61-27	14509-14512	and	_	
61-28	14513-14521	deferred	_	
61-29	14522-14528	memory	_	
61-30	14529-14535	recall	_	
61-31	14535-14536	.	_	

#Text=The participants will also complete the computerized Balloon Analogue Risk Task (BART:).
62-1	14537-14540	The	_	
62-2	14541-14553	participants	_	
62-3	14554-14558	will	_	
62-4	14559-14563	also	_	
62-5	14564-14572	complete	_	
62-6	14573-14576	the	_	
62-7	14577-14589	computerized	_	
62-8	14590-14597	Balloon	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[55]	
62-9	14598-14606	Analogue	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[55]	
62-10	14607-14611	Risk	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[55]	
62-11	14612-14616	Task	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[55]	
62-12	14617-14618	(	_	
62-13	14618-14622	BART	_	
62-14	14622-14623	:	_	
62-15	14623-14624	)	_	
62-16	14624-14625	.	_	

#Text=The BART assesses real-world risk taking behavior by balancing the potential for reward (inflating the balloon) versus loss (balloon exploded).
63-1	14626-14629	The	_	
63-2	14630-14634	BART	_	
63-3	14635-14643	assesses	_	
63-4	14644-14654	real-world	_	
63-5	14655-14659	risk	_	
63-6	14660-14666	taking	_	
63-7	14667-14675	behavior	_	
63-8	14676-14678	by	_	
63-9	14679-14688	balancing	_	
63-10	14689-14692	the	_	
63-11	14693-14702	potential	_	
63-12	14703-14706	for	_	
63-13	14707-14713	reward	_	
63-14	14714-14715	(	_	
63-15	14715-14724	inflating	_	
63-16	14725-14728	the	_	
63-17	14729-14736	balloon	_	
63-18	14736-14737	)	_	
63-19	14738-14744	versus	_	
63-20	14745-14749	loss	_	
63-21	14750-14751	(	_	
63-22	14751-14758	balloon	_	
63-23	14759-14767	exploded	_	
63-24	14767-14768	)	_	
63-25	14768-14769	.	_	

#Text=Finally the sub-tests of the Vocabulary and Block Design will be used as an estimate of the Wechsler Intelligence Scale for Children 4th Edition full scale IQ.
64-1	14770-14777	Finally	_	
64-2	14778-14781	the	_	
64-3	14782-14791	sub-tests	_	
64-4	14792-14794	of	_	
64-5	14795-14798	the	_	
64-6	14799-14809	Vocabulary	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-7	14810-14813	and	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-8	14814-14819	Block	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-9	14820-14826	Design	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-10	14827-14831	will	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-11	14832-14834	be	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-12	14835-14839	used	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-13	14840-14842	as	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-14	14843-14845	an	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-15	14846-14854	estimate	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-16	14855-14857	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-17	14858-14861	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-18	14862-14870	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-19	14871-14883	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-20	14884-14889	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-21	14890-14893	for	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-22	14894-14902	Children	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-23	14903-14906	4th	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-24	14907-14914	Edition	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-25	14915-14919	full	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-26	14920-14925	scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-27	14926-14928	IQ	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[56]	
64-28	14928-14929	.	_	

#Text=Scanning protocol
#Text=Functional MRI (fMRI) data will be acquired on a 3T Siemens Magnetom Trio MRI scanner using whole brain gradient echo planar imaging (EPI) sequence sensitive to blood oxygenation level dependent (BOLD) contrast in 47 slices (Repetition time (TR) = 2.5 s; Echo time (TE) = 30 ms; 3 mm thickness; voxel size: 3 × 3 × 3 mm3).
65-1	14930-14938	Scanning	_	
65-2	14939-14947	protocol	_	
65-3	14948-14958	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[57]	
65-4	14959-14962	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[57]	
65-5	14963-14964	(	_	
65-6	14964-14968	fMRI	_	
65-7	14968-14969	)	_	
65-8	14970-14974	data	_	
65-9	14975-14979	will	_	
65-10	14980-14982	be	_	
65-11	14983-14991	acquired	_	
65-12	14992-14994	on	_	
65-13	14995-14996	a	_	
65-14	14997-14999	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[58]	
65-15	15000-15007	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[58]	
65-16	15008-15016	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[58]	
65-17	15017-15021	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[58]	
65-18	15022-15025	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[58]	
65-19	15026-15033	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[58]	
65-20	15034-15039	using	_	
65-21	15040-15045	whole	_	
65-22	15046-15051	brain	_	
65-23	15052-15060	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-24	15061-15065	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-25	15066-15072	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-26	15073-15080	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-27	15081-15082	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-28	15082-15085	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-29	15085-15086	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-30	15087-15095	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-31	15096-15105	sensitive	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-32	15106-15108	to	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-33	15109-15114	blood	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-34	15115-15126	oxygenation	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-35	15127-15132	level	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-36	15133-15142	dependent	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-37	15143-15144	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-38	15144-15148	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-39	15148-15149	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-40	15150-15158	contrast	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
65-41	15159-15161	in	_	
65-42	15162-15164	47	_	
65-43	15165-15171	slices	_	
65-44	15172-15173	(	_	
65-45	15173-15183	Repetition	_	
65-46	15184-15188	time	_	
65-47	15189-15190	(	_	
65-48	15190-15192	TR	_	
65-49	15192-15193	)	_	
65-50	15194-15195	=	_	
65-51	15196-15199	2.5	_	
65-52	15199-15200	 	_	
65-53	15200-15201	s	_	
65-54	15201-15202	;	_	
65-55	15203-15207	Echo	_	
65-56	15208-15212	time	_	
65-57	15213-15214	(	_	
65-58	15214-15216	TE	_	
65-59	15216-15217	)	_	
65-60	15218-15219	=	_	
65-61	15220-15222	30	_	
65-62	15222-15223	 	_	
65-63	15223-15225	ms	_	
65-64	15225-15226	;	_	
65-65	15227-15228	3	_	
65-66	15228-15229	 	_	
65-67	15229-15231	mm	_	
65-68	15232-15241	thickness	_	
65-69	15241-15242	;	_	
65-70	15243-15248	voxel	_	
65-71	15249-15253	size	_	
65-72	15253-15254	:	_	
65-73	15255-15256	3	_	
65-74	15257-15258	×	_	
65-75	15259-15260	3	_	
65-76	15261-15262	×	_	
65-77	15263-15264	3	_	
65-78	15265-15268	mm3	_	
65-79	15268-15269	)	_	
65-80	15269-15270	.	_	

#Text=A higher resolution structural scan using an ultrafast gradient echo 3D sequence (MPRAGE) will also be collected for structural analyses and to aid functional data registration (TR = 2.3 s; TE = 2.96 ms; 1 mm thickness; voxel size: 1 × 1 × 1 mm3).
66-1	15271-15272	A	_	
66-2	15273-15279	higher	_	
66-3	15280-15290	resolution	_	
66-4	15291-15301	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[60]	
66-5	15302-15306	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[60]	
66-6	15307-15312	using	_	
66-7	15313-15315	an	_	
66-8	15316-15325	ultrafast	_	
66-9	15326-15334	gradient	_	
66-10	15335-15339	echo	_	
66-11	15340-15342	3D	_	
66-12	15343-15351	sequence	_	
66-13	15352-15353	(	_	
66-14	15353-15359	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	
66-15	15359-15360	)	_	
66-16	15361-15365	will	_	
66-17	15366-15370	also	_	
66-18	15371-15373	be	_	
66-19	15374-15383	collected	_	
66-20	15384-15387	for	_	
66-21	15388-15398	structural	_	
66-22	15399-15407	analyses	_	
66-23	15408-15411	and	_	
66-24	15412-15414	to	_	
66-25	15415-15418	aid	_	
66-26	15419-15429	functional	_	
66-27	15430-15434	data	_	
66-28	15435-15447	registration	_	
66-29	15448-15449	(	_	
66-30	15449-15451	TR	_	
66-31	15452-15453	=	_	
66-32	15454-15457	2.3	_	
66-33	15457-15458	 	_	
66-34	15458-15459	s	_	
66-35	15459-15460	;	_	
66-36	15461-15463	TE	_	
66-37	15464-15465	=	_	
66-38	15466-15470	2.96	_	
66-39	15470-15471	 	_	
66-40	15471-15473	ms	_	
66-41	15473-15474	;	_	
66-42	15475-15476	1	_	
66-43	15476-15477	 	_	
66-44	15477-15479	mm	_	
66-45	15480-15489	thickness	_	
66-46	15489-15490	;	_	
66-47	15491-15496	voxel	_	
66-48	15497-15501	size	_	
66-49	15501-15502	:	_	
66-50	15503-15504	1	_	
66-51	15505-15506	×	_	
66-52	15507-15508	1	_	
66-53	15509-15510	×	_	
66-54	15511-15512	1	_	
66-55	15513-15516	mm3	_	
66-56	15516-15517	)	_	
66-57	15517-15518	.	_	

#Text=Diffusion weighted imaging (DWI) data will be acquired during a peripherally gated spin echo EPI sequence with diffusion sensitization gradients (‘b value’ of 100 s/mm-2) applied in 64 directions (HARDI protocol); this will provide whole brain coverage at 2.0 mm isotropic resolution.
67-1	15519-15528	Diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[61]	
67-2	15529-15537	weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[61]	
67-3	15538-15545	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[61]	
67-4	15546-15547	(	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[61]	
67-5	15547-15550	DWI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[61]	
67-6	15550-15551	)	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[61]	
67-7	15552-15556	data	_	
67-8	15557-15561	will	_	
67-9	15562-15564	be	_	
67-10	15565-15573	acquired	_	
67-11	15574-15580	during	_	
67-12	15581-15582	a	_	
67-13	15583-15595	peripherally	_	
67-14	15596-15601	gated	_	
67-15	15602-15606	spin	_	
67-16	15607-15611	echo	_	
67-17	15612-15615	EPI	_	
67-18	15616-15624	sequence	_	
67-19	15625-15629	with	_	
67-20	15630-15639	diffusion	_	
67-21	15640-15653	sensitization	_	
67-22	15654-15663	gradients	_	
67-23	15664-15665	(	_	
67-24	15665-15666	‘	_	
67-25	15666-15667	b	_	
67-26	15668-15673	value	_	
67-27	15673-15674	’	_	
67-28	15675-15677	of	_	
67-29	15678-15681	100	_	
67-30	15681-15682	 	_	
67-31	15682-15683	s	_	
67-32	15683-15684	/	_	
67-33	15684-15686	mm	_	
67-34	15686-15687	-	_	
67-35	15687-15688	2	_	
67-36	15688-15689	)	_	
67-37	15690-15697	applied	_	
67-38	15698-15700	in	_	
67-39	15701-15703	64	_	
67-40	15704-15714	directions	_	
67-41	15715-15716	(	_	
67-42	15716-15721	HARDI	_	
67-43	15722-15730	protocol	_	
67-44	15730-15731	)	_	
67-45	15731-15732	;	_	
67-46	15733-15737	this	_	
67-47	15738-15742	will	_	
67-48	15743-15750	provide	_	
67-49	15751-15756	whole	_	
67-50	15757-15762	brain	_	
67-51	15763-15771	coverage	_	
67-52	15772-15774	at	_	
67-53	15775-15778	2.0	_	
67-54	15778-15779	 	_	
67-55	15779-15781	mm	_	
67-56	15782-15791	isotropic	_	
67-57	15792-15802	resolution	_	
67-58	15802-15803	.	_	

#Text=Rapid, event related, BOLD fMRI will be performed while participants complete tasks that engage two specific domains of cognitive performance: a modified version of the Monetary Incentive Delay Task (MIDT) and a motor response inhibition task (Stop-Signal task) (for further details please refer to).
68-1	15804-15809	Rapid	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-2	15809-15810	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-3	15811-15816	event	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-4	15817-15824	related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-5	15824-15825	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-6	15826-15830	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-7	15831-15835	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-8	15836-15840	will	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-9	15841-15843	be	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-10	15844-15853	performed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[63]	
68-11	15854-15859	while	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]	
68-12	15860-15872	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]	
68-13	15873-15881	complete	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]	
68-14	15882-15887	tasks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[62]	
68-15	15888-15892	that	_	
68-16	15893-15899	engage	_	
68-17	15900-15903	two	_	
68-18	15904-15912	specific	_	
68-19	15913-15920	domains	_	
68-20	15921-15923	of	_	
68-21	15924-15933	cognitive	_	
68-22	15934-15945	performance	_	
68-23	15945-15946	:	_	
68-24	15947-15948	a	_	
68-25	15949-15957	modified	_	
68-26	15958-15965	version	_	
68-27	15966-15968	of	_	
68-28	15969-15972	the	_	
68-29	15973-15981	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[64]	
68-30	15982-15991	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[64]	
68-31	15992-15997	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[64]	
68-32	15998-16002	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[64]	
68-33	16003-16004	(	_	
68-34	16004-16008	MIDT	_	
68-35	16008-16009	)	_	
68-36	16010-16013	and	_	
68-37	16014-16015	a	_	
68-38	16016-16021	motor	_	
68-39	16022-16030	response	_	
68-40	16031-16041	inhibition	_	
68-41	16042-16046	task	_	
68-42	16047-16048	(	_	
68-43	16048-16059	Stop-Signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[65]	
68-44	16060-16064	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[65]	
68-45	16064-16065	)	_	
68-46	16066-16067	(	_	
68-47	16067-16070	for	_	
68-48	16071-16078	further	_	
68-49	16079-16086	details	_	
68-50	16087-16093	please	_	
68-51	16094-16099	refer	_	
68-52	16100-16102	to	_	
68-53	16102-16103	)	_	
68-54	16103-16104	.	_	

#Text=The MIDT has been used extensively to investigate changes in neural activity in response to different stages of reward processing (e.g., anticipation, outcome processing, and consumption), as well as the processing of tasks under different reward conditions.
69-1	16105-16108	The	_	
69-2	16109-16113	MIDT	_	
69-3	16114-16117	has	_	
69-4	16118-16122	been	_	
69-5	16123-16127	used	_	
69-6	16128-16139	extensively	_	
69-7	16140-16142	to	_	
69-8	16143-16154	investigate	_	
69-9	16155-16162	changes	_	
69-10	16163-16165	in	_	
69-11	16166-16172	neural	_	
69-12	16173-16181	activity	_	
69-13	16182-16184	in	_	
69-14	16185-16193	response	_	
69-15	16194-16196	to	_	
69-16	16197-16206	different	_	
69-17	16207-16213	stages	_	
69-18	16214-16216	of	_	
69-19	16217-16223	reward	_	
69-20	16224-16234	processing	_	
69-21	16235-16236	(	_	
69-22	16236-16239	e.g	_	
69-23	16239-16240	.	_	
69-24	16240-16241	,	_	
69-25	16242-16254	anticipation	_	
69-26	16254-16255	,	_	
69-27	16256-16263	outcome	_	
69-28	16264-16274	processing	_	
69-29	16274-16275	,	_	
69-30	16276-16279	and	_	
69-31	16280-16291	consumption	_	
69-32	16291-16292	)	_	
69-33	16292-16293	,	_	
69-34	16294-16296	as	_	
69-35	16297-16301	well	_	
69-36	16302-16304	as	_	
69-37	16305-16308	the	_	
69-38	16309-16319	processing	_	
69-39	16320-16322	of	_	
69-40	16323-16328	tasks	_	
69-41	16329-16334	under	_	
69-42	16335-16344	different	_	
69-43	16345-16351	reward	_	
69-44	16352-16362	conditions	_	
69-45	16362-16363	.	_	

#Text=This modified version uses non-monetary incentives (points) to invoke anticipation of reward and punishment.
70-1	16364-16368	This	_	
70-2	16369-16377	modified	_	
70-3	16378-16385	version	_	
70-4	16386-16390	uses	_	
70-5	16391-16403	non-monetary	_	
70-6	16404-16414	incentives	_	
70-7	16415-16416	(	_	
70-8	16416-16422	points	_	
70-9	16422-16423	)	_	
70-10	16424-16426	to	_	
70-11	16427-16433	invoke	_	
70-12	16434-16446	anticipation	_	
70-13	16447-16449	of	_	
70-14	16450-16456	reward	_	
70-15	16457-16460	and	_	
70-16	16461-16471	punishment	_	
70-17	16471-16472	.	_	

#Text=Participants’ outcome (score) is dependent upon their performance in a simple reaction time task, divided into control (no reward or punishment – 32 trials), potential reward (win 10 points – 32 trials) and potential punishment (lose 10 points – 32 trials) sub-tasks.
71-1	16473-16485	Participants	_	
71-2	16485-16486	’	_	
71-3	16487-16494	outcome	_	
71-4	16495-16496	(	_	
71-5	16496-16501	score	_	
71-6	16501-16502	)	_	
71-7	16503-16505	is	_	
71-8	16506-16515	dependent	_	
71-9	16516-16520	upon	_	
71-10	16521-16526	their	_	
71-11	16527-16538	performance	_	
71-12	16539-16541	in	_	
71-13	16542-16543	a	_	
71-14	16544-16550	simple	_	
71-15	16551-16559	reaction	_	
71-16	16560-16564	time	_	
71-17	16565-16569	task	_	
71-18	16569-16570	,	_	
71-19	16571-16578	divided	_	
71-20	16579-16583	into	_	
71-21	16584-16591	control	_	
71-22	16592-16593	(	_	
71-23	16593-16595	no	_	
71-24	16596-16602	reward	_	
71-25	16603-16605	or	_	
71-26	16606-16616	punishment	_	
71-27	16617-16618	–	_	
71-28	16619-16621	32	_	
71-29	16622-16628	trials	_	
71-30	16628-16629	)	_	
71-31	16629-16630	,	_	
71-32	16631-16640	potential	_	
71-33	16641-16647	reward	_	
71-34	16648-16649	(	_	
71-35	16649-16652	win	_	
71-36	16653-16655	10	_	
71-37	16656-16662	points	_	
71-38	16663-16664	–	_	
71-39	16665-16667	32	_	
71-40	16668-16674	trials	_	
71-41	16674-16675	)	_	
71-42	16676-16679	and	_	
71-43	16680-16689	potential	_	
71-44	16690-16700	punishment	_	
71-45	16701-16702	(	_	
71-46	16702-16706	lose	_	
71-47	16707-16709	10	_	
71-48	16710-16716	points	_	
71-49	16717-16718	–	_	
71-50	16719-16721	32	_	
71-51	16722-16728	trials	_	
71-52	16728-16729	)	_	
71-53	16730-16739	sub-tasks	_	
71-54	16739-16740	.	_	

#Text=The MIDT is sensitive to developmental and individual differences in sensitivity to cues for reward and punishment and three studies show relationships between ventral striatal activation on this task and risk taking and/or substance use in the IMAGEN sample.
72-1	16741-16744	The	_	
72-2	16745-16749	MIDT	_	
72-3	16750-16752	is	_	
72-4	16753-16762	sensitive	_	
72-5	16763-16765	to	_	
72-6	16766-16779	developmental	_	
72-7	16780-16783	and	_	
72-8	16784-16794	individual	_	
72-9	16795-16806	differences	_	
72-10	16807-16809	in	_	
72-11	16810-16821	sensitivity	_	
72-12	16822-16824	to	_	
72-13	16825-16829	cues	_	
72-14	16830-16833	for	_	
72-15	16834-16840	reward	_	
72-16	16841-16844	and	_	
72-17	16845-16855	punishment	_	
72-18	16856-16859	and	_	
72-19	16860-16865	three	_	
72-20	16866-16873	studies	_	
72-21	16874-16878	show	_	
72-22	16879-16892	relationships	_	
72-23	16893-16900	between	_	
72-24	16901-16908	ventral	_	
72-25	16909-16917	striatal	_	
72-26	16918-16928	activation	_	
72-27	16929-16931	on	_	
72-28	16932-16936	this	_	
72-29	16937-16941	task	_	
72-30	16942-16945	and	_	
72-31	16946-16950	risk	_	
72-32	16951-16957	taking	_	
72-33	16958-16961	and	_	
72-34	16961-16962	/	_	
72-35	16962-16964	or	_	
72-36	16965-16974	substance	_	
72-37	16975-16978	use	_	
72-38	16979-16981	in	_	
72-39	16982-16985	the	_	
72-40	16986-16992	IMAGEN	_	
72-41	16993-16999	sample	_	
72-42	16999-17000	.	_	

#Text=The fMRI adaptation of the Stop-Signal Task measures activity in brain areas related to the inhibition of an already planned motor response as well as error detection.
73-1	17001-17004	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-2	17005-17009	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-3	17010-17020	adaptation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-4	17021-17023	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-5	17024-17027	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-6	17028-17039	Stop-Signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-7	17040-17044	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[66]	
73-8	17045-17053	measures	_	
73-9	17054-17062	activity	_	
73-10	17063-17065	in	_	
73-11	17066-17071	brain	_	
73-12	17072-17077	areas	_	
73-13	17078-17085	related	_	
73-14	17086-17088	to	_	
73-15	17089-17092	the	_	
73-16	17093-17103	inhibition	_	
73-17	17104-17106	of	_	
73-18	17107-17109	an	_	
73-19	17110-17117	already	_	
73-20	17118-17125	planned	_	
73-21	17126-17131	motor	_	
73-22	17132-17140	response	_	
73-23	17141-17143	as	_	
73-24	17144-17148	well	_	
73-25	17149-17151	as	_	
73-26	17152-17157	error	_	
73-27	17158-17167	detection	_	
73-28	17167-17168	.	_	

#Text=On a total of 300 trials, a motor response to high frequency go signals (75% of trials) has to be inhibited when infrequently and unexpectedly (in randomized 25% of trials), a stop signal appears after the go signal.
74-1	17169-17171	On	_	
74-2	17172-17173	a	_	
74-3	17174-17179	total	_	
74-4	17180-17182	of	_	
74-5	17183-17186	300	_	
74-6	17187-17193	trials	_	
74-7	17193-17194	,	_	
74-8	17195-17196	a	_	
74-9	17197-17202	motor	_	
74-10	17203-17211	response	_	
74-11	17212-17214	to	_	
74-12	17215-17219	high	_	
74-13	17220-17229	frequency	_	
74-14	17230-17232	go	_	
74-15	17233-17240	signals	_	
74-16	17241-17242	(	_	
74-17	17242-17245	75%	_	
74-18	17246-17248	of	_	
74-19	17249-17255	trials	_	
74-20	17255-17256	)	_	
74-21	17257-17260	has	_	
74-22	17261-17263	to	_	
74-23	17264-17266	be	_	
74-24	17267-17276	inhibited	_	
74-25	17277-17281	when	_	
74-26	17282-17294	infrequently	_	
74-27	17295-17298	and	_	
74-28	17299-17311	unexpectedly	_	
74-29	17312-17313	(	_	
74-30	17313-17315	in	_	
74-31	17316-17326	randomized	_	
74-32	17327-17330	25%	_	
74-33	17331-17333	of	_	
74-34	17334-17340	trials	_	
74-35	17340-17341	)	_	
74-36	17341-17342	,	_	
74-37	17343-17344	a	_	
74-38	17345-17349	stop	_	
74-39	17350-17356	signal	_	
74-40	17357-17364	appears	_	
74-41	17365-17370	after	_	
74-42	17371-17374	the	_	
74-43	17375-17377	go	_	
74-44	17378-17384	signal	_	
74-45	17384-17385	.	_	

#Text=The task is individually titrated to force every subject to fail on 50% of stop trials, making every subject work at the edge of their own inhibitory capacity, and therefore adjusting for differences in success levels between subjects and groups, making it ideal for developmental studies.
75-1	17386-17389	The	_	
75-2	17390-17394	task	_	
75-3	17395-17397	is	_	
75-4	17398-17410	individually	_	
75-5	17411-17419	titrated	_	
75-6	17420-17422	to	_	
75-7	17423-17428	force	_	
75-8	17429-17434	every	_	
75-9	17435-17442	subject	_	
75-10	17443-17445	to	_	
75-11	17446-17450	fail	_	
75-12	17451-17453	on	_	
75-13	17454-17457	50%	_	
75-14	17458-17460	of	_	
75-15	17461-17465	stop	_	
75-16	17466-17472	trials	_	
75-17	17472-17473	,	_	
75-18	17474-17480	making	_	
75-19	17481-17486	every	_	
75-20	17487-17494	subject	_	
75-21	17495-17499	work	_	
75-22	17500-17502	at	_	
75-23	17503-17506	the	_	
75-24	17507-17511	edge	_	
75-25	17512-17514	of	_	
75-26	17515-17520	their	_	
75-27	17521-17524	own	_	
75-28	17525-17535	inhibitory	_	
75-29	17536-17544	capacity	_	
75-30	17544-17545	,	_	
75-31	17546-17549	and	_	
75-32	17550-17559	therefore	_	
75-33	17560-17569	adjusting	_	
75-34	17570-17573	for	_	
75-35	17574-17585	differences	_	
75-36	17586-17588	in	_	
75-37	17589-17596	success	_	
75-38	17597-17603	levels	_	
75-39	17604-17611	between	_	
75-40	17612-17620	subjects	_	
75-41	17621-17624	and	_	
75-42	17625-17631	groups	_	
75-43	17631-17632	,	_	
75-44	17633-17639	making	_	
75-45	17640-17642	it	_	
75-46	17643-17648	ideal	_	
75-47	17649-17652	for	_	
75-48	17653-17666	developmental	_	
75-49	17667-17674	studies	_	
75-50	17674-17675	.	_	

#Text=The fronto-striato-thalamic network during successful inhibition shows a progressive functional maturation between childhood and adulthood.
76-1	17676-17679	The	_	
76-2	17680-17703	fronto-striato-thalamic	_	
76-3	17704-17711	network	_	
76-4	17712-17718	during	_	
76-5	17719-17729	successful	_	
76-6	17730-17740	inhibition	_	
76-7	17741-17746	shows	_	
76-8	17747-17748	a	_	
76-9	17749-17760	progressive	_	
76-10	17761-17771	functional	_	
76-11	17772-17782	maturation	_	
76-12	17783-17790	between	_	
76-13	17791-17800	childhood	_	
76-14	17801-17804	and	_	
76-15	17805-17814	adulthood	_	
76-16	17814-17815	.	_	

#Text=Sample size justification
#Text=An estimated 125 subjects in total will be required to identify a moderate effect of personality group (high SS, high IMP, low-risk) on brain measures, prior to the initiation of alcohol use, with 4 covariates, critical F(2, 118) = 3.07, p = 0.05, 85% power.
77-1	17816-17822	Sample	_	
77-2	17823-17827	size	_	
77-3	17828-17841	justification	_	
77-4	17842-17844	An	_	
77-5	17845-17854	estimated	_	
77-6	17855-17858	125	_	
77-7	17859-17867	subjects	_	
77-8	17868-17870	in	_	
77-9	17871-17876	total	_	
77-10	17877-17881	will	_	
77-11	17882-17884	be	_	
77-12	17885-17893	required	_	
77-13	17894-17896	to	_	
77-14	17897-17905	identify	_	
77-15	17906-17907	a	_	
77-16	17908-17916	moderate	_	
77-17	17917-17923	effect	_	
77-18	17924-17926	of	_	
77-19	17927-17938	personality	_	
77-20	17939-17944	group	_	
77-21	17945-17946	(	_	
77-22	17946-17950	high	_	
77-23	17951-17953	SS	_	
77-24	17953-17954	,	_	
77-25	17955-17959	high	_	
77-26	17960-17963	IMP	_	
77-27	17963-17964	,	_	
77-28	17965-17973	low-risk	_	
77-29	17973-17974	)	_	
77-30	17975-17977	on	_	
77-31	17978-17983	brain	_	
77-32	17984-17992	measures	_	
77-33	17992-17993	,	_	
77-34	17994-17999	prior	_	
77-35	18000-18002	to	_	
77-36	18003-18006	the	_	
77-37	18007-18017	initiation	_	
77-38	18018-18020	of	_	
77-39	18021-18028	alcohol	_	
77-40	18029-18032	use	_	
77-41	18032-18033	,	_	
77-42	18034-18038	with	_	
77-43	18039-18040	4	_	
77-44	18041-18051	covariates	_	
77-45	18051-18052	,	_	
77-46	18053-18061	critical	_	
77-47	18062-18063	F	_	
77-48	18063-18064	(	_	
77-49	18064-18065	2	_	
77-50	18065-18066	,	_	
77-51	18067-18070	118	_	
77-52	18070-18071	)	_	
77-53	18072-18073	=	_	
77-54	18074-18078	3.07	_	
77-55	18078-18079	,	_	
77-56	18080-18081	p	_	
77-57	18082-18083	=	_	
77-58	18084-18088	0.05	_	
77-59	18088-18089	,	_	
77-60	18090-18093	85%	_	
77-61	18094-18099	power	_	
77-62	18099-18100	.	_	

#Text=Another 25 participants will be added to the sample to allow for attrition (15% over 4 years, based on previous studies).
78-1	18101-18108	Another	_	
78-2	18109-18111	25	_	
78-3	18112-18124	participants	_	
78-4	18125-18129	will	_	
78-5	18130-18132	be	_	
78-6	18133-18138	added	_	
78-7	18139-18141	to	_	
78-8	18142-18145	the	_	
78-9	18146-18152	sample	_	
78-10	18153-18155	to	_	
78-11	18156-18161	allow	_	
78-12	18162-18165	for	_	
78-13	18166-18175	attrition	_	
78-14	18176-18177	(	_	
78-15	18177-18180	15%	_	
78-16	18181-18185	over	_	
78-17	18186-18187	4	_	
78-18	18187-18188	 	_	
78-19	18188-18193	years	_	
78-20	18193-18194	,	_	
78-21	18195-18200	based	_	
78-22	18201-18203	on	_	
78-23	18204-18212	previous	_	
78-24	18213-18220	studies	_	
78-25	18220-18221	)	_	
78-26	18221-18222	.	_	

#Text=This sample size will provide 90% power to assess moderate group differences in developmental trajectories of alcohol use (group by time interactions) within a longitudinal design with 3 repeated assessments and corrections for multiple testing, critical F(4240) = 3.40, p = 0.001.
79-1	18223-18227	This	_	
79-2	18228-18234	sample	_	
79-3	18235-18239	size	_	
79-4	18240-18244	will	_	
79-5	18245-18252	provide	_	
79-6	18253-18256	90%	_	
79-7	18257-18262	power	_	
79-8	18263-18265	to	_	
79-9	18266-18272	assess	_	
79-10	18273-18281	moderate	_	
79-11	18282-18287	group	_	
79-12	18288-18299	differences	_	
79-13	18300-18302	in	_	
79-14	18303-18316	developmental	_	
79-15	18317-18329	trajectories	_	
79-16	18330-18332	of	_	
79-17	18333-18340	alcohol	_	
79-18	18341-18344	use	_	
79-19	18345-18346	(	_	
79-20	18346-18351	group	_	
79-21	18352-18354	by	_	
79-22	18355-18359	time	_	
79-23	18360-18372	interactions	_	
79-24	18372-18373	)	_	
79-25	18374-18380	within	_	
79-26	18381-18382	a	_	
79-27	18383-18395	longitudinal	_	
79-28	18396-18402	design	_	
79-29	18403-18407	with	_	
79-30	18408-18409	3	_	
79-31	18410-18418	repeated	_	
79-32	18419-18430	assessments	_	
79-33	18431-18434	and	_	
79-34	18435-18446	corrections	_	
79-35	18447-18450	for	_	
79-36	18451-18459	multiple	_	
79-37	18460-18467	testing	_	
79-38	18467-18468	,	_	
79-39	18469-18477	critical	_	
79-40	18478-18479	F	_	
79-41	18479-18480	(	_	
79-42	18480-18484	4240	_	
79-43	18484-18485	)	_	
79-44	18486-18487	=	_	
79-45	18488-18492	3.40	_	
79-46	18492-18493	,	_	
79-47	18494-18495	p	_	
79-48	18496-18497	=	_	
79-49	18498-18503	0.001	_	
79-50	18503-18504	.	_	

#Text=The current study will be sufficiently powered to detect two-year changes on functional and structural data, considering numerous previous studies of similar size showing moderate (r = .30) age-related activation in cortical and subcortical regions of the brain when performing fMRI tasks tapping attention and higher cognitive abilities.
80-1	18505-18508	The	_	
80-2	18509-18516	current	_	
80-3	18517-18522	study	_	
80-4	18523-18527	will	_	
80-5	18528-18530	be	_	
80-6	18531-18543	sufficiently	_	
80-7	18544-18551	powered	_	
80-8	18552-18554	to	_	
80-9	18555-18561	detect	_	
80-10	18562-18570	two-year	_	
80-11	18571-18578	changes	_	
80-12	18579-18581	on	_	
80-13	18582-18592	functional	_	
80-14	18593-18596	and	_	
80-15	18597-18607	structural	_	
80-16	18608-18612	data	_	
80-17	18612-18613	,	_	
80-18	18614-18625	considering	_	
80-19	18626-18634	numerous	_	
80-20	18635-18643	previous	_	
80-21	18644-18651	studies	_	
80-22	18652-18654	of	_	
80-23	18655-18662	similar	_	
80-24	18663-18667	size	_	
80-25	18668-18675	showing	_	
80-26	18676-18684	moderate	_	
80-27	18685-18686	(	_	
80-28	18686-18687	r	_	
80-29	18688-18689	=	_	
80-30	18690-18693	.30	_	
80-31	18693-18694	)	_	
80-32	18695-18706	age-related	_	
80-33	18707-18717	activation	_	
80-34	18718-18720	in	_	
80-35	18721-18729	cortical	_	
80-36	18730-18733	and	_	
80-37	18734-18745	subcortical	_	
80-38	18746-18753	regions	_	
80-39	18754-18756	of	_	
80-40	18757-18760	the	_	
80-41	18761-18766	brain	_	
80-42	18767-18771	when	_	
80-43	18772-18782	performing	_	
80-44	18783-18787	fMRI	_	
80-45	18788-18793	tasks	_	
80-46	18794-18801	tapping	_	
80-47	18802-18811	attention	_	
80-48	18812-18815	and	_	
80-49	18816-18822	higher	_	
80-50	18823-18832	cognitive	_	
80-51	18833-18842	abilities	_	
80-52	18842-18843	.	_	

#Text=Similar power is required to test the effects of intervention.
81-1	18844-18851	Similar	_	
81-2	18852-18857	power	_	
81-3	18858-18860	is	_	
81-4	18861-18869	required	_	
81-5	18870-18872	to	_	
81-6	18873-18877	test	_	
81-7	18878-18881	the	_	
81-8	18882-18889	effects	_	
81-9	18890-18892	of	_	
81-10	18893-18905	intervention	_	
81-11	18905-18906	.	_	

#Text=Data analysis
#Text=Structural image analysis will be conducted with the cortical thickness and voxel based morphometry (VBM) analysis pipeline, CIVET (version 2.0) (http://www.bic.mni.mcgill.ca/ServicesSoftware/CIVET-2-0-0-Introduction.
82-1	18907-18911	Data	_	
82-2	18912-18920	analysis	_	
82-3	18921-18931	Structural	_	
82-4	18932-18937	image	_	
82-5	18938-18946	analysis	_	
82-6	18947-18951	will	_	
82-7	18952-18954	be	_	
82-8	18955-18964	conducted	_	
82-9	18965-18969	with	_	
82-10	18970-18973	the	_	
82-11	18974-18982	cortical	_	
82-12	18983-18992	thickness	_	
82-13	18993-18996	and	_	
82-14	18997-19002	voxel	_	
82-15	19003-19008	based	_	
82-16	19009-19020	morphometry	_	
82-17	19021-19022	(	_	
82-18	19022-19025	VBM	_	
82-19	19025-19026	)	_	
82-20	19027-19035	analysis	_	
82-21	19036-19044	pipeline	_	
82-22	19044-19045	,	_	
82-23	19046-19051	CIVET	_	
82-24	19052-19053	(	_	
82-25	19053-19060	version	_	
82-26	19061-19064	2.0	_	
82-27	19064-19065	)	_	
82-28	19066-19067	(	_	
82-29	19067-19071	http	_	
82-30	19071-19072	:	_	
82-31	19072-19073	/	_	
82-32	19073-19074	/	_	
82-33	19074-19095	www.bic.mni.mcgill.ca	_	
82-34	19095-19096	/	_	
82-35	19096-19112	ServicesSoftware	_	
82-36	19112-19113	/	_	
82-37	19113-19118	CIVET	_	
82-38	19118-19119	-	_	
82-39	19119-19120	2	_	
82-40	19120-19121	-	_	
82-41	19121-19122	0	_	
82-42	19122-19123	-	_	
82-43	19123-19124	0	_	
82-44	19124-19125	-	_	
82-45	19125-19137	Introduction	_	
82-46	19137-19138	.	_	

#Text=T1-weighted MRI images will be corrected for non-uniformity artifacts using the N3 algorithm, masked and registered into stereotaxic space, and then segmented into grey matter, white matter and cerebral spinal fluid using an advanced neural net classifier.
83-1	19139-19141	T1	_	
83-2	19141-19142	-	_	
83-3	19142-19150	weighted	_	
83-4	19151-19154	MRI	_	
83-5	19155-19161	images	_	
83-6	19162-19166	will	_	
83-7	19167-19169	be	_	
83-8	19170-19179	corrected	_	
83-9	19180-19183	for	_	
83-10	19184-19198	non-uniformity	_	
83-11	19199-19208	artifacts	_	
83-12	19209-19214	using	_	
83-13	19215-19218	the	_	
83-14	19219-19221	N3	_	
83-15	19222-19231	algorithm	_	
83-16	19231-19232	,	_	
83-17	19233-19239	masked	_	
83-18	19240-19243	and	_	
83-19	19244-19254	registered	_	
83-20	19255-19259	into	_	
83-21	19260-19271	stereotaxic	_	
83-22	19272-19277	space	_	
83-23	19277-19278	,	_	
83-24	19279-19282	and	_	
83-25	19283-19287	then	_	
83-26	19288-19297	segmented	_	
83-27	19298-19302	into	_	
83-28	19303-19307	grey	_	
83-29	19308-19314	matter	_	
83-30	19314-19315	,	_	
83-31	19316-19321	white	_	
83-32	19322-19328	matter	_	
83-33	19329-19332	and	_	
83-34	19333-19341	cerebral	_	
83-35	19342-19348	spinal	_	
83-36	19349-19354	fluid	_	
83-37	19355-19360	using	_	
83-38	19361-19363	an	_	
83-39	19364-19372	advanced	_	
83-40	19373-19379	neural	_	
83-41	19380-19383	net	_	
83-42	19384-19394	classifier	_	
83-43	19394-19395	.	_	

#Text=The white and grey matter surfaces will be extracted using the Constrained Laplacian-based Automated Segmentation with Proximities algorithm.
84-1	19396-19399	The	_	
84-2	19400-19405	white	_	
84-3	19406-19409	and	_	
84-4	19410-19414	grey	_	
84-5	19415-19421	matter	_	
84-6	19422-19430	surfaces	_	
84-7	19431-19435	will	_	
84-8	19436-19438	be	_	
84-9	19439-19448	extracted	_	
84-10	19449-19454	using	_	
84-11	19455-19458	the	_	
84-12	19459-19470	Constrained	_	
84-13	19471-19486	Laplacian-based	_	
84-14	19487-19496	Automated	_	
84-15	19497-19509	Segmentation	_	
84-16	19510-19514	with	_	
84-17	19515-19526	Proximities	_	
84-18	19527-19536	algorithm	_	
84-19	19536-19537	.	_	

#Text=The resulting surfaces will be resampled to a stereotaxic surface template to provide vertex based measures of cortical thickness.
85-1	19538-19541	The	_	
85-2	19542-19551	resulting	_	
85-3	19552-19560	surfaces	_	
85-4	19561-19565	will	_	
85-5	19566-19568	be	_	
85-6	19569-19578	resampled	_	
85-7	19579-19581	to	_	
85-8	19582-19583	a	_	
85-9	19584-19595	stereotaxic	_	
85-10	19596-19603	surface	_	
85-11	19604-19612	template	_	
85-12	19613-19615	to	_	
85-13	19616-19623	provide	_	
85-14	19624-19630	vertex	_	
85-15	19631-19636	based	_	
85-16	19637-19645	measures	_	
85-17	19646-19648	of	_	
85-18	19649-19657	cortical	_	
85-19	19658-19667	thickness	_	
85-20	19667-19668	.	_	

#Text=For each participant, cortical thickness will then be measured in native space using the linked distance between the two surfaces across 81,924 vertices and a 20 mm surface smoothing kernel will be applied to the data.
86-1	19669-19672	For	_	
86-2	19673-19677	each	_	
86-3	19678-19689	participant	_	
86-4	19689-19690	,	_	
86-5	19691-19699	cortical	_	
86-6	19700-19709	thickness	_	
86-7	19710-19714	will	_	
86-8	19715-19719	then	_	
86-9	19720-19722	be	_	
86-10	19723-19731	measured	_	
86-11	19732-19734	in	_	
86-12	19735-19741	native	_	
86-13	19742-19747	space	_	
86-14	19748-19753	using	_	
86-15	19754-19757	the	_	
86-16	19758-19764	linked	_	
86-17	19765-19773	distance	_	
86-18	19774-19781	between	_	
86-19	19782-19785	the	_	
86-20	19786-19789	two	_	
86-21	19790-19798	surfaces	_	
86-22	19799-19805	across	_	
86-23	19806-19812	81,924	_	
86-24	19813-19821	vertices	_	
86-25	19822-19825	and	_	
86-26	19826-19827	a	_	
86-27	19828-19830	20	_	
86-28	19830-19831	 	_	
86-29	19831-19833	mm	_	
86-30	19834-19841	surface	_	
86-31	19842-19851	smoothing	_	
86-32	19852-19858	kernel	_	
86-33	19859-19863	will	_	
86-34	19864-19866	be	_	
86-35	19867-19874	applied	_	
86-36	19875-19877	to	_	
86-37	19878-19881	the	_	
86-38	19882-19886	data	_	
86-39	19886-19887	.	_	

#Text=Statistical analyses will be performed using SurfStat (http://www.math.mcgill.ca/keith/surfstat/), a statistical toolbox created for MATLAB (The MathWorks, Inc., Nathan, MA, USA).
87-1	19888-19899	Statistical	_	
87-2	19900-19908	analyses	_	
87-3	19909-19913	will	_	
87-4	19914-19916	be	_	
87-5	19917-19926	performed	_	
87-6	19927-19932	using	_	
87-7	19933-19941	SurfStat	_	
87-8	19942-19943	(	_	
87-9	19943-19947	http	_	
87-10	19947-19948	:	_	
87-11	19948-19949	/	_	
87-12	19949-19950	/	_	
87-13	19950-19968	www.math.mcgill.ca	_	
87-14	19968-19969	/	_	
87-15	19969-19974	keith	_	
87-16	19974-19975	/	_	
87-17	19975-19983	surfstat	_	
87-18	19983-19984	/	_	
87-19	19984-19985	)	_	
87-20	19985-19986	,	_	
87-21	19987-19988	a	_	
87-22	19989-20000	statistical	_	
87-23	20001-20008	toolbox	_	
87-24	20009-20016	created	_	
87-25	20017-20020	for	_	
87-26	20021-20027	MATLAB	_	
87-27	20028-20029	(	_	
87-28	20029-20032	The	_	
87-29	20033-20042	MathWorks	_	
87-30	20042-20043	,	_	
87-31	20044-20047	Inc	_	
87-32	20047-20048	.	_	
87-33	20048-20049	,	_	
87-34	20050-20056	Nathan	_	
87-35	20056-20057	,	_	
87-36	20058-20060	MA	_	
87-37	20060-20061	,	_	
87-38	20062-20065	USA	_	
87-39	20065-20066	)	_	
87-40	20066-20067	.	_	

#Text=Diffusion images will be processed with FSL (FMRIB Diffusion Toolbox, http://www.fmrib.ox.ac.uk/fsl/).
88-1	20068-20077	Diffusion	_	
88-2	20078-20084	images	_	
88-3	20085-20089	will	_	
88-4	20090-20092	be	_	
88-5	20093-20102	processed	_	
88-6	20103-20107	with	_	
88-7	20108-20111	FSL	_	
88-8	20112-20113	(	_	
88-9	20113-20118	FMRIB	_	
88-10	20119-20128	Diffusion	_	
88-11	20129-20136	Toolbox	_	
88-12	20136-20137	,	_	
88-13	20138-20142	http	_	
88-14	20142-20143	:	_	
88-15	20143-20144	/	_	
88-16	20144-20145	/	_	
88-17	20145-20163	www.fmrib.ox.ac.uk	_	
88-18	20163-20164	/	_	
88-19	20164-20167	fsl	_	
88-20	20167-20168	/	_	
88-21	20168-20169	)	_	
88-22	20169-20170	.	_	

#Text=Motion artifacts and eddy current distortions will be corrected by using affine registration of DWI to the b0 image.
89-1	20171-20177	Motion	_	
89-2	20178-20187	artifacts	_	
89-3	20188-20191	and	_	
89-4	20192-20196	eddy	_	
89-5	20197-20204	current	_	
89-6	20205-20216	distortions	_	
89-7	20217-20221	will	_	
89-8	20222-20224	be	_	
89-9	20225-20234	corrected	_	
89-10	20235-20237	by	_	
89-11	20238-20243	using	_	
89-12	20244-20250	affine	_	
89-13	20251-20263	registration	_	
89-14	20264-20266	of	_	
89-15	20267-20270	DWI	_	
89-16	20271-20273	to	_	
89-17	20274-20277	the	_	
89-18	20278-20280	b0	_	
89-19	20281-20286	image	_	
89-20	20286-20287	.	_	

#Text=Diffusion data will be registered to standard MNI152 space (2 mm isotropic) using a two-stage registration: rigid-body alignment and nonlinear transformation.
90-1	20288-20297	Diffusion	_	
90-2	20298-20302	data	_	
90-3	20303-20307	will	_	
90-4	20308-20310	be	_	
90-5	20311-20321	registered	_	
90-6	20322-20324	to	_	
90-7	20325-20333	standard	_	
90-8	20334-20340	MNI152	_	
90-9	20341-20346	space	_	
90-10	20347-20348	(	_	
90-11	20348-20349	2	_	
90-12	20349-20350	 	_	
90-13	20350-20352	mm	_	
90-14	20353-20362	isotropic	_	
90-15	20362-20363	)	_	
90-16	20364-20369	using	_	
90-17	20370-20371	a	_	
90-18	20372-20381	two-stage	_	
90-19	20382-20394	registration	_	
90-20	20394-20395	:	_	
90-21	20396-20406	rigid-body	_	
90-22	20407-20416	alignment	_	
90-23	20417-20420	and	_	
90-24	20421-20430	nonlinear	_	
90-25	20431-20445	transformation	_	
90-26	20445-20446	.	_	

#Text=A diffusion tensor model will be fitted for each voxel to estimate the principle fiber directions and calculate a fractional anisotropy (FA) map.
91-1	20447-20448	A	_	
91-2	20449-20458	diffusion	_	
91-3	20459-20465	tensor	_	
91-4	20466-20471	model	_	
91-5	20472-20476	will	_	
91-6	20477-20479	be	_	
91-7	20480-20486	fitted	_	
91-8	20487-20490	for	_	
91-9	20491-20495	each	_	
91-10	20496-20501	voxel	_	
91-11	20502-20504	to	_	
91-12	20505-20513	estimate	_	
91-13	20514-20517	the	_	
91-14	20518-20527	principle	_	
91-15	20528-20533	fiber	_	
91-16	20534-20544	directions	_	
91-17	20545-20548	and	_	
91-18	20549-20558	calculate	_	
91-19	20559-20560	a	_	
91-20	20561-20571	fractional	_	
91-21	20572-20582	anisotropy	_	
91-22	20583-20584	(	_	
91-23	20584-20586	FA	_	
91-24	20586-20587	)	_	
91-25	20588-20591	map	_	
91-26	20591-20592	.	_	

#Text=Then, the probabilistic distribution of fiber orientations will be estimated using FSL’s BEDPOSTX with a maximum of 2 fiber directions per voxel.
92-1	20593-20597	Then	_	
92-2	20597-20598	,	_	
92-3	20599-20602	the	_	
92-4	20603-20616	probabilistic	_	
92-5	20617-20629	distribution	_	
92-6	20630-20632	of	_	
92-7	20633-20638	fiber	_	
92-8	20639-20651	orientations	_	
92-9	20652-20656	will	_	
92-10	20657-20659	be	_	
92-11	20660-20669	estimated	_	
92-12	20670-20675	using	_	
92-13	20676-20679	FSL	_	
92-14	20679-20680	’	_	
92-15	20680-20681	s	_	
92-16	20682-20690	BEDPOSTX	_	
92-17	20691-20695	with	_	
92-18	20696-20697	a	_	
92-19	20698-20705	maximum	_	
92-20	20706-20708	of	_	
92-21	20709-20710	2	_	
92-22	20711-20716	fiber	_	
92-23	20717-20727	directions	_	
92-24	20728-20731	per	_	
92-25	20732-20737	voxel	_	
92-26	20737-20738	.	_	

#Text=The probabilistic tractography will be applied by sampling 10,000 streamline fibers per voxel within the seed region using FSL’s PROBTRACKX.
93-1	20739-20742	The	_	
93-2	20743-20756	probabilistic	_	
93-3	20757-20769	tractography	_	
93-4	20770-20774	will	_	
93-5	20775-20777	be	_	
93-6	20778-20785	applied	_	
93-7	20786-20788	by	_	
93-8	20789-20797	sampling	_	
93-9	20798-20804	10,000	_	
93-10	20805-20815	streamline	_	
93-11	20816-20822	fibers	_	
93-12	20823-20826	per	_	
93-13	20827-20832	voxel	_	
93-14	20833-20839	within	_	
93-15	20840-20843	the	_	
93-16	20844-20848	seed	_	
93-17	20849-20855	region	_	
93-18	20856-20861	using	_	
93-19	20862-20865	FSL	_	
93-20	20865-20866	’	_	
93-21	20866-20867	s	_	
93-22	20868-20878	PROBTRACKX	_	
93-23	20878-20879	.	_	

#Text=Functional image analysis will be carried out using FSL (FEAT – FMRI Expert Analysis Tool).
94-1	20880-20890	Functional	_	
94-2	20891-20896	image	_	
94-3	20897-20905	analysis	_	
94-4	20906-20910	will	_	
94-5	20911-20913	be	_	
94-6	20914-20921	carried	_	
94-7	20922-20925	out	_	
94-8	20926-20931	using	_	
94-9	20932-20935	FSL	_	
94-10	20936-20937	(	_	
94-11	20937-20941	FEAT	_	
94-12	20942-20943	–	_	
94-13	20944-20948	FMRI	_	
94-14	20949-20955	Expert	_	
94-15	20956-20964	Analysis	_	
94-16	20965-20969	Tool	_	
94-17	20969-20970	)	_	
94-18	20970-20971	.	_	

#Text=The following pre-processing steps will be applied: motion correction using MCFLIRT, non-brain removal using BET, and spatial smoothing with a Gaussian kernel of FWHM 6 mm.
95-1	20972-20975	The	_	
95-2	20976-20985	following	_	
95-3	20986-21000	pre-processing	_	
95-4	21001-21006	steps	_	
95-5	21007-21011	will	_	
95-6	21012-21014	be	_	
95-7	21015-21022	applied	_	
95-8	21022-21023	:	_	
95-9	21024-21030	motion	_	
95-10	21031-21041	correction	_	
95-11	21042-21047	using	_	
95-12	21048-21055	MCFLIRT	_	
95-13	21055-21056	,	_	
95-14	21057-21066	non-brain	_	
95-15	21067-21074	removal	_	
95-16	21075-21080	using	_	
95-17	21081-21084	BET	_	
95-18	21084-21085	,	_	
95-19	21086-21089	and	_	
95-20	21090-21097	spatial	_	
95-21	21098-21107	smoothing	_	
95-22	21108-21112	with	_	
95-23	21113-21114	a	_	
95-24	21115-21123	Gaussian	_	
95-25	21124-21130	kernel	_	
95-26	21131-21133	of	_	
95-27	21134-21138	FWHM	_	
95-28	21139-21140	6	_	
95-29	21140-21141	 	_	
95-30	21141-21143	mm	_	
95-31	21143-21144	.	_	

#Text=Time-series general linear model will be carried out using FILM with an autocorrelation correction.
96-1	21145-21156	Time-series	_	
96-2	21157-21164	general	_	
96-3	21165-21171	linear	_	
96-4	21172-21177	model	_	
96-5	21178-21182	will	_	
96-6	21183-21185	be	_	
96-7	21186-21193	carried	_	
96-8	21194-21197	out	_	
96-9	21198-21203	using	_	
96-10	21204-21208	FILM	_	
96-11	21209-21213	with	_	
96-12	21214-21216	an	_	
96-13	21217-21232	autocorrelation	_	
96-14	21233-21243	correction	_	
96-15	21243-21244	.	_	

#Text=At the first level, the following contrasts: anticipation/feedback of win and lose vs reference (MIDT) and successful and failed inhibition vs baseline (Stop-Signal Task) will be estimated for each participant.
97-1	21245-21247	At	_	
97-2	21248-21251	the	_	
97-3	21252-21257	first	_	
97-4	21258-21263	level	_	
97-5	21263-21264	,	_	
97-6	21265-21268	the	_	
97-7	21269-21278	following	_	
97-8	21279-21288	contrasts	_	
97-9	21288-21289	:	_	
97-10	21290-21302	anticipation	_	
97-11	21302-21303	/	_	
97-12	21303-21311	feedback	_	
97-13	21312-21314	of	_	
97-14	21315-21318	win	_	
97-15	21319-21322	and	_	
97-16	21323-21327	lose	_	
97-17	21328-21330	vs	_	
97-18	21331-21340	reference	_	
97-19	21341-21342	(	_	
97-20	21342-21346	MIDT	_	
97-21	21346-21347	)	_	
97-22	21348-21351	and	_	
97-23	21352-21362	successful	_	
97-24	21363-21366	and	_	
97-25	21367-21373	failed	_	
97-26	21374-21384	inhibition	_	
97-27	21385-21387	vs	_	
97-28	21388-21396	baseline	_	
97-29	21397-21398	(	_	
97-30	21398-21409	Stop-Signal	_	
97-31	21410-21414	Task	_	
97-32	21414-21415	)	_	
97-33	21416-21420	will	_	
97-34	21421-21423	be	_	
97-35	21424-21433	estimated	_	
97-36	21434-21437	for	_	
97-37	21438-21442	each	_	
97-38	21443-21454	participant	_	
97-39	21454-21455	.	_	

#Text=Group-level (second level) analysis will be carried out using a fixed effects model, by forcing the random effects variance to zero in FLAME (FMRIB’s Local Analysis of Mixed Effects).
98-1	21456-21467	Group-level	_	
98-2	21468-21469	(	_	
98-3	21469-21475	second	_	
98-4	21476-21481	level	_	
98-5	21481-21482	)	_	
98-6	21483-21491	analysis	_	
98-7	21492-21496	will	_	
98-8	21497-21499	be	_	
98-9	21500-21507	carried	_	
98-10	21508-21511	out	_	
98-11	21512-21517	using	_	
98-12	21518-21519	a	_	
98-13	21520-21525	fixed	_	
98-14	21526-21533	effects	_	
98-15	21534-21539	model	_	
98-16	21539-21540	,	_	
98-17	21541-21543	by	_	
98-18	21544-21551	forcing	_	
98-19	21552-21555	the	_	
98-20	21556-21562	random	_	
98-21	21563-21570	effects	_	
98-22	21571-21579	variance	_	
98-23	21580-21582	to	_	
98-24	21583-21587	zero	_	
98-25	21588-21590	in	_	
98-26	21591-21596	FLAME	_	
98-27	21597-21598	(	_	
98-28	21598-21603	FMRIB	_	
98-29	21603-21604	’	_	
98-30	21604-21605	s	_	
98-31	21606-21611	Local	_	
98-32	21612-21620	Analysis	_	
98-33	21621-21623	of	_	
98-34	21624-21629	Mixed	_	
98-35	21630-21637	Effects	_	
98-36	21637-21638	)	_	
98-37	21638-21639	.	_	

#Text=Z (Gaussianised T/F) statistic images will be thresholded using clusters determined by Z > 2.3 and a corrected cluster significance threshold of p = 0.05.
99-1	21640-21641	Z	_	
99-2	21642-21643	(	_	
99-3	21643-21655	Gaussianised	_	
99-4	21656-21657	T	_	
99-5	21657-21658	/	_	
99-6	21658-21659	F	_	
99-7	21659-21660	)	_	
99-8	21661-21670	statistic	_	
99-9	21671-21677	images	_	
99-10	21678-21682	will	_	
99-11	21683-21685	be	_	
99-12	21686-21697	thresholded	_	
99-13	21698-21703	using	_	
99-14	21704-21712	clusters	_	
99-15	21713-21723	determined	_	
99-16	21724-21726	by	_	
99-17	21727-21728	Z	_	
99-18	21729-21730	>	_	
99-19	21731-21734	2.3	_	
99-20	21735-21738	and	_	
99-21	21739-21740	a	_	
99-22	21741-21750	corrected	_	
99-23	21751-21758	cluster	_	
99-24	21759-21771	significance	_	
99-25	21772-21781	threshold	_	
99-26	21782-21784	of	_	
99-27	21785-21786	p	_	
99-28	21787-21788	=	_	
99-29	21789-21793	0.05	_	
99-30	21793-21794	.	_	

#Text=Statistical analyses
#Text=The main objectives of the statistical analyses will be to characterize differences for fMRI, cortical thickness, VBM, DWI and behavioral measures between high (SS and IMP) and low-risk youth, binge drinkers and non-drinker trajectory, and those assigned to the intervention or not (with and without exposure to alcohol) over time.
100-1	21795-21806	Statistical	_	
100-2	21807-21815	analyses	_	
100-3	21816-21819	The	_	
100-4	21820-21824	main	_	
100-5	21825-21835	objectives	_	
100-6	21836-21838	of	_	
100-7	21839-21842	the	_	
100-8	21843-21854	statistical	_	
100-9	21855-21863	analyses	_	
100-10	21864-21868	will	_	
100-11	21869-21871	be	_	
100-12	21872-21874	to	_	
100-13	21875-21887	characterize	_	
100-14	21888-21899	differences	_	
100-15	21900-21903	for	_	
100-16	21904-21908	fMRI	_	
100-17	21908-21909	,	_	
100-18	21910-21918	cortical	_	
100-19	21919-21928	thickness	_	
100-20	21928-21929	,	_	
100-21	21930-21933	VBM	_	
100-22	21933-21934	,	_	
100-23	21935-21938	DWI	_	
100-24	21939-21942	and	_	
100-25	21943-21953	behavioral	_	
100-26	21954-21962	measures	_	
100-27	21963-21970	between	_	
100-28	21971-21975	high	_	
100-29	21976-21977	(	_	
100-30	21977-21979	SS	_	
100-31	21980-21983	and	_	
100-32	21984-21987	IMP	_	
100-33	21987-21988	)	_	
100-34	21989-21992	and	_	
100-35	21993-22001	low-risk	_	
100-36	22002-22007	youth	_	
100-37	22007-22008	,	_	
100-38	22009-22014	binge	_	
100-39	22015-22023	drinkers	_	
100-40	22024-22027	and	_	
100-41	22028-22039	non-drinker	_	
100-42	22040-22050	trajectory	_	
100-43	22050-22051	,	_	
100-44	22052-22055	and	_	
100-45	22056-22061	those	_	
100-46	22062-22070	assigned	_	
100-47	22071-22073	to	_	
100-48	22074-22077	the	_	
100-49	22078-22090	intervention	_	
100-50	22091-22093	or	_	
100-51	22094-22097	not	_	
100-52	22098-22099	(	_	
100-53	22099-22103	with	_	
100-54	22104-22107	and	_	
100-55	22108-22115	without	_	
100-56	22116-22124	exposure	_	
100-57	22125-22127	to	_	
100-58	22128-22135	alcohol	_	
100-59	22135-22136	)	_	
100-60	22137-22141	over	_	
100-61	22142-22146	time	_	
100-62	22146-22147	.	_	

#Text=Two- and three-way repeated measures analyses of covariance (ANCOVA) will be performed based on region of interest (ROI) scores with covariates such as age, socioeconomic status, pubertal stage, IQ, and other drug use.
101-1	22148-22151	Two	_	
101-2	22151-22152	-	_	
101-3	22153-22156	and	_	
101-4	22157-22166	three-way	_	
101-5	22167-22175	repeated	_	
101-6	22176-22184	measures	_	
101-7	22185-22193	analyses	_	
101-8	22194-22196	of	_	
101-9	22197-22207	covariance	_	
101-10	22208-22209	(	_	
101-11	22209-22215	ANCOVA	_	
101-12	22215-22216	)	_	
101-13	22217-22221	will	_	
101-14	22222-22224	be	_	
101-15	22225-22234	performed	_	
101-16	22235-22240	based	_	
101-17	22241-22243	on	_	
101-18	22244-22250	region	_	
101-19	22251-22253	of	_	
101-20	22254-22262	interest	_	
101-21	22263-22264	(	_	
101-22	22264-22267	ROI	_	
101-23	22267-22268	)	_	
101-24	22269-22275	scores	_	
101-25	22276-22280	with	_	
101-26	22281-22291	covariates	_	
101-27	22292-22296	such	_	
101-28	22297-22299	as	_	
101-29	22300-22303	age	_	
101-30	22303-22304	,	_	
101-31	22305-22318	socioeconomic	_	
101-32	22319-22325	status	_	
101-33	22325-22326	,	_	
101-34	22327-22335	pubertal	_	
101-35	22336-22341	stage	_	
101-36	22341-22342	,	_	
101-37	22343-22345	IQ	_	
101-38	22345-22346	,	_	
101-39	22347-22350	and	_	
101-40	22351-22356	other	_	
101-41	22357-22361	drug	_	
101-42	22362-22365	use	_	
101-43	22365-22366	.	_	

#Text=For cortical thickness and VBM only a-priori defined ROI will be used (i.e., prefrontal lobes, basal ganglia, limbic brain regions and corpus callosum), as previous studies have shown that alcohol affects these regions.
102-1	22367-22370	For	_	
102-2	22371-22379	cortical	_	
102-3	22380-22389	thickness	_	
102-4	22390-22393	and	_	
102-5	22394-22397	VBM	_	
102-6	22398-22402	only	_	
102-7	22403-22411	a-priori	_	
102-8	22412-22419	defined	_	
102-9	22420-22423	ROI	_	
102-10	22424-22428	will	_	
102-11	22429-22431	be	_	
102-12	22432-22436	used	_	
102-13	22437-22438	(	_	
102-14	22438-22441	i.e	_	
102-15	22441-22442	.	_	
102-16	22442-22443	,	_	
102-17	22444-22454	prefrontal	_	
102-18	22455-22460	lobes	_	
102-19	22460-22461	,	_	
102-20	22462-22467	basal	_	
102-21	22468-22475	ganglia	_	
102-22	22475-22476	,	_	
102-23	22477-22483	limbic	_	
102-24	22484-22489	brain	_	
102-25	22490-22497	regions	_	
102-26	22498-22501	and	_	
102-27	22502-22508	corpus	_	
102-28	22509-22517	callosum	_	
102-29	22517-22518	)	_	
102-30	22518-22519	,	_	
102-31	22520-22522	as	_	
102-32	22523-22531	previous	_	
102-33	22532-22539	studies	_	
102-34	22540-22544	have	_	
102-35	22545-22550	shown	_	
102-36	22551-22555	that	_	
102-37	22556-22563	alcohol	_	
102-38	22564-22571	affects	_	
102-39	22572-22577	these	_	
102-40	22578-22585	regions	_	
102-41	22585-22586	.	_	

#Text=For fMRI, we will conduct both exploratory and ROI analyses, and for the DWI data, the regions showing linear age trends in the fMRI analysis will be used as start/finish points for probabilistic tractography.
103-1	22587-22590	For	_	
103-2	22591-22595	fMRI	_	
103-3	22595-22596	,	_	
103-4	22597-22599	we	_	
103-5	22600-22604	will	_	
103-6	22605-22612	conduct	_	
103-7	22613-22617	both	_	
103-8	22618-22629	exploratory	_	
103-9	22630-22633	and	_	
103-10	22634-22637	ROI	_	
103-11	22638-22646	analyses	_	
103-12	22646-22647	,	_	
103-13	22648-22651	and	_	
103-14	22652-22655	for	_	
103-15	22656-22659	the	_	
103-16	22660-22663	DWI	_	
103-17	22664-22668	data	_	
103-18	22668-22669	,	_	
103-19	22670-22673	the	_	
103-20	22674-22681	regions	_	
103-21	22682-22689	showing	_	
103-22	22690-22696	linear	_	
103-23	22697-22700	age	_	
103-24	22701-22707	trends	_	
103-25	22708-22710	in	_	
103-26	22711-22714	the	_	
103-27	22715-22719	fMRI	_	
103-28	22720-22728	analysis	_	
103-29	22729-22733	will	_	
103-30	22734-22736	be	_	
103-31	22737-22741	used	_	
103-32	22742-22744	as	_	
103-33	22745-22750	start	_	
103-34	22750-22751	/	_	
103-35	22751-22757	finish	_	
103-36	22758-22764	points	_	
103-37	22765-22768	for	_	
103-38	22769-22782	probabilistic	_	
103-39	22783-22795	tractography	_	
103-40	22795-22796	.	_	

#Text=Discussion
#Text=Imaging studies using different modalities have consistently reported that alcohol use during adolescence is associated with abnormalities in brain structure, function and connectivity.
104-1	22797-22807	Discussion	_	
104-2	22808-22815	Imaging	_	
104-3	22816-22823	studies	_	
104-4	22824-22829	using	_	
104-5	22830-22839	different	_	
104-6	22840-22850	modalities	_	
104-7	22851-22855	have	_	
104-8	22856-22868	consistently	_	
104-9	22869-22877	reported	_	
104-10	22878-22882	that	_	
104-11	22883-22890	alcohol	_	
104-12	22891-22894	use	_	
104-13	22895-22901	during	_	
104-14	22902-22913	adolescence	_	
104-15	22914-22916	is	_	
104-16	22917-22927	associated	_	
104-17	22928-22932	with	_	
104-18	22933-22946	abnormalities	_	
104-19	22947-22949	in	_	
104-20	22950-22955	brain	_	
104-21	22956-22965	structure	_	
104-22	22965-22966	,	_	
104-23	22967-22975	function	_	
104-24	22976-22979	and	_	
104-25	22980-22992	connectivity	_	
104-26	22992-22993	.	_	

#Text=However, the critical question of whether these anomalies are consequences of alcohol abuse or preexisting vulnerability factors for early use and misuse remains unanswered in the literature.
105-1	22994-23001	However	_	
105-2	23001-23002	,	_	
105-3	23003-23006	the	_	
105-4	23007-23015	critical	_	
105-5	23016-23024	question	_	
105-6	23025-23027	of	_	
105-7	23028-23035	whether	_	
105-8	23036-23041	these	_	
105-9	23042-23051	anomalies	_	
105-10	23052-23055	are	_	
105-11	23056-23068	consequences	_	
105-12	23069-23071	of	_	
105-13	23072-23079	alcohol	_	
105-14	23080-23085	abuse	_	
105-15	23086-23088	or	_	
105-16	23089-23100	preexisting	_	
105-17	23101-23114	vulnerability	_	
105-18	23115-23122	factors	_	
105-19	23123-23126	for	_	
105-20	23127-23132	early	_	
105-21	23133-23136	use	_	
105-22	23137-23140	and	_	
105-23	23141-23147	misuse	_	
105-24	23148-23155	remains	_	
105-25	23156-23166	unanswered	_	
105-26	23167-23169	in	_	
105-27	23170-23173	the	_	
105-28	23174-23184	literature	_	
105-29	23184-23185	.	_	

#Text=This prospective, intervention study will allow us to identify brain, cognitive, and behavioral factors that precede (and predispose to) adolescent alcohol misuse versus factors that are consequential to such use.
106-1	23186-23190	This	_	
106-2	23191-23202	prospective	_	
106-3	23202-23203	,	_	
106-4	23204-23216	intervention	_	
106-5	23217-23222	study	_	
106-6	23223-23227	will	_	
106-7	23228-23233	allow	_	
106-8	23234-23236	us	_	
106-9	23237-23239	to	_	
106-10	23240-23248	identify	_	
106-11	23249-23254	brain	_	
106-12	23254-23255	,	_	
106-13	23256-23265	cognitive	_	
106-14	23265-23266	,	_	
106-15	23267-23270	and	_	
106-16	23271-23281	behavioral	_	
106-17	23282-23289	factors	_	
106-18	23290-23294	that	_	
106-19	23295-23302	precede	_	
106-20	23303-23304	(	_	
106-21	23304-23307	and	_	
106-22	23308-23318	predispose	_	
106-23	23319-23321	to	_	
106-24	23321-23322	)	_	
106-25	23323-23333	adolescent	_	
106-26	23334-23341	alcohol	_	
106-27	23342-23348	misuse	_	
106-28	23349-23355	versus	_	
106-29	23356-23363	factors	_	
106-30	23364-23368	that	_	
106-31	23369-23372	are	_	
106-32	23373-23386	consequential	_	
106-33	23387-23389	to	_	
106-34	23390-23394	such	_	
106-35	23395-23398	use	_	
106-36	23398-23399	.	_	

#Text=Moreover, this unique study will enable us to test whether an early alcohol prevention intervention produces protective effects on brain structure, function and connectivity in adolescents, while controlling for potential pre-morbid factors associated with a susceptibility to early onset drinking.
107-1	23400-23408	Moreover	_	
107-2	23408-23409	,	_	
107-3	23410-23414	this	_	
107-4	23415-23421	unique	_	
107-5	23422-23427	study	_	
107-6	23428-23432	will	_	
107-7	23433-23439	enable	_	
107-8	23440-23442	us	_	
107-9	23443-23445	to	_	
107-10	23446-23450	test	_	
107-11	23451-23458	whether	_	
107-12	23459-23461	an	_	
107-13	23462-23467	early	_	
107-14	23468-23475	alcohol	_	
107-15	23476-23486	prevention	_	
107-16	23487-23499	intervention	_	
107-17	23500-23508	produces	_	
107-18	23509-23519	protective	_	
107-19	23520-23527	effects	_	
107-20	23528-23530	on	_	
107-21	23531-23536	brain	_	
107-22	23537-23546	structure	_	
107-23	23546-23547	,	_	
107-24	23548-23556	function	_	
107-25	23557-23560	and	_	
107-26	23561-23573	connectivity	_	
107-27	23574-23576	in	_	
107-28	23577-23588	adolescents	_	
107-29	23588-23589	,	_	
107-30	23590-23595	while	_	
107-31	23596-23607	controlling	_	
107-32	23608-23611	for	_	
107-33	23612-23621	potential	_	
107-34	23622-23632	pre-morbid	_	
107-35	23633-23640	factors	_	
107-36	23641-23651	associated	_	
107-37	23652-23656	with	_	
107-38	23657-23658	a	_	
107-39	23659-23673	susceptibility	_	
107-40	23674-23676	to	_	
107-41	23677-23682	early	_	
107-42	23683-23688	onset	_	
107-43	23689-23697	drinking	_	
107-44	23697-23698	.	_	

#Text=By focusing on the neural correlates of adolescents at risk for harmful drinking, and by examining the effects of adolescent drinking and binge drinking on the development of brain structure and function, the study will extend the knowledge gained from other large-scale studies (e.g., European Commission FP6-Health www.imagen-europe.com and National Institutes of Health’s “Longitudinal Studies on the Impact of Adolescent Drinking on the Adolescent Brain”).
108-1	23699-23701	By	_	
108-2	23702-23710	focusing	_	
108-3	23711-23713	on	_	
108-4	23714-23717	the	_	
108-5	23718-23724	neural	_	
108-6	23725-23735	correlates	_	
108-7	23736-23738	of	_	
108-8	23739-23750	adolescents	_	
108-9	23751-23753	at	_	
108-10	23754-23758	risk	_	
108-11	23759-23762	for	_	
108-12	23763-23770	harmful	_	
108-13	23771-23779	drinking	_	
108-14	23779-23780	,	_	
108-15	23781-23784	and	_	
108-16	23785-23787	by	_	
108-17	23788-23797	examining	_	
108-18	23798-23801	the	_	
108-19	23802-23809	effects	_	
108-20	23810-23812	of	_	
108-21	23813-23823	adolescent	_	
108-22	23824-23832	drinking	_	
108-23	23833-23836	and	_	
108-24	23837-23842	binge	_	
108-25	23843-23851	drinking	_	
108-26	23852-23854	on	_	
108-27	23855-23858	the	_	
108-28	23859-23870	development	_	
108-29	23871-23873	of	_	
108-30	23874-23879	brain	_	
108-31	23880-23889	structure	_	
108-32	23890-23893	and	_	
108-33	23894-23902	function	_	
108-34	23902-23903	,	_	
108-35	23904-23907	the	_	
108-36	23908-23913	study	_	
108-37	23914-23918	will	_	
108-38	23919-23925	extend	_	
108-39	23926-23929	the	_	
108-40	23930-23939	knowledge	_	
108-41	23940-23946	gained	_	
108-42	23947-23951	from	_	
108-43	23952-23957	other	_	
108-44	23958-23969	large-scale	_	
108-45	23970-23977	studies	_	
108-46	23978-23979	(	_	
108-47	23979-23982	e.g	_	
108-48	23982-23983	.	_	
108-49	23983-23984	,	_	
108-50	23985-23993	European	_	
108-51	23994-24004	Commission	_	
108-52	24005-24008	FP6	_	
108-53	24008-24009	-	_	
108-54	24009-24015	Health	_	
108-55	24016-24037	www.imagen-europe.com	_	
108-56	24038-24041	and	_	
108-57	24042-24050	National	_	
108-58	24051-24061	Institutes	_	
108-59	24062-24064	of	_	
108-60	24065-24071	Health	_	
108-61	24071-24072	’	_	
108-62	24072-24073	s	_	
108-63	24074-24075	“	_	
108-64	24075-24087	Longitudinal	_	
108-65	24088-24095	Studies	_	
108-66	24096-24098	on	_	
108-67	24099-24102	the	_	
108-68	24103-24109	Impact	_	
108-69	24110-24112	of	_	
108-70	24113-24123	Adolescent	_	
108-71	24124-24132	Drinking	_	
108-72	24133-24135	on	_	
108-73	24136-24139	the	_	
108-74	24140-24150	Adolescent	_	
108-75	24151-24156	Brain	_	
108-76	24156-24157	”	_	
108-77	24157-24158	)	_	
108-78	24158-24159	.	_	

#Text=Perhaps more importantly, this innovative experimental design will allow us to test the causal relationship between early alcohol exposure and neurocognitive and addiction outcomes by showing that delaying drinking in those most at-risk protects normal neurocognitive development.
109-1	24160-24167	Perhaps	_	
109-2	24168-24172	more	_	
109-3	24173-24184	importantly	_	
109-4	24184-24185	,	_	
109-5	24186-24190	this	_	
109-6	24191-24201	innovative	_	
109-7	24202-24214	experimental	_	
109-8	24215-24221	design	_	
109-9	24222-24226	will	_	
109-10	24227-24232	allow	_	
109-11	24233-24235	us	_	
109-12	24236-24238	to	_	
109-13	24239-24243	test	_	
109-14	24244-24247	the	_	
109-15	24248-24254	causal	_	
109-16	24255-24267	relationship	_	
109-17	24268-24275	between	_	
109-18	24276-24281	early	_	
109-19	24282-24289	alcohol	_	
109-20	24290-24298	exposure	_	
109-21	24299-24302	and	_	
109-22	24303-24317	neurocognitive	_	
109-23	24318-24321	and	_	
109-24	24322-24331	addiction	_	
109-25	24332-24340	outcomes	_	
109-26	24341-24343	by	_	
109-27	24344-24351	showing	_	
109-28	24352-24356	that	_	
109-29	24357-24365	delaying	_	
109-30	24366-24374	drinking	_	
109-31	24375-24377	in	_	
109-32	24378-24383	those	_	
109-33	24384-24388	most	_	
109-34	24389-24396	at-risk	_	
109-35	24397-24405	protects	_	
109-36	24406-24412	normal	_	
109-37	24413-24427	neurocognitive	_	
109-38	24428-24439	development	_	
109-39	24439-24440	.	_	

#Text=The main strengths of the study are that (i) the selection, intervention and measurement models are highly time-sensitive, capturing critical periods (12–14 and 14–16 years of age) when personality endophenotypes translate to risk for binge drinking and when early intervention can produce preventative effects.
110-1	24441-24444	The	_	
110-2	24445-24449	main	_	
110-3	24450-24459	strengths	_	
110-4	24460-24462	of	_	
110-5	24463-24466	the	_	
110-6	24467-24472	study	_	
110-7	24473-24476	are	_	
110-8	24477-24481	that	_	
110-9	24482-24483	(	_	
110-10	24483-24484	i	_	
110-11	24484-24485	)	_	
110-12	24486-24489	the	_	
110-13	24490-24499	selection	_	
110-14	24499-24500	,	_	
110-15	24501-24513	intervention	_	
110-16	24514-24517	and	_	
110-17	24518-24529	measurement	_	
110-18	24530-24536	models	_	
110-19	24537-24540	are	_	
110-20	24541-24547	highly	_	
110-21	24548-24562	time-sensitive	_	
110-22	24562-24563	,	_	
110-23	24564-24573	capturing	_	
110-24	24574-24582	critical	_	
110-25	24583-24590	periods	_	
110-26	24591-24592	(	_	
110-27	24592-24594	12	_	
110-28	24594-24595	–	_	
110-29	24595-24597	14	_	
110-30	24598-24601	and	_	
110-31	24602-24604	14	_	
110-32	24604-24605	–	_	
110-33	24605-24607	16	_	
110-34	24608-24613	years	_	
110-35	24614-24616	of	_	
110-36	24617-24620	age	_	
110-37	24620-24621	)	_	
110-38	24622-24626	when	_	
110-39	24627-24638	personality	_	
110-40	24639-24653	endophenotypes	_	
110-41	24654-24663	translate	_	
110-42	24664-24666	to	_	
110-43	24667-24671	risk	_	
110-44	24672-24675	for	_	
110-45	24676-24681	binge	_	
110-46	24682-24690	drinking	_	
110-47	24691-24694	and	_	
110-48	24695-24699	when	_	
110-49	24700-24705	early	_	
110-50	24706-24718	intervention	_	
110-51	24719-24722	can	_	
110-52	24723-24730	produce	_	
110-53	24731-24743	preventative	_	
110-54	24744-24751	effects	_	
110-55	24751-24752	.	_	

#Text=Furthermore, (ii) this critical period appears to overlap with the age at which drinking onset is highly related to future drinking, and when important brain maturation occurs.
111-1	24753-24764	Furthermore	_	
111-2	24764-24765	,	_	
111-3	24766-24767	(	_	
111-4	24767-24769	ii	_	
111-5	24769-24770	)	_	
111-6	24771-24775	this	_	
111-7	24776-24784	critical	_	
111-8	24785-24791	period	_	
111-9	24792-24799	appears	_	
111-10	24800-24802	to	_	
111-11	24803-24810	overlap	_	
111-12	24811-24815	with	_	
111-13	24816-24819	the	_	
111-14	24820-24823	age	_	
111-15	24824-24826	at	_	
111-16	24827-24832	which	_	
111-17	24833-24841	drinking	_	
111-18	24842-24847	onset	_	
111-19	24848-24850	is	_	
111-20	24851-24857	highly	_	
111-21	24858-24865	related	_	
111-22	24866-24868	to	_	
111-23	24869-24875	future	_	
111-24	24876-24884	drinking	_	
111-25	24884-24885	,	_	
111-26	24886-24889	and	_	
111-27	24890-24894	when	_	
111-28	24895-24904	important	_	
111-29	24905-24910	brain	_	
111-30	24911-24921	maturation	_	
111-31	24922-24928	occurs	_	
111-32	24928-24929	.	_	

#Text=In addition, (iii) this research design is highly powered as our screening procedure, which is largely based on personality assessment at 12–13 years of age, identifies individuals, SS and IMP youth, for whom binge drinking is almost certain to develop within the next 12 months.
112-1	24930-24932	In	_	
112-2	24933-24941	addition	_	
112-3	24941-24942	,	_	
112-4	24943-24944	(	_	
112-5	24944-24947	iii	_	
112-6	24947-24948	)	_	
112-7	24949-24953	this	_	
112-8	24954-24962	research	_	
112-9	24963-24969	design	_	
112-10	24970-24972	is	_	
112-11	24973-24979	highly	_	
112-12	24980-24987	powered	_	
112-13	24988-24990	as	_	
112-14	24991-24994	our	_	
112-15	24995-25004	screening	_	
112-16	25005-25014	procedure	_	
112-17	25014-25015	,	_	
112-18	25016-25021	which	_	
112-19	25022-25024	is	_	
112-20	25025-25032	largely	_	
112-21	25033-25038	based	_	
112-22	25039-25041	on	_	
112-23	25042-25053	personality	_	
112-24	25054-25064	assessment	_	
112-25	25065-25067	at	_	
112-26	25068-25070	12	_	
112-27	25070-25071	–	_	
112-28	25071-25073	13	_	
112-29	25074-25079	years	_	
112-30	25080-25082	of	_	
112-31	25083-25086	age	_	
112-32	25086-25087	,	_	
112-33	25088-25098	identifies	_	
112-34	25099-25110	individuals	_	
112-35	25110-25111	,	_	
112-36	25112-25114	SS	_	
112-37	25115-25118	and	_	
112-38	25119-25122	IMP	_	
112-39	25123-25128	youth	_	
112-40	25128-25129	,	_	
112-41	25130-25133	for	_	
112-42	25134-25138	whom	_	
112-43	25139-25144	binge	_	
112-44	25145-25153	drinking	_	
112-45	25154-25156	is	_	
112-46	25157-25163	almost	_	
112-47	25164-25171	certain	_	
112-48	25172-25174	to	_	
112-49	25175-25182	develop	_	
112-50	25183-25189	within	_	
112-51	25190-25193	the	_	
112-52	25194-25198	next	_	
112-53	25199-25201	12	_	
112-54	25201-25202	 	_	
112-55	25202-25208	months	_	
112-56	25208-25209	.	_	

#Text=Our previous research has shown that at 13 years of age, high SS and IMP adolescents have normal rates of drinking and binge drinking (around 40%), but experience a rapid rate of onset of binge drinking between 14 and 15 years of age, with approximately 95% reporting binge drinking at 15 years of age.
113-1	25210-25213	Our	_	
113-2	25214-25222	previous	_	
113-3	25223-25231	research	_	
113-4	25232-25235	has	_	
113-5	25236-25241	shown	_	
113-6	25242-25246	that	_	
113-7	25247-25249	at	_	
113-8	25250-25252	13	_	
113-9	25252-25253	 	_	
113-10	25253-25258	years	_	
113-11	25259-25261	of	_	
113-12	25262-25265	age	_	
113-13	25265-25266	,	_	
113-14	25267-25271	high	_	
113-15	25272-25274	SS	_	
113-16	25275-25278	and	_	
113-17	25279-25282	IMP	_	
113-18	25283-25294	adolescents	_	
113-19	25295-25299	have	_	
113-20	25300-25306	normal	_	
113-21	25307-25312	rates	_	
113-22	25313-25315	of	_	
113-23	25316-25324	drinking	_	
113-24	25325-25328	and	_	
113-25	25329-25334	binge	_	
113-26	25335-25343	drinking	_	
113-27	25344-25345	(	_	
113-28	25345-25351	around	_	
113-29	25352-25355	40%	_	
113-30	25355-25356	)	_	
113-31	25356-25357	,	_	
113-32	25358-25361	but	_	
113-33	25362-25372	experience	_	
113-34	25373-25374	a	_	
113-35	25375-25380	rapid	_	
113-36	25381-25385	rate	_	
113-37	25386-25388	of	_	
113-38	25389-25394	onset	_	
113-39	25395-25397	of	_	
113-40	25398-25403	binge	_	
113-41	25404-25412	drinking	_	
113-42	25413-25420	between	_	
113-43	25421-25423	14	_	
113-44	25424-25427	and	_	
113-45	25428-25430	15	_	
113-46	25430-25431	 	_	
113-47	25431-25436	years	_	
113-48	25437-25439	of	_	
113-49	25440-25443	age	_	
113-50	25443-25444	,	_	
113-51	25445-25449	with	_	
113-52	25450-25463	approximately	_	
113-53	25464-25467	95%	_	
113-54	25468-25477	reporting	_	
113-55	25478-25483	binge	_	
113-56	25484-25492	drinking	_	
113-57	25493-25495	at	_	
113-58	25496-25498	15	_	
113-59	25498-25499	 	_	
113-60	25499-25504	years	_	
113-61	25505-25507	of	_	
113-62	25508-25511	age	_	
113-63	25511-25512	.	_	

#Text=We will also be able to (iv) test critical questions on the causal pathway from premorbid risk markers to early onset drinking, disruptions in brain function and, in turn, addiction outcomes.
114-1	25513-25515	We	_	
114-2	25516-25520	will	_	
114-3	25521-25525	also	_	
114-4	25526-25528	be	_	
114-5	25529-25533	able	_	
114-6	25534-25536	to	_	
114-7	25537-25538	(	_	
114-8	25538-25540	iv	_	
114-9	25540-25541	)	_	
114-10	25542-25546	test	_	
114-11	25547-25555	critical	_	
114-12	25556-25565	questions	_	
114-13	25566-25568	on	_	
114-14	25569-25572	the	_	
114-15	25573-25579	causal	_	
114-16	25580-25587	pathway	_	
114-17	25588-25592	from	_	
114-18	25593-25602	premorbid	_	
114-19	25603-25607	risk	_	
114-20	25608-25615	markers	_	
114-21	25616-25618	to	_	
114-22	25619-25624	early	_	
114-23	25625-25630	onset	_	
114-24	25631-25639	drinking	_	
114-25	25639-25640	,	_	
114-26	25641-25652	disruptions	_	
114-27	25653-25655	in	_	
114-28	25656-25661	brain	_	
114-29	25662-25670	function	_	
114-30	25671-25674	and	_	
114-31	25674-25675	,	_	
114-32	25676-25678	in	_	
114-33	25679-25683	turn	_	
114-34	25683-25684	,	_	
114-35	25685-25694	addiction	_	
114-36	25695-25703	outcomes	_	
114-37	25703-25704	.	_	

#Text=Finally, by being embedded into a larger population-based 5-year longitudinal randomized controlled trial, we will be able to directly (v) test the generalizability of our sample and findings to the general population, which is unique for pediatric neuroimaging studies, which tend to involve highly selective clinical samples or families with high education and socio-economic characteristics.
115-1	25705-25712	Finally	_	
115-2	25712-25713	,	_	
115-3	25714-25716	by	_	
115-4	25717-25722	being	_	
115-5	25723-25731	embedded	_	
115-6	25732-25736	into	_	
115-7	25737-25738	a	_	
115-8	25739-25745	larger	_	
115-9	25746-25762	population-based	_	
115-10	25763-25764	5	_	
115-11	25764-25765	-	_	
115-12	25765-25769	year	_	
115-13	25770-25782	longitudinal	_	
115-14	25783-25793	randomized	_	
115-15	25794-25804	controlled	_	
115-16	25805-25810	trial	_	
115-17	25810-25811	,	_	
115-18	25812-25814	we	_	
115-19	25815-25819	will	_	
115-20	25820-25822	be	_	
115-21	25823-25827	able	_	
115-22	25828-25830	to	_	
115-23	25831-25839	directly	_	
115-24	25840-25841	(	_	
115-25	25841-25842	v	_	
115-26	25842-25843	)	_	
115-27	25844-25848	test	_	
115-28	25849-25852	the	_	
115-29	25853-25869	generalizability	_	
115-30	25870-25872	of	_	
115-31	25873-25876	our	_	
115-32	25877-25883	sample	_	
115-33	25884-25887	and	_	
115-34	25888-25896	findings	_	
115-35	25897-25899	to	_	
115-36	25900-25903	the	_	
115-37	25904-25911	general	_	
115-38	25912-25922	population	_	
115-39	25922-25923	,	_	
115-40	25924-25929	which	_	
115-41	25930-25932	is	_	
115-42	25933-25939	unique	_	
115-43	25940-25943	for	_	
115-44	25944-25953	pediatric	_	
115-45	25954-25966	neuroimaging	_	
115-46	25967-25974	studies	_	
115-47	25974-25975	,	_	
115-48	25976-25981	which	_	
115-49	25982-25986	tend	_	
115-50	25987-25989	to	_	
115-51	25990-25997	involve	_	
115-52	25998-26004	highly	_	
115-53	26005-26014	selective	_	
115-54	26015-26023	clinical	_	
115-55	26024-26031	samples	_	
115-56	26032-26034	or	_	
115-57	26035-26043	families	_	
115-58	26044-26048	with	_	
115-59	26049-26053	high	_	
115-60	26054-26063	education	_	
115-61	26064-26067	and	_	
115-62	26068-26082	socio-economic	_	
115-63	26083-26098	characteristics	_	
115-64	26098-26099	.	_	

#Text=Harmful alcohol use in early adolescence is associated with a more severe and protracted course of adult alcohol abuse and dependence and greater risk for severe psychiatric and other consequences of drinking.
116-1	26100-26107	Harmful	_	
116-2	26108-26115	alcohol	_	
116-3	26116-26119	use	_	
116-4	26120-26122	in	_	
116-5	26123-26128	early	_	
116-6	26129-26140	adolescence	_	
116-7	26141-26143	is	_	
116-8	26144-26154	associated	_	
116-9	26155-26159	with	_	
116-10	26160-26161	a	_	
116-11	26162-26166	more	_	
116-12	26167-26173	severe	_	
116-13	26174-26177	and	_	
116-14	26178-26188	protracted	_	
116-15	26189-26195	course	_	
116-16	26196-26198	of	_	
116-17	26199-26204	adult	_	
116-18	26205-26212	alcohol	_	
116-19	26213-26218	abuse	_	
116-20	26219-26222	and	_	
116-21	26223-26233	dependence	_	
116-22	26234-26237	and	_	
116-23	26238-26245	greater	_	
116-24	26246-26250	risk	_	
116-25	26251-26254	for	_	
116-26	26255-26261	severe	_	
116-27	26262-26273	psychiatric	_	
116-28	26274-26277	and	_	
116-29	26278-26283	other	_	
116-30	26284-26296	consequences	_	
116-31	26297-26299	of	_	
116-32	26300-26308	drinking	_	
116-33	26308-26309	.	_	

#Text=While these facts clearly indicate a need to focus our efforts on early intervention and prevention, particularly with vulnerable groups, only a fraction of the annual health budget dedicated to the treatment of substance abuse goes toward alcohol and drug prevention.
117-1	26310-26315	While	_	
117-2	26316-26321	these	_	
117-3	26322-26327	facts	_	
117-4	26328-26335	clearly	_	
117-5	26336-26344	indicate	_	
117-6	26345-26346	a	_	
117-7	26347-26351	need	_	
117-8	26352-26354	to	_	
117-9	26355-26360	focus	_	
117-10	26361-26364	our	_	
117-11	26365-26372	efforts	_	
117-12	26373-26375	on	_	
117-13	26376-26381	early	_	
117-14	26382-26394	intervention	_	
117-15	26395-26398	and	_	
117-16	26399-26409	prevention	_	
117-17	26409-26410	,	_	
117-18	26411-26423	particularly	_	
117-19	26424-26428	with	_	
117-20	26429-26439	vulnerable	_	
117-21	26440-26446	groups	_	
117-22	26446-26447	,	_	
117-23	26448-26452	only	_	
117-24	26453-26454	a	_	
117-25	26455-26463	fraction	_	
117-26	26464-26466	of	_	
117-27	26467-26470	the	_	
117-28	26471-26477	annual	_	
117-29	26478-26484	health	_	
117-30	26485-26491	budget	_	
117-31	26492-26501	dedicated	_	
117-32	26502-26504	to	_	
117-33	26505-26508	the	_	
117-34	26509-26518	treatment	_	
117-35	26519-26521	of	_	
117-36	26522-26531	substance	_	
117-37	26532-26537	abuse	_	
117-38	26538-26542	goes	_	
117-39	26543-26549	toward	_	
117-40	26550-26557	alcohol	_	
117-41	26558-26561	and	_	
117-42	26562-26566	drug	_	
117-43	26567-26577	prevention	_	
117-44	26577-26578	.	_	

#Text=This research will directly feed public knowledge on the harms associated with youth alcohol misuse, as well as the evidence base for selective interventions.
118-1	26579-26583	This	_	
118-2	26584-26592	research	_	
118-3	26593-26597	will	_	
118-4	26598-26606	directly	_	
118-5	26607-26611	feed	_	
118-6	26612-26618	public	_	
118-7	26619-26628	knowledge	_	
118-8	26629-26631	on	_	
118-9	26632-26635	the	_	
118-10	26636-26641	harms	_	
118-11	26642-26652	associated	_	
118-12	26653-26657	with	_	
118-13	26658-26663	youth	_	
118-14	26664-26671	alcohol	_	
118-15	26672-26678	misuse	_	
118-16	26678-26679	,	_	
118-17	26680-26682	as	_	
118-18	26683-26687	well	_	
118-19	26688-26690	as	_	
118-20	26691-26694	the	_	
118-21	26695-26703	evidence	_	
118-22	26704-26708	base	_	
118-23	26709-26712	for	_	
118-24	26713-26722	selective	_	
118-25	26723-26736	interventions	_	
118-26	26736-26737	.	_	

#Text=The expected results will show direct effects of drinking on brain development and the benefits of early intervention and prevention efforts, effects that will be difficult to ignore in public policy on youth drinking.
119-1	26738-26741	The	_	
119-2	26742-26750	expected	_	
119-3	26751-26758	results	_	
119-4	26759-26763	will	_	
119-5	26764-26768	show	_	
119-6	26769-26775	direct	_	
119-7	26776-26783	effects	_	
119-8	26784-26786	of	_	
119-9	26787-26795	drinking	_	
119-10	26796-26798	on	_	
119-11	26799-26804	brain	_	
119-12	26805-26816	development	_	
119-13	26817-26820	and	_	
119-14	26821-26824	the	_	
119-15	26825-26833	benefits	_	
119-16	26834-26836	of	_	
119-17	26837-26842	early	_	
119-18	26843-26855	intervention	_	
119-19	26856-26859	and	_	
119-20	26860-26870	prevention	_	
119-21	26871-26878	efforts	_	
119-22	26878-26879	,	_	
119-23	26880-26887	effects	_	
119-24	26888-26892	that	_	
119-25	26893-26897	will	_	
119-26	26898-26900	be	_	
119-27	26901-26910	difficult	_	
119-28	26911-26913	to	_	
119-29	26914-26920	ignore	_	
119-30	26921-26923	in	_	
119-31	26924-26930	public	_	
119-32	26931-26937	policy	_	
119-33	26938-26940	on	_	
119-34	26941-26946	youth	_	
119-35	26947-26955	drinking	_	
119-36	26955-26956	.	_	

#Text=Abbreviations
#Text=BART
#Text=Balloon Analogue Risk Task
#Text=BOLD
#Text=Blood oxygenation level dependent
#Text=CIHR
#Text=Canadian Institutes of Health Research
#Text=CMS
#Text=Children’s memory scale
#Text=DWI
#Text=Diffusion weighted imaging
#Text=EPI
#Text=Echo planar imaging
#Text=FA
#Text=Fractional anisotropy
#Text=fMRI
#Text=Functional magnetic resonance imaging
#Text=IMP
#Text=Impulsivity
#Text=MIDT
#Text=Monetary Incentive Delay Task
#Text=MRI
#Text=Magnetic resonance imaging
#Text=ROI
#Text=Region of interest
#Text=SOPT
#Text=Self-Ordered Pointing Test
#Text=SS
#Text=Sensation-seeking
#Text=SURPS
#Text=Substance Use Risk Profile Scale
#Text=TE
#Text=Echo time
#Text=TR
#Text=Repetition time
#Text=VBM
#Text=Voxel based morphometry
#Text=References
#Text=Age at drinking onset and alcohol dependence: age at onset, duration, and severity
#Text=Structural magnetic resonance imaging of the adolescent brain
#Text=Neurodevelopmental trajectories of the human cerebral cortex
#Text=In vivo evidence for post-adolescent brain maturation in frontal and striatal regions
#Text=Imaging the developing brain: what have we learned about cognitive development?
120-1	26957-26970	Abbreviations	_	
120-2	26971-26975	BART	_	
120-3	26976-26983	Balloon	_	
120-4	26984-26992	Analogue	_	
120-5	26993-26997	Risk	_	
120-6	26998-27002	Task	_	
120-7	27003-27007	BOLD	_	
120-8	27008-27013	Blood	_	
120-9	27014-27025	oxygenation	_	
120-10	27026-27031	level	_	
120-11	27032-27041	dependent	_	
120-12	27042-27046	CIHR	_	
120-13	27047-27055	Canadian	_	
120-14	27056-27066	Institutes	_	
120-15	27067-27069	of	_	
120-16	27070-27076	Health	_	
120-17	27077-27085	Research	_	
120-18	27086-27089	CMS	_	
120-19	27090-27098	Children	_	
120-20	27098-27099	’	_	
120-21	27099-27100	s	_	
120-22	27101-27107	memory	_	
120-23	27108-27113	scale	_	
120-24	27114-27117	DWI	_	
120-25	27118-27127	Diffusion	_	
120-26	27128-27136	weighted	_	
120-27	27137-27144	imaging	_	
120-28	27145-27148	EPI	_	
120-29	27149-27153	Echo	_	
120-30	27154-27160	planar	_	
120-31	27161-27168	imaging	_	
120-32	27169-27171	FA	_	
120-33	27172-27182	Fractional	_	
120-34	27183-27193	anisotropy	_	
120-35	27194-27198	fMRI	_	
120-36	27199-27209	Functional	_	
120-37	27210-27218	magnetic	_	
120-38	27219-27228	resonance	_	
120-39	27229-27236	imaging	_	
120-40	27237-27240	IMP	_	
120-41	27241-27252	Impulsivity	_	
120-42	27253-27257	MIDT	_	
120-43	27258-27266	Monetary	_	
120-44	27267-27276	Incentive	_	
120-45	27277-27282	Delay	_	
120-46	27283-27287	Task	_	
120-47	27288-27291	MRI	_	
120-48	27292-27300	Magnetic	_	
120-49	27301-27310	resonance	_	
120-50	27311-27318	imaging	_	
120-51	27319-27322	ROI	_	
120-52	27323-27329	Region	_	
120-53	27330-27332	of	_	
120-54	27333-27341	interest	_	
120-55	27342-27346	SOPT	_	
120-56	27347-27359	Self-Ordered	_	
120-57	27360-27368	Pointing	_	
120-58	27369-27373	Test	_	
120-59	27374-27376	SS	_	
120-60	27377-27394	Sensation-seeking	_	
120-61	27395-27400	SURPS	_	
120-62	27401-27410	Substance	_	
120-63	27411-27414	Use	_	
120-64	27415-27419	Risk	_	
120-65	27420-27427	Profile	_	
120-66	27428-27433	Scale	_	
120-67	27434-27436	TE	_	
120-68	27437-27441	Echo	_	
120-69	27442-27446	time	_	
120-70	27447-27449	TR	_	
120-71	27450-27460	Repetition	_	
120-72	27461-27465	time	_	
120-73	27466-27469	VBM	_	
120-74	27470-27475	Voxel	_	
120-75	27476-27481	based	_	
120-76	27482-27493	morphometry	_	
120-77	27494-27504	References	_	
120-78	27505-27508	Age	_	
120-79	27509-27511	at	_	
120-80	27512-27520	drinking	_	
120-81	27521-27526	onset	_	
120-82	27527-27530	and	_	
120-83	27531-27538	alcohol	_	
120-84	27539-27549	dependence	_	
120-85	27549-27550	:	_	
120-86	27551-27554	age	_	
120-87	27555-27557	at	_	
120-88	27558-27563	onset	_	
120-89	27563-27564	,	_	
120-90	27565-27573	duration	_	
120-91	27573-27574	,	_	
120-92	27575-27578	and	_	
120-93	27579-27587	severity	_	
120-94	27588-27598	Structural	_	
120-95	27599-27607	magnetic	_	
120-96	27608-27617	resonance	_	
120-97	27618-27625	imaging	_	
120-98	27626-27628	of	_	
120-99	27629-27632	the	_	
120-100	27633-27643	adolescent	_	
120-101	27644-27649	brain	_	
120-102	27650-27668	Neurodevelopmental	_	
120-103	27669-27681	trajectories	_	
120-104	27682-27684	of	_	
120-105	27685-27688	the	_	
120-106	27689-27694	human	_	
120-107	27695-27703	cerebral	_	
120-108	27704-27710	cortex	_	
120-109	27711-27713	In	_	
120-110	27714-27718	vivo	_	
120-111	27719-27727	evidence	_	
120-112	27728-27731	for	_	
120-113	27732-27747	post-adolescent	_	
120-114	27748-27753	brain	_	
120-115	27754-27764	maturation	_	
120-116	27765-27767	in	_	
120-117	27768-27775	frontal	_	
120-118	27776-27779	and	_	
120-119	27780-27788	striatal	_	
120-120	27789-27796	regions	_	
120-121	27797-27804	Imaging	_	
120-122	27805-27808	the	_	
120-123	27809-27819	developing	_	
120-124	27820-27825	brain	_	
120-125	27825-27826	:	_	
120-126	27827-27831	what	_	
120-127	27832-27836	have	_	
120-128	27837-27839	we	_	
120-129	27840-27847	learned	_	
120-130	27848-27853	about	_	
120-131	27854-27863	cognitive	_	
120-132	27864-27875	development	_	
120-133	27875-27876	?	_	

#Text=Combined analysis of DTI and fMRI data reveals a joint maturation of white and grey matter in a fronto-parietal network
#Text=The dual systems model: review, reappraisal, and reaffirmation
#Text=Age differences in sensation seeking and impulsivity as indexed by behavior and self-report: evidence for a dual systems model
#Text=Functional frontalisation with age: mapping neurodevelopmental trajectories with fMRI
#Text=Progressive increase of frontostriatal brain activation from childhood to adulthood during event-related tasks of cognitive control
#Text=Longitudinal changes in prefrontal cortex activation underlie declines in adolescent risk taking
#Text=Neurocognitive functioning of adolescents: effects of protracted alcohol use
#Text=Neuropsychological correlates of adolescent substance abuse: four-year outcomes
#Text=Substance use and withdrawal: neuropsychological functioning over 8 years in youth
#Text=Hippocampal volume in adolescent-onset alcohol use disorders
#Text=Neural response to alcohol stimuli in adolescents with alcohol use disorder
#Text=Gender and adolescent alcohol use disorders on BOLD (blood oxygen level dependent) response to spatial working memory
#Text=Individual differences in childhood neurobehavior disinhibition predict decision to desist substance use during adolescence and substance use disorder in young adulthood: a prospective study
#Text=Temporal lobe dysfunction in medication-naive boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability
#Text=Cognitive function, cardiovascular reactivity, and behavior in boys at high risk for alcoholism
#Text=Response inhibition in AD/HD, CD, comorbid AD/HD+ CD, anxious, and control children: a meta-analysis of studies with the stop task
#Text=Cognitive dysfunction and the inherited predisposition to alcoholism
#Text=Are planning, working memory, and inhibition associated with individual differences in preschool ADHD symptoms?
121-1	27877-27885	Combined	_	
121-2	27886-27894	analysis	_	
121-3	27895-27897	of	_	
121-4	27898-27901	DTI	_	
121-5	27902-27905	and	_	
121-6	27906-27910	fMRI	_	
121-7	27911-27915	data	_	
121-8	27916-27923	reveals	_	
121-9	27924-27925	a	_	
121-10	27926-27931	joint	_	
121-11	27932-27942	maturation	_	
121-12	27943-27945	of	_	
121-13	27946-27951	white	_	
121-14	27952-27955	and	_	
121-15	27956-27960	grey	_	
121-16	27961-27967	matter	_	
121-17	27968-27970	in	_	
121-18	27971-27972	a	_	
121-19	27973-27988	fronto-parietal	_	
121-20	27989-27996	network	_	
121-21	27997-28000	The	_	
121-22	28001-28005	dual	_	
121-23	28006-28013	systems	_	
121-24	28014-28019	model	_	
121-25	28019-28020	:	_	
121-26	28021-28027	review	_	
121-27	28027-28028	,	_	
121-28	28029-28040	reappraisal	_	
121-29	28040-28041	,	_	
121-30	28042-28045	and	_	
121-31	28046-28059	reaffirmation	_	
121-32	28060-28063	Age	_	
121-33	28064-28075	differences	_	
121-34	28076-28078	in	_	
121-35	28079-28088	sensation	_	
121-36	28089-28096	seeking	_	
121-37	28097-28100	and	_	
121-38	28101-28112	impulsivity	_	
121-39	28113-28115	as	_	
121-40	28116-28123	indexed	_	
121-41	28124-28126	by	_	
121-42	28127-28135	behavior	_	
121-43	28136-28139	and	_	
121-44	28140-28151	self-report	_	
121-45	28151-28152	:	_	
121-46	28153-28161	evidence	_	
121-47	28162-28165	for	_	
121-48	28166-28167	a	_	
121-49	28168-28172	dual	_	
121-50	28173-28180	systems	_	
121-51	28181-28186	model	_	
121-52	28187-28197	Functional	_	
121-53	28198-28212	frontalisation	_	
121-54	28213-28217	with	_	
121-55	28218-28221	age	_	
121-56	28221-28222	:	_	
121-57	28223-28230	mapping	_	
121-58	28231-28249	neurodevelopmental	_	
121-59	28250-28262	trajectories	_	
121-60	28263-28267	with	_	
121-61	28268-28272	fMRI	_	
121-62	28273-28284	Progressive	_	
121-63	28285-28293	increase	_	
121-64	28294-28296	of	_	
121-65	28297-28311	frontostriatal	_	
121-66	28312-28317	brain	_	
121-67	28318-28328	activation	_	
121-68	28329-28333	from	_	
121-69	28334-28343	childhood	_	
121-70	28344-28346	to	_	
121-71	28347-28356	adulthood	_	
121-72	28357-28363	during	_	
121-73	28364-28377	event-related	_	
121-74	28378-28383	tasks	_	
121-75	28384-28386	of	_	
121-76	28387-28396	cognitive	_	
121-77	28397-28404	control	_	
121-78	28405-28417	Longitudinal	_	
121-79	28418-28425	changes	_	
121-80	28426-28428	in	_	
121-81	28429-28439	prefrontal	_	
121-82	28440-28446	cortex	_	
121-83	28447-28457	activation	_	
121-84	28458-28466	underlie	_	
121-85	28467-28475	declines	_	
121-86	28476-28478	in	_	
121-87	28479-28489	adolescent	_	
121-88	28490-28494	risk	_	
121-89	28495-28501	taking	_	
121-90	28502-28516	Neurocognitive	_	
121-91	28517-28528	functioning	_	
121-92	28529-28531	of	_	
121-93	28532-28543	adolescents	_	
121-94	28543-28544	:	_	
121-95	28545-28552	effects	_	
121-96	28553-28555	of	_	
121-97	28556-28566	protracted	_	
121-98	28567-28574	alcohol	_	
121-99	28575-28578	use	_	
121-100	28579-28597	Neuropsychological	_	
121-101	28598-28608	correlates	_	
121-102	28609-28611	of	_	
121-103	28612-28622	adolescent	_	
121-104	28623-28632	substance	_	
121-105	28633-28638	abuse	_	
121-106	28638-28639	:	_	
121-107	28640-28649	four-year	_	
121-108	28650-28658	outcomes	_	
121-109	28659-28668	Substance	_	
121-110	28669-28672	use	_	
121-111	28673-28676	and	_	
121-112	28677-28687	withdrawal	_	
121-113	28687-28688	:	_	
121-114	28689-28707	neuropsychological	_	
121-115	28708-28719	functioning	_	
121-116	28720-28724	over	_	
121-117	28725-28726	8	_	
121-118	28727-28732	years	_	
121-119	28733-28735	in	_	
121-120	28736-28741	youth	_	
121-121	28742-28753	Hippocampal	_	
121-122	28754-28760	volume	_	
121-123	28761-28763	in	_	
121-124	28764-28780	adolescent-onset	_	
121-125	28781-28788	alcohol	_	
121-126	28789-28792	use	_	
121-127	28793-28802	disorders	_	
121-128	28803-28809	Neural	_	
121-129	28810-28818	response	_	
121-130	28819-28821	to	_	
121-131	28822-28829	alcohol	_	
121-132	28830-28837	stimuli	_	
121-133	28838-28840	in	_	
121-134	28841-28852	adolescents	_	
121-135	28853-28857	with	_	
121-136	28858-28865	alcohol	_	
121-137	28866-28869	use	_	
121-138	28870-28878	disorder	_	
121-139	28879-28885	Gender	_	
121-140	28886-28889	and	_	
121-141	28890-28900	adolescent	_	
121-142	28901-28908	alcohol	_	
121-143	28909-28912	use	_	
121-144	28913-28922	disorders	_	
121-145	28923-28925	on	_	
121-146	28926-28930	BOLD	_	
121-147	28931-28932	(	_	
121-148	28932-28937	blood	_	
121-149	28938-28944	oxygen	_	
121-150	28945-28950	level	_	
121-151	28951-28960	dependent	_	
121-152	28960-28961	)	_	
121-153	28962-28970	response	_	
121-154	28971-28973	to	_	
121-155	28974-28981	spatial	_	
121-156	28982-28989	working	_	
121-157	28990-28996	memory	_	
121-158	28997-29007	Individual	_	
121-159	29008-29019	differences	_	
121-160	29020-29022	in	_	
121-161	29023-29032	childhood	_	
121-162	29033-29046	neurobehavior	_	
121-163	29047-29060	disinhibition	_	
121-164	29061-29068	predict	_	
121-165	29069-29077	decision	_	
121-166	29078-29080	to	_	
121-167	29081-29087	desist	_	
121-168	29088-29097	substance	_	
121-169	29098-29101	use	_	
121-170	29102-29108	during	_	
121-171	29109-29120	adolescence	_	
121-172	29121-29124	and	_	
121-173	29125-29134	substance	_	
121-174	29135-29138	use	_	
121-175	29139-29147	disorder	_	
121-176	29148-29150	in	_	
121-177	29151-29156	young	_	
121-178	29157-29166	adulthood	_	
121-179	29166-29167	:	_	
121-180	29168-29169	a	_	
121-181	29170-29181	prospective	_	
121-182	29182-29187	study	_	
121-183	29188-29196	Temporal	_	
121-184	29197-29201	lobe	_	
121-185	29202-29213	dysfunction	_	
121-186	29214-29216	in	_	
121-187	29217-29233	medication-naive	_	
121-188	29234-29238	boys	_	
121-189	29239-29243	with	_	
121-190	29244-29261	attention-deficit	_	
121-191	29261-29262	/	_	
121-192	29262-29275	hyperactivity	_	
121-193	29276-29284	disorder	_	
121-194	29285-29291	during	_	
121-195	29292-29301	attention	_	
121-196	29302-29312	allocation	_	
121-197	29313-29316	and	_	
121-198	29317-29320	its	_	
121-199	29321-29329	relation	_	
121-200	29330-29332	to	_	
121-201	29333-29341	response	_	
121-202	29342-29353	variability	_	
121-203	29354-29363	Cognitive	_	
121-204	29364-29372	function	_	
121-205	29372-29373	,	_	
121-206	29374-29388	cardiovascular	_	
121-207	29389-29399	reactivity	_	
121-208	29399-29400	,	_	
121-209	29401-29404	and	_	
121-210	29405-29413	behavior	_	
121-211	29414-29416	in	_	
121-212	29417-29421	boys	_	
121-213	29422-29424	at	_	
121-214	29425-29429	high	_	
121-215	29430-29434	risk	_	
121-216	29435-29438	for	_	
121-217	29439-29449	alcoholism	_	
121-218	29450-29458	Response	_	
121-219	29459-29469	inhibition	_	
121-220	29470-29472	in	_	
121-221	29473-29475	AD	_	
121-222	29475-29476	/	_	
121-223	29476-29478	HD	_	
121-224	29478-29479	,	_	
121-225	29480-29482	CD	_	
121-226	29482-29483	,	_	
121-227	29484-29492	comorbid	_	
121-228	29493-29495	AD	_	
121-229	29495-29496	/	_	
121-230	29496-29498	HD	_	
121-231	29498-29499	+	_	
121-232	29500-29502	CD	_	
121-233	29502-29503	,	_	
121-234	29504-29511	anxious	_	
121-235	29511-29512	,	_	
121-236	29513-29516	and	_	
121-237	29517-29524	control	_	
121-238	29525-29533	children	_	
121-239	29533-29534	:	_	
121-240	29535-29536	a	_	
121-241	29537-29550	meta-analysis	_	
121-242	29551-29553	of	_	
121-243	29554-29561	studies	_	
121-244	29562-29566	with	_	
121-245	29567-29570	the	_	
121-246	29571-29575	stop	_	
121-247	29576-29580	task	_	
121-248	29581-29590	Cognitive	_	
121-249	29591-29602	dysfunction	_	
121-250	29603-29606	and	_	
121-251	29607-29610	the	_	
121-252	29611-29620	inherited	_	
121-253	29621-29635	predisposition	_	
121-254	29636-29638	to	_	
121-255	29639-29649	alcoholism	_	
121-256	29650-29653	Are	_	
121-257	29654-29662	planning	_	
121-258	29662-29663	,	_	
121-259	29664-29671	working	_	
121-260	29672-29678	memory	_	
121-261	29678-29679	,	_	
121-262	29680-29683	and	_	
121-263	29684-29694	inhibition	_	
121-264	29695-29705	associated	_	
121-265	29706-29710	with	_	
121-266	29711-29721	individual	_	
121-267	29722-29733	differences	_	
121-268	29734-29736	in	_	
121-269	29737-29746	preschool	_	
121-270	29747-29751	ADHD	_	
121-271	29752-29760	symptoms	_	
121-272	29760-29761	?	_	

#Text=Common structural correlates of trait impulsiveness and perceptual reasoning in adolescence
#Text=Neural and cognitive correlates of the common and specific variance across externalizing problems in young adolescence
#Text=Substance dependence, family history of alcohol dependence and neuropsychological functioning in adolescence
#Text=Zuckerman M.
122-1	29762-29768	Common	_	
122-2	29769-29779	structural	_	
122-3	29780-29790	correlates	_	
122-4	29791-29793	of	_	
122-5	29794-29799	trait	_	
122-6	29800-29813	impulsiveness	_	
122-7	29814-29817	and	_	
122-8	29818-29828	perceptual	_	
122-9	29829-29838	reasoning	_	
122-10	29839-29841	in	_	
122-11	29842-29853	adolescence	_	
122-12	29854-29860	Neural	_	
122-13	29861-29864	and	_	
122-14	29865-29874	cognitive	_	
122-15	29875-29885	correlates	_	
122-16	29886-29888	of	_	
122-17	29889-29892	the	_	
122-18	29893-29899	common	_	
122-19	29900-29903	and	_	
122-20	29904-29912	specific	_	
122-21	29913-29921	variance	_	
122-22	29922-29928	across	_	
122-23	29929-29942	externalizing	_	
122-24	29943-29951	problems	_	
122-25	29952-29954	in	_	
122-26	29955-29960	young	_	
122-27	29961-29972	adolescence	_	
122-28	29973-29982	Substance	_	
122-29	29983-29993	dependence	_	
122-30	29993-29994	,	_	
122-31	29995-30001	family	_	
122-32	30002-30009	history	_	
122-33	30010-30012	of	_	
122-34	30013-30020	alcohol	_	
122-35	30021-30031	dependence	_	
122-36	30032-30035	and	_	
122-37	30036-30054	neuropsychological	_	
122-38	30055-30066	functioning	_	
122-39	30067-30069	in	_	
122-40	30070-30081	adolescence	_	
122-41	30082-30091	Zuckerman	_	
122-42	30092-30093	M	_	
122-43	30093-30094	.	_	

#Text=Behavioral expressions and biosocial bases of sensation seeking.
123-1	30095-30105	Behavioral	_	
123-2	30106-30117	expressions	_	
123-3	30118-30121	and	_	
123-4	30122-30131	biosocial	_	
123-5	30132-30137	bases	_	
123-6	30138-30140	of	_	
123-7	30141-30150	sensation	_	
123-8	30151-30158	seeking	_	
123-9	30158-30159	.	_	

#Text=Cambridge: Cambridge University Press; 1994.
124-1	30160-30169	Cambridge	_	
124-2	30169-30170	:	_	
124-3	30171-30180	Cambridge	_	
124-4	30181-30191	University	_	
124-5	30192-30197	Press	_	
124-6	30197-30198	;	_	
124-7	30199-30203	1994	_	
124-8	30203-30204	.	_	

#Text=Sensation seeking, aggressiveness, and adolescent reckless behavior
#Text=The relations of trait anxiety, anxiety sensitivity, and sensation seeking to adolescents’ motivations for alcohol, cigarette, and marijuana use
#Text=Drinking to regulate positive and negative emotions: a motivational model of alcohol use
#Text=Factors associated with alcohol use in university students
#Text=Response inhibition and reward response bias mediate the predictive relationships between impulsivity and sensation seeking and common and unique variance in conduct disorder and substance misuse
#Text=Can cannabis use be prevented by targeting personality risk in schools?
125-1	30205-30214	Sensation	_	
125-2	30215-30222	seeking	_	
125-3	30222-30223	,	_	
125-4	30224-30238	aggressiveness	_	
125-5	30238-30239	,	_	
125-6	30240-30243	and	_	
125-7	30244-30254	adolescent	_	
125-8	30255-30263	reckless	_	
125-9	30264-30272	behavior	_	
125-10	30273-30276	The	_	
125-11	30277-30286	relations	_	
125-12	30287-30289	of	_	
125-13	30290-30295	trait	_	
125-14	30296-30303	anxiety	_	
125-15	30303-30304	,	_	
125-16	30305-30312	anxiety	_	
125-17	30313-30324	sensitivity	_	
125-18	30324-30325	,	_	
125-19	30326-30329	and	_	
125-20	30330-30339	sensation	_	
125-21	30340-30347	seeking	_	
125-22	30348-30350	to	_	
125-23	30351-30362	adolescents	_	
125-24	30362-30363	’	_	
125-25	30364-30375	motivations	_	
125-26	30376-30379	for	_	
125-27	30380-30387	alcohol	_	
125-28	30387-30388	,	_	
125-29	30389-30398	cigarette	_	
125-30	30398-30399	,	_	
125-31	30400-30403	and	_	
125-32	30404-30413	marijuana	_	
125-33	30414-30417	use	_	
125-34	30418-30426	Drinking	_	
125-35	30427-30429	to	_	
125-36	30430-30438	regulate	_	
125-37	30439-30447	positive	_	
125-38	30448-30451	and	_	
125-39	30452-30460	negative	_	
125-40	30461-30469	emotions	_	
125-41	30469-30470	:	_	
125-42	30471-30472	a	_	
125-43	30473-30485	motivational	_	
125-44	30486-30491	model	_	
125-45	30492-30494	of	_	
125-46	30495-30502	alcohol	_	
125-47	30503-30506	use	_	
125-48	30507-30514	Factors	_	
125-49	30515-30525	associated	_	
125-50	30526-30530	with	_	
125-51	30531-30538	alcohol	_	
125-52	30539-30542	use	_	
125-53	30543-30545	in	_	
125-54	30546-30556	university	_	
125-55	30557-30565	students	_	
125-56	30566-30574	Response	_	
125-57	30575-30585	inhibition	_	
125-58	30586-30589	and	_	
125-59	30590-30596	reward	_	
125-60	30597-30605	response	_	
125-61	30606-30610	bias	_	
125-62	30611-30618	mediate	_	
125-63	30619-30622	the	_	
125-64	30623-30633	predictive	_	
125-65	30634-30647	relationships	_	
125-66	30648-30655	between	_	
125-67	30656-30667	impulsivity	_	
125-68	30668-30671	and	_	
125-69	30672-30681	sensation	_	
125-70	30682-30689	seeking	_	
125-71	30690-30693	and	_	
125-72	30694-30700	common	_	
125-73	30701-30704	and	_	
125-74	30705-30711	unique	_	
125-75	30712-30720	variance	_	
125-76	30721-30723	in	_	
125-77	30724-30731	conduct	_	
125-78	30732-30740	disorder	_	
125-79	30741-30744	and	_	
125-80	30745-30754	substance	_	
125-81	30755-30761	misuse	_	
125-82	30762-30765	Can	_	
125-83	30766-30774	cannabis	_	
125-84	30775-30778	use	_	
125-85	30779-30781	be	_	
125-86	30782-30791	prevented	_	
125-87	30792-30794	by	_	
125-88	30795-30804	targeting	_	
125-89	30805-30816	personality	_	
125-90	30817-30821	risk	_	
125-91	30822-30824	in	_	
125-92	30825-30832	schools	_	
125-93	30832-30833	?	_	

#Text=Twenty-four-month outcome of the adventure trial on cannabis use: a cluster-randomized controlled trial
#Text=Personality-targeted interventions delay the growth of adolescent drinking and binge drinking
#Text=Brief, personality-targeted coping skills interventions and survival as a non-drug user over a 2-year period during adolescence
#Text=The substance use risk profile scale: a scale measuring traits linked to reinforcement-specific substance use profiles
#Text=Relations between personality and drinking motives in young adults
#Text=Personality-targeted interventions delay uptake of drinking and decrease risk of alcohol-related problems when delivered by teachers
#Text=Efficacy of cognitive-behavioral interventions targeting personality risk factors for youth alcohol misuse
#Text=Effectiveness of a selective, personality-targeted prevention program for adolescent alcohol use and misuse: a cluster randomized controlled trial
#Text=Personality-targeted interventions for adolescence substance misuse
#Text=Neuropsychosocial profiles of current and future adolescent alcohol misusers
#Text=Psychometric evaluation of self- and collateral timeline follow-back reports of drug and alcohol use in a sample of drug-abusing and conduct-disordered adolescents and their parents
#Text=Reliability of alcohol abusers’ self-reports of drinking behavior
#Text=Studies of interference in serial verbal reactions
#Text=Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man
#Text=Age differences in short-term retention of rapidly changing information
#Text=
#Text=Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART)
#Text=
#Text=The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology
#Text=Anticipation of increasing monetary reward selectively recruits nucleus accumbens
#Text=Incentive-elicited brain activation in adolescents: similarities and differences from young adults
#Text=Lower ventral striatal activation during reward anticipation in adolescent smokers
#Text=Risk taking and the adolescent reward system: a potential common link to substance abuse
#Text=Linear age-correlated functional development of right inferior fronto-striato-cerebellar networks during response inhibition and anterior cingulate during error-related processes
#Text=Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD
#Text=Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection
#Text=Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks
#Text=Impulsivity and inhibitory control
#Text=A fully automatic and robust brain MRI tissue classification method
#Text=Automatic “pipeline” analysis of 3-D MRI data for clinical trials: application to multiple sclerosis
#Text=Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification
#Text=Automated cortical thickness measurements from MRI can accurately separate Alzheimer’s patients from normal elderly controls
#Text=Probabilistic diffusion tractography with multiple fibre orientations: What can we gain?
126-1	30834-30851	Twenty-four-month	_	
126-2	30852-30859	outcome	_	
126-3	30860-30862	of	_	
126-4	30863-30866	the	_	
126-5	30867-30876	adventure	_	
126-6	30877-30882	trial	_	
126-7	30883-30885	on	_	
126-8	30886-30894	cannabis	_	
126-9	30895-30898	use	_	
126-10	30898-30899	:	_	
126-11	30900-30901	a	_	
126-12	30902-30920	cluster-randomized	_	
126-13	30921-30931	controlled	_	
126-14	30932-30937	trial	_	
126-15	30938-30958	Personality-targeted	_	
126-16	30959-30972	interventions	_	
126-17	30973-30978	delay	_	
126-18	30979-30982	the	_	
126-19	30983-30989	growth	_	
126-20	30990-30992	of	_	
126-21	30993-31003	adolescent	_	
126-22	31004-31012	drinking	_	
126-23	31013-31016	and	_	
126-24	31017-31022	binge	_	
126-25	31023-31031	drinking	_	
126-26	31032-31037	Brief	_	
126-27	31037-31038	,	_	
126-28	31039-31059	personality-targeted	_	
126-29	31060-31066	coping	_	
126-30	31067-31073	skills	_	
126-31	31074-31087	interventions	_	
126-32	31088-31091	and	_	
126-33	31092-31100	survival	_	
126-34	31101-31103	as	_	
126-35	31104-31105	a	_	
126-36	31106-31114	non-drug	_	
126-37	31115-31119	user	_	
126-38	31120-31124	over	_	
126-39	31125-31126	a	_	
126-40	31127-31128	2	_	
126-41	31128-31129	-	_	
126-42	31129-31133	year	_	
126-43	31134-31140	period	_	
126-44	31141-31147	during	_	
126-45	31148-31159	adolescence	_	
126-46	31160-31163	The	_	
126-47	31164-31173	substance	_	
126-48	31174-31177	use	_	
126-49	31178-31182	risk	_	
126-50	31183-31190	profile	_	
126-51	31191-31196	scale	_	
126-52	31196-31197	:	_	
126-53	31198-31199	a	_	
126-54	31200-31205	scale	_	
126-55	31206-31215	measuring	_	
126-56	31216-31222	traits	_	
126-57	31223-31229	linked	_	
126-58	31230-31232	to	_	
126-59	31233-31255	reinforcement-specific	_	
126-60	31256-31265	substance	_	
126-61	31266-31269	use	_	
126-62	31270-31278	profiles	_	
126-63	31279-31288	Relations	_	
126-64	31289-31296	between	_	
126-65	31297-31308	personality	_	
126-66	31309-31312	and	_	
126-67	31313-31321	drinking	_	
126-68	31322-31329	motives	_	
126-69	31330-31332	in	_	
126-70	31333-31338	young	_	
126-71	31339-31345	adults	_	
126-72	31346-31366	Personality-targeted	_	
126-73	31367-31380	interventions	_	
126-74	31381-31386	delay	_	
126-75	31387-31393	uptake	_	
126-76	31394-31396	of	_	
126-77	31397-31405	drinking	_	
126-78	31406-31409	and	_	
126-79	31410-31418	decrease	_	
126-80	31419-31423	risk	_	
126-81	31424-31426	of	_	
126-82	31427-31442	alcohol-related	_	
126-83	31443-31451	problems	_	
126-84	31452-31456	when	_	
126-85	31457-31466	delivered	_	
126-86	31467-31469	by	_	
126-87	31470-31478	teachers	_	
126-88	31479-31487	Efficacy	_	
126-89	31488-31490	of	_	
126-90	31491-31511	cognitive-behavioral	_	
126-91	31512-31525	interventions	_	
126-92	31526-31535	targeting	_	
126-93	31536-31547	personality	_	
126-94	31548-31552	risk	_	
126-95	31553-31560	factors	_	
126-96	31561-31564	for	_	
126-97	31565-31570	youth	_	
126-98	31571-31578	alcohol	_	
126-99	31579-31585	misuse	_	
126-100	31586-31599	Effectiveness	_	
126-101	31600-31602	of	_	
126-102	31603-31604	a	_	
126-103	31605-31614	selective	_	
126-104	31614-31615	,	_	
126-105	31616-31636	personality-targeted	_	
126-106	31637-31647	prevention	_	
126-107	31648-31655	program	_	
126-108	31656-31659	for	_	
126-109	31660-31670	adolescent	_	
126-110	31671-31678	alcohol	_	
126-111	31679-31682	use	_	
126-112	31683-31686	and	_	
126-113	31687-31693	misuse	_	
126-114	31693-31694	:	_	
126-115	31695-31696	a	_	
126-116	31697-31704	cluster	_	
126-117	31705-31715	randomized	_	
126-118	31716-31726	controlled	_	
126-119	31727-31732	trial	_	
126-120	31733-31753	Personality-targeted	_	
126-121	31754-31767	interventions	_	
126-122	31768-31771	for	_	
126-123	31772-31783	adolescence	_	
126-124	31784-31793	substance	_	
126-125	31794-31800	misuse	_	
126-126	31801-31818	Neuropsychosocial	_	
126-127	31819-31827	profiles	_	
126-128	31828-31830	of	_	
126-129	31831-31838	current	_	
126-130	31839-31842	and	_	
126-131	31843-31849	future	_	
126-132	31850-31860	adolescent	_	
126-133	31861-31868	alcohol	_	
126-134	31869-31877	misusers	_	
126-135	31878-31890	Psychometric	_	
126-136	31891-31901	evaluation	_	
126-137	31902-31904	of	_	
126-138	31905-31909	self	_	
126-139	31909-31910	-	_	
126-140	31911-31914	and	_	
126-141	31915-31925	collateral	_	
126-142	31926-31934	timeline	_	
126-143	31935-31946	follow-back	_	
126-144	31947-31954	reports	_	
126-145	31955-31957	of	_	
126-146	31958-31962	drug	_	
126-147	31963-31966	and	_	
126-148	31967-31974	alcohol	_	
126-149	31975-31978	use	_	
126-150	31979-31981	in	_	
126-151	31982-31983	a	_	
126-152	31984-31990	sample	_	
126-153	31991-31993	of	_	
126-154	31994-32006	drug-abusing	_	
126-155	32007-32010	and	_	
126-156	32011-32029	conduct-disordered	_	
126-157	32030-32041	adolescents	_	
126-158	32042-32045	and	_	
126-159	32046-32051	their	_	
126-160	32052-32059	parents	_	
126-161	32060-32071	Reliability	_	
126-162	32072-32074	of	_	
126-163	32075-32082	alcohol	_	
126-164	32083-32090	abusers	_	
126-165	32090-32091	’	_	
126-166	32092-32104	self-reports	_	
126-167	32105-32107	of	_	
126-168	32108-32116	drinking	_	
126-169	32117-32125	behavior	_	
126-170	32126-32133	Studies	_	
126-171	32134-32136	of	_	
126-172	32137-32149	interference	_	
126-173	32150-32152	in	_	
126-174	32153-32159	serial	_	
126-175	32160-32166	verbal	_	
126-176	32167-32176	reactions	_	
126-177	32177-32185	Deficits	_	
126-178	32186-32188	on	_	
126-179	32189-32204	subject-ordered	_	
126-180	32205-32210	tasks	_	
126-181	32211-32216	after	_	
126-182	32217-32224	frontal	_	
126-183	32224-32225	-	_	
126-184	32226-32229	and	_	
126-185	32230-32243	temporal-lobe	_	
126-186	32244-32251	lesions	_	
126-187	32252-32254	in	_	
126-188	32255-32258	man	_	
126-189	32259-32262	Age	_	
126-190	32263-32274	differences	_	
126-191	32275-32277	in	_	
126-192	32278-32288	short-term	_	
126-193	32289-32298	retention	_	
126-194	32299-32301	of	_	
126-195	32302-32309	rapidly	_	
126-196	32310-32318	changing	_	
126-197	32319-32330	information	_	
126-198	32332-32342	Evaluation	_	
126-199	32343-32345	of	_	
126-200	32346-32347	a	_	
126-201	32348-32358	behavioral	_	
126-202	32359-32366	measure	_	
126-203	32367-32369	of	_	
126-204	32370-32374	risk	_	
126-205	32375-32381	taking	_	
126-206	32381-32382	:	_	
126-207	32383-32386	the	_	
126-208	32387-32394	Balloon	_	
126-209	32395-32403	Analogue	_	
126-210	32404-32408	Risk	_	
126-211	32409-32413	Task	_	
126-212	32414-32415	(	_	
126-213	32415-32419	BART	_	
126-214	32419-32420	)	_	
126-215	32422-32425	The	_	
126-216	32426-32432	IMAGEN	_	
126-217	32433-32438	study	_	
126-218	32438-32439	:	_	
126-219	32440-32461	reinforcement-related	_	
126-220	32462-32471	behaviour	_	
126-221	32472-32474	in	_	
126-222	32475-32481	normal	_	
126-223	32482-32487	brain	_	
126-224	32488-32496	function	_	
126-225	32497-32500	and	_	
126-226	32501-32516	psychopathology	_	
126-227	32517-32529	Anticipation	_	
126-228	32530-32532	of	_	
126-229	32533-32543	increasing	_	
126-230	32544-32552	monetary	_	
126-231	32553-32559	reward	_	
126-232	32560-32571	selectively	_	
126-233	32572-32580	recruits	_	
126-234	32581-32588	nucleus	_	
126-235	32589-32598	accumbens	_	
126-236	32599-32617	Incentive-elicited	_	
126-237	32618-32623	brain	_	
126-238	32624-32634	activation	_	
126-239	32635-32637	in	_	
126-240	32638-32649	adolescents	_	
126-241	32649-32650	:	_	
126-242	32651-32663	similarities	_	
126-243	32664-32667	and	_	
126-244	32668-32679	differences	_	
126-245	32680-32684	from	_	
126-246	32685-32690	young	_	
126-247	32691-32697	adults	_	
126-248	32698-32703	Lower	_	
126-249	32704-32711	ventral	_	
126-250	32712-32720	striatal	_	
126-251	32721-32731	activation	_	
126-252	32732-32738	during	_	
126-253	32739-32745	reward	_	
126-254	32746-32758	anticipation	_	
126-255	32759-32761	in	_	
126-256	32762-32772	adolescent	_	
126-257	32773-32780	smokers	_	
126-258	32781-32785	Risk	_	
126-259	32786-32792	taking	_	
126-260	32793-32796	and	_	
126-261	32797-32800	the	_	
126-262	32801-32811	adolescent	_	
126-263	32812-32818	reward	_	
126-264	32819-32825	system	_	
126-265	32825-32826	:	_	
126-266	32827-32828	a	_	
126-267	32829-32838	potential	_	
126-268	32839-32845	common	_	
126-269	32846-32850	link	_	
126-270	32851-32853	to	_	
126-271	32854-32863	substance	_	
126-272	32864-32869	abuse	_	
126-273	32870-32876	Linear	_	
126-274	32877-32891	age-correlated	_	
126-275	32892-32902	functional	_	
126-276	32903-32914	development	_	
126-277	32915-32917	of	_	
126-278	32918-32923	right	_	
126-279	32924-32932	inferior	_	
126-280	32933-32958	fronto-striato-cerebellar	_	
126-281	32959-32967	networks	_	
126-282	32968-32974	during	_	
126-283	32975-32983	response	_	
126-284	32984-32994	inhibition	_	
126-285	32995-32998	and	_	
126-286	32999-33007	anterior	_	
126-287	33008-33017	cingulate	_	
126-288	33018-33024	during	_	
126-289	33025-33038	error-related	_	
126-290	33039-33048	processes	_	
126-291	33049-33057	Abnormal	_	
126-292	33058-33063	brain	_	
126-293	33064-33074	activation	_	
126-294	33075-33081	during	_	
126-295	33082-33092	inhibition	_	
126-296	33093-33096	and	_	
126-297	33097-33102	error	_	
126-298	33103-33112	detection	_	
126-299	33113-33115	in	_	
126-300	33116-33132	medication-naive	_	
126-301	33133-33144	adolescents	_	
126-302	33145-33149	with	_	
126-303	33150-33154	ADHD	_	
126-304	33155-33160	Right	_	
126-305	33161-33169	inferior	_	
126-306	33170-33180	prefrontal	_	
126-307	33181-33187	cortex	_	
126-308	33188-33196	mediates	_	
126-309	33197-33205	response	_	
126-310	33206-33216	inhibition	_	
126-311	33217-33222	while	_	
126-312	33223-33229	mesial	_	
126-313	33230-33240	prefrontal	_	
126-314	33241-33247	cortex	_	
126-315	33248-33250	is	_	
126-316	33251-33262	responsible	_	
126-317	33263-33266	for	_	
126-318	33267-33272	error	_	
126-319	33273-33282	detection	_	
126-320	33283-33290	Mapping	_	
126-321	33291-33296	motor	_	
126-322	33297-33307	inhibition	_	
126-323	33307-33308	:	_	
126-324	33309-33320	conjunctive	_	
126-325	33321-33326	brain	_	
126-326	33327-33338	activations	_	
126-327	33339-33345	across	_	
126-328	33346-33355	different	_	
126-329	33356-33364	versions	_	
126-330	33365-33367	of	_	
126-331	33368-33370	go	_	
126-332	33370-33371	/	_	
126-333	33371-33376	no-go	_	
126-334	33377-33380	and	_	
126-335	33381-33385	stop	_	
126-336	33386-33391	tasks	_	
126-337	33392-33403	Impulsivity	_	
126-338	33404-33407	and	_	
126-339	33408-33418	inhibitory	_	
126-340	33419-33426	control	_	
126-341	33427-33428	A	_	
126-342	33429-33434	fully	_	
126-343	33435-33444	automatic	_	
126-344	33445-33448	and	_	
126-345	33449-33455	robust	_	
126-346	33456-33461	brain	_	
126-347	33462-33465	MRI	_	
126-348	33466-33472	tissue	_	
126-349	33473-33487	classification	_	
126-350	33488-33494	method	_	
126-351	33495-33504	Automatic	_	
126-352	33505-33506	“	_	
126-353	33506-33514	pipeline	_	
126-354	33514-33515	”	_	
126-355	33516-33524	analysis	_	
126-356	33525-33527	of	_	
126-357	33528-33529	3	_	
126-358	33529-33530	-	_	
126-359	33530-33531	D	_	
126-360	33532-33535	MRI	_	
126-361	33536-33540	data	_	
126-362	33541-33544	for	_	
126-363	33545-33553	clinical	_	
126-364	33554-33560	trials	_	
126-365	33560-33561	:	_	
126-366	33562-33573	application	_	
126-367	33574-33576	to	_	
126-368	33577-33585	multiple	_	
126-369	33586-33595	sclerosis	_	
126-370	33596-33605	Automated	_	
126-371	33606-33607	3	_	
126-372	33607-33608	-	_	
126-373	33608-33609	D	_	
126-374	33610-33620	extraction	_	
126-375	33621-33624	and	_	
126-376	33625-33635	evaluation	_	
126-377	33636-33638	of	_	
126-378	33639-33642	the	_	
126-379	33643-33648	inner	_	
126-380	33649-33652	and	_	
126-381	33653-33658	outer	_	
126-382	33659-33667	cortical	_	
126-383	33668-33676	surfaces	_	
126-384	33677-33682	using	_	
126-385	33683-33684	a	_	
126-386	33685-33694	Laplacian	_	
126-387	33695-33698	map	_	
126-388	33699-33702	and	_	
126-389	33703-33710	partial	_	
126-390	33711-33717	volume	_	
126-391	33718-33724	effect	_	
126-392	33725-33739	classification	_	
126-393	33740-33749	Automated	_	
126-394	33750-33758	cortical	_	
126-395	33759-33768	thickness	_	
126-396	33769-33781	measurements	_	
126-397	33782-33786	from	_	
126-398	33787-33790	MRI	_	
126-399	33791-33794	can	_	
126-400	33795-33805	accurately	_	
126-401	33806-33814	separate	_	
126-402	33815-33824	Alzheimer	_	
126-403	33824-33825	’	_	
126-404	33825-33826	s	_	
126-405	33827-33835	patients	_	
126-406	33836-33840	from	_	
126-407	33841-33847	normal	_	
126-408	33848-33855	elderly	_	
126-409	33856-33864	controls	_	
126-410	33865-33878	Probabilistic	_	
126-411	33879-33888	diffusion	_	
126-412	33889-33901	tractography	_	
126-413	33902-33906	with	_	
126-414	33907-33915	multiple	_	
126-415	33916-33921	fibre	_	
126-416	33922-33934	orientations	_	
126-417	33934-33935	:	_	
126-418	33936-33940	What	_	
126-419	33941-33944	can	_	
126-420	33945-33947	we	_	
126-421	33948-33952	gain	_	
126-422	33952-33953	?	_	

#Text=Hemispheric asymmetries in language-related pathways: a combined functional MRI and tractography study
#Text=A framework for a streamline-based probabilistic index of connectivity (PICo) using a structural interpretation of MRI diffusion measurements
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Fast robust automated brain extraction
#Text=Temporal autocorrelation in univariate linear modeling of FMRI data
#Text=General multilevel linear modeling for group analysis in FMRI
#Text=Alcohol and drug use and the developing brain
#Text=Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey
127-1	33954-33965	Hemispheric	_	
127-2	33966-33977	asymmetries	_	
127-3	33978-33980	in	_	
127-4	33981-33997	language-related	_	
127-5	33998-34006	pathways	_	
127-6	34006-34007	:	_	
127-7	34008-34009	a	_	
127-8	34010-34018	combined	_	
127-9	34019-34029	functional	_	
127-10	34030-34033	MRI	_	
127-11	34034-34037	and	_	
127-12	34038-34050	tractography	_	
127-13	34051-34056	study	_	
127-14	34057-34058	A	_	
127-15	34059-34068	framework	_	
127-16	34069-34072	for	_	
127-17	34073-34074	a	_	
127-18	34075-34091	streamline-based	_	
127-19	34092-34105	probabilistic	_	
127-20	34106-34111	index	_	
127-21	34112-34114	of	_	
127-22	34115-34127	connectivity	_	
127-23	34128-34129	(	_	
127-24	34129-34133	PICo	_	
127-25	34133-34134	)	_	
127-26	34135-34140	using	_	
127-27	34141-34142	a	_	
127-28	34143-34153	structural	_	
127-29	34154-34168	interpretation	_	
127-30	34169-34171	of	_	
127-31	34172-34175	MRI	_	
127-32	34176-34185	diffusion	_	
127-33	34186-34198	measurements	_	
127-34	34199-34207	Improved	_	
127-35	34208-34220	optimization	_	
127-36	34221-34224	for	_	
127-37	34225-34228	the	_	
127-38	34229-34235	robust	_	
127-39	34236-34239	and	_	
127-40	34240-34248	accurate	_	
127-41	34249-34255	linear	_	
127-42	34256-34268	registration	_	
127-43	34269-34272	and	_	
127-44	34273-34279	motion	_	
127-45	34280-34290	correction	_	
127-46	34291-34293	of	_	
127-47	34294-34299	brain	_	
127-48	34300-34306	images	_	
127-49	34307-34311	Fast	_	
127-50	34312-34318	robust	_	
127-51	34319-34328	automated	_	
127-52	34329-34334	brain	_	
127-53	34335-34345	extraction	_	
127-54	34346-34354	Temporal	_	
127-55	34355-34370	autocorrelation	_	
127-56	34371-34373	in	_	
127-57	34374-34384	univariate	_	
127-58	34385-34391	linear	_	
127-59	34392-34400	modeling	_	
127-60	34401-34403	of	_	
127-61	34404-34408	FMRI	_	
127-62	34409-34413	data	_	
127-63	34414-34421	General	_	
127-64	34422-34432	multilevel	_	
127-65	34433-34439	linear	_	
127-66	34440-34448	modeling	_	
127-67	34449-34452	for	_	
127-68	34453-34458	group	_	
127-69	34459-34467	analysis	_	
127-70	34468-34470	in	_	
127-71	34471-34475	FMRI	_	
127-72	34476-34483	Alcohol	_	
127-73	34484-34487	and	_	
127-74	34488-34492	drug	_	
127-75	34493-34496	use	_	
127-76	34497-34500	and	_	
127-77	34501-34504	the	_	
127-78	34505-34515	developing	_	
127-79	34516-34521	brain	_	
127-80	34522-34525	Age	_	
127-81	34526-34528	at	_	
127-82	34529-34534	onset	_	
127-83	34535-34537	of	_	
127-84	34538-34545	alcohol	_	
127-85	34546-34549	use	_	
127-86	34550-34553	and	_	
127-87	34554-34557	its	_	
127-88	34558-34569	association	_	
127-89	34570-34574	with	_	
127-90	34575-34581	DSM-IV	_	
127-91	34582-34589	alcohol	_	
127-92	34590-34595	abuse	_	
127-93	34596-34599	and	_	
127-94	34600-34610	dependence	_	
127-95	34610-34611	:	_	
127-96	34612-34619	results	_	
127-97	34620-34624	from	_	
127-98	34625-34628	the	_	
127-99	34629-34637	National	_	
127-100	34638-34650	Longitudinal	_	
127-101	34651-34658	Alcohol	_	
127-102	34659-34672	Epidemiologic	_	
127-103	34673-34679	Survey	_	
